<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006378" GROUP_ID="DEMENTIA" ID="911906033017290602" MERGED_FROM="" MODIFIED="2012-01-11 15:35:53 +0100" MODIFIED_BY="Sue Marcus" REVIEW_NO="119" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2012-01-11 15:35:53 +0100" MODIFIED_BY="Sue Marcus">
<TITLE MODIFIED="2011-12-07 15:14:17 +0000" MODIFIED_BY="[Empty name]">Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease</TITLE>
<CONTACT MODIFIED="2012-01-11 15:35:53 +0100" MODIFIED_BY="Sue Marcus"><PERSON ID="FEE123C482E26AA2002F1D7A84A06D23" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Darin</FIRST_NAME><LAST_NAME>Jaturapatporn</LAST_NAME><EMAIL_1>drdarinj@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Family Medicine, Ramathibodi Hospital</DEPARTMENT><ORGANISATION>Mahidol University, Bangkok and Baycrest Centre for Geriatric Care, University of Toronto</ORGANISATION><CITY>Toronto</CITY><COUNTRY CODE="CA">Canada</COUNTRY><FAX_1>001 416 785 2863</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-01-11 15:35:53 +0100" MODIFIED_BY="Sue Marcus"><PERSON ID="FEE123C482E26AA2002F1D7A84A06D23" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Darin</FIRST_NAME><LAST_NAME>Jaturapatporn</LAST_NAME><EMAIL_1>drdarinj@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Family Medicine, Ramathibodi Hospital</DEPARTMENT><ORGANISATION>Mahidol University, Bangkok and Baycrest Centre for Geriatric Care, University of Toronto</ORGANISATION><CITY>Toronto</CITY><COUNTRY CODE="CA">Canada</COUNTRY><FAX_1>001 416 785 2863</FAX_1></ADDRESS></PERSON><PERSON ID="17431" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mokhtar Gad El Kareem Nasr</FIRST_NAME><LAST_NAME>Isaac</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>mokhtarisa@hotmail.com</EMAIL_1><MOBILE_PHONE>07786163643</MOBILE_PHONE><ADDRESS><DEPARTMENT>Old Age Psychiatry</DEPARTMENT><ORGANISATION>Sussex Partnership NHS Foundation Trust</ORGANISATION><ADDRESS_1>Master's House</ADDRESS_1><ADDRESS_2>Compton Place Road</ADDRESS_2><CITY>Eastbourne</CITY><ZIP>BN20 8BJ</ZIP><REGION>East Sussex</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01323 432200</PHONE_1><FAX_1>01323 532224</FAX_1></ADDRESS></PERSON><PERSON ID="A690A6AE82E26AA2005347C3EE527B6F" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jenny</FIRST_NAME><LAST_NAME>McCleery</LAST_NAME><POSITION>Consultant Psychiatrist (Older Adults)</POSITION><EMAIL_1>jenny.mccleery@doctors.org.uk</EMAIL_1><EMAIL_2>jenny.mccleery@obmh.nhs.uk</EMAIL_2><MOBILE_PHONE>07779 586306</MOBILE_PHONE><ADDRESS><DEPARTMENT>Cochrane Dementia and Cognitive Improvement Group</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>John Radcliffe Hospital</ADDRESS_1><ADDRESS_2>Level 4, Main Hospital, Room 4401c</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX39DU</ZIP><REGION>Oxfordshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+ 44 1865 234 307</PHONE_1></ADDRESS></PERSON><PERSON ID="13079" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Naji</FIRST_NAME><LAST_NAME>Tabet</LAST_NAME><POSITION>Senior Lecturer</POSITION><EMAIL_1>N.T.Tabet@bton.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Institute of Postgraduate Medicine</DEPARTMENT><ORGANISATION>Brighton and Sussex Medical School &amp; Cognitive Treatment and Research Unit, Sussex Partnership NHS Foundation Trust</ORGANISATION><ADDRESS_2>Falmer</ADDRESS_2><CITY>Brighton</CITY><ZIP>BN1 9PH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01273 644005</PHONE_1><FAX_1>01273 644002</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-10-06 09:17:02 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="5" MONTH="6" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="4" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="6" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2011-12-19 13:58:17 +0000" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2008-08-26 13:29:44 +0100" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-08-26 13:29:41 +0100" MODIFIED_BY="Helen Collins">
<DATE DAY="26" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>When the full review of "Aspirin and anti-inflammatory drugs for Alzheimer's Disease" is published, it will replace the previously published reviews "Ibuprofen for Alzheimer's Disease", "Indomethacin for Alzheimer's Disease", and the previously published protocol "Naproxen for Alzheimer's Disease".<BR/>
<BR/>At that time, these ibuprofen and indomethacin reviews and this naproxen protocol will be withdrawn from the Cochrane Library.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-08-26 13:29:44 +0100" MODIFIED_BY="Helen Collins">
<DATE DAY="26" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-02-20 05:51:14 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<INTERNAL_SOURCES MODIFIED="2009-02-20 05:51:14 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<SOURCE MODIFIED="2009-02-20 05:51:14 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<NAME>New Source of support</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-01-11 14:23:45 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-01-02 07:58:39 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-01-02 07:41:38 +0000" MODIFIED_BY="Darin   Jaturapatporn">Aspirin, steroid and non-steroidal anti-inflammatory drugs use for treating Alzheimer's disease</TITLE>
<SUMMARY_BODY MODIFIED="2012-01-02 07:58:39 +0000" MODIFIED_BY="[Empty name]">
<P>Inflammation may play an important role in the development of Alzheimer&#8217;s disease. There is also some evidence from community surveys that people receiving anti-inflammatory drugs for various medical conditions may be less likely to develop Alzheimer's disease. Fourteen studies met our inclusion criteria for this review and none of the exclusion criteria. Aspirin, steroid and non-steroidal anti-inflammatory drugs (NSAIDs) (traditional and the selective cyclooxygenase-2 (COX-2) inhibitors) showed no significant benefit in the treatment of Alzheimer's disease. Therefore, the use of these drugs cannot be recommended for the treatment of Alzheimer's disease.         </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-01-02 07:55:20 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-06-05 17:22:24 +0100" MODIFIED_BY="[Empty name]">
<P>Alzheimer&#8217;s disease (AD) is the most common form of dementia. The incidence of AD rises exponentially with age and its prevalence will increase significantly worldwide in the next few decades. Inflammatory processes have been suspected in the pathogenesis of the disease.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-01-02 07:55:06 +0000" MODIFIED_BY="[Empty name]">
<P>To review the efficacy and side effects of aspirin, steroidal and non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of AD, compared to placebo.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-04-26 13:36:39 +0100" MODIFIED_BY="[Empty name]">
<P>We searched ALOIS: the Cochrane Dementia and Cognitive Improvement Group&#8217;s Specialized Register on 12 April 2011 using the terms: aspirin OR "cyclooxygenase 2 inhibitor" OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflunisal OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indometacin OR indomethacin OR ketoprofen OR lumiracoxib OR mefenamic OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR "anti-inflammatory" OR prednisone OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR NSAIDS OR NSAID. ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases (including MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS), numerous trial registries (including national, international and pharmacuetical registries) and grey literature sources.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-02-23 00:54:56 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>All randomised controlled trials assessing the efficacy of aspirin, steroidal and non-steroidal anti-inflammatory drugs in AD.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-01-02 07:52:01 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>One author assessed risk of bias of each study and extracted data. A second author verified data selection.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-01-02 07:55:20 +0000" MODIFIED_BY="[Empty name]">
<P>Our search identified 604 potentially relevant studies. Of these, 14 studies (15 interventions) were RCTs and met our inclusion criteria. The numbers of participants were 352, 138 and 1745 for aspirin, steroid and NSAIDs groups, respectively. One selected study comprised two separate interventions. Interventions assessed in these studies were grouped into four categories: aspirin (three interventions), steroids (one intervention), traditional NSAIDs (six interventions), and selective cyclooxygenase-2 (COX-2) inhibitors (five interventions). All studies were evaluated for internal validity using a risk of bias assessment tool. The risk of bias was low for five studies, high for seven studies, and unclear for two studies.There was no significant improvement in cognitive decline for aspirin, steroid, traditional NSAIDs and selective COX-2 inhibitors. Compared to controls, patients receiving aspirin experienced more bleeding while patients receiving steroid experienced more hyperglycaemia, abnormal lab results and face edema. Patients receiving NSAIDs experienced nausea, vomiting, elevated creatinine, elevated LFT and hypertension. A trend towards higher death rates was observed among patients treated with NSAIDS compared with placebo and this was somewhat higher for selective COX-2 inhibitors than for traditional NSAIDs.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-12-07 15:14:45 +0000" MODIFIED_BY="[Empty name]">
<P>Based on the studies carried out so far, the efficacy of aspirin, steroid and NSAIDs (traditional NSAIDs and COX-2 inhibitors) is not proven. Therefore, these drugs cannot be recommended for the treatment of AD.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-01-11 14:23:45 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-01-02 08:03:39 +0000" MODIFIED_BY="[Empty name]">
<P>Alzheimer's disease (AD) is the most common form of dementia, and its incidence increases exponentially with age. AD affects 1-2% of people aged 65-70 and approximately 20% of those over 80 years (<LINK REF="REF-Jorm-2003" TYPE="REFERENCE">Jorm 2003</LINK>). It results in a progressive deterioration of intellect, memory and personality. AD is an important health problem that has a significant impact on national economies. In the United States, there are approximately 5.2 million AD patients and the cost of care for an average patient is about 24,500 dollars per year (<LINK REF="REF-Wimo-2005" TYPE="REFERENCE">Wimo 2005</LINK>). By 2030, an estimated 7.7 million Americans aged 65 and older will have AD (<LINK REF="REF-Hebert-2003" TYPE="REFERENCE">Hebert 2003</LINK>). The disease is increasing worldwide.</P>
<P>The exact mechanism underlying the pathogenesis of AD is still unclear and remains a topic of intense debate. However, two hypotheses revolving around amyloid and inflammation have been particularly influential in trying to understand the neuropathological processes underlying AD. Beta amyloid (AB) is a proteolytic fragment of 40-42 residues derived from Amyloid Precursor Protein (APP). In vitro, the longer AB-42 fragment aggregates much more readily, and is hypothesised to be the main pathological agent in the pathogenesis of AD ( <LINK REF="REF-Joachim-1992" TYPE="REFERENCE">Joachim 1992</LINK>; <LINK REF="REF-Selkoe-1991" TYPE="REFERENCE">Selkoe 1991</LINK>; <LINK REF="REF-Younkin-1995" TYPE="REFERENCE">Younkin 1995</LINK>). Altered production, aggregation and deposition of AB may play a critical role in the development of AD (<LINK REF="REF-Citron-1992" TYPE="REFERENCE">Citron 1992</LINK>; <LINK REF="REF-Haass-1994" TYPE="REFERENCE">Haass 1994</LINK>). Significantly, it is suspected that this deposition of amyloid may directly contribute to the inflammatory environment seen (<LINK REF="REF-Ruan-2009" TYPE="REFERENCE">Ruan 2009</LINK>; <LINK REF="REF-Salminen-2009" TYPE="REFERENCE">Salminen 2009</LINK>). The inflammatory hypothesis of AD proposes that specific inflammatory mechanisms, including the cytokine-driven acute-phase response, complement activation and microglial activation, contribute to neurodegeneration (<LINK REF="REF-Aisen-1994" TYPE="REFERENCE">Aisen 1994</LINK>; <LINK REF="REF-McGeer-1989" TYPE="REFERENCE">McGeer 1989</LINK>). In addition, AD may be associated with loss of the capacity to control inflammation in the brain (<LINK REF="REF-Bazan-2009" TYPE="REFERENCE">Bazan 2009</LINK>).</P>
<P>In view of the strong association between inflammation and AD, attempts have been made to assess whether anti-inflammatory pharmaceutical agents may have a role in the management of AD. An important mechanism of attenuating inflammatory processes can be achieved through inhibition of the activity of the enzyme cyclooxygenase (COX) which is critical to the production of prostaglandins (<LINK REF="REF-Fiebich-1997" TYPE="REFERENCE">Fiebich 1997</LINK>). This inhibition can occur through the use of various non-steroidal anti-inflammatory drugs (NSAIDs) which might thereby diminish  the inflammatory response in degenerative dementias. There is evidence that the enzyme cyclooxygenase-2 (COX-2) might be involved in neurodegenerative mechanisms in AD (<A HREF="http://www.archie.cochrane.org/sections/documents/viewDiff?documentPK=4BC5AB7E82E26AA200618B080F91E8ED&amp;versionPK1=D9BE3CEC82E26AA20176F764BB866FCE&amp;versionPK2=54765562462673621437091022161744#REF-Ho-1999">Ho 1999</A>; <A HREF="http://www.archie.cochrane.org/sections/documents/viewDiff?documentPK=4BC5AB7E82E26AA200618B080F91E8ED&amp;versionPK1=D9BE3CEC82E26AA20176F764BB866FCE&amp;versionPK2=54765562462673621437091022161744#REF-Pasinetti-1998">Pasinetti 1998</A>). This has given rise to the hypothesis that drugs which inhibit COX-2 in the brain, including certain steroids, aspirin, traditional non-steroidal anti-inflammatory drug (NSAIDs) and selective COX-2 inhibitors could possibly slow the rate of progression or alleviate the symptoms of AD. Likewise, it has also been suspected that corticosteroids (namely synthetic glucocorticoids) may offer some neuroprotection in AD patients (<A HREF="http://www.archie.cochrane.org/sections/documents/viewDiff?documentPK=4BC5AB7E82E26AA200618B080F91E8ED&amp;versionPK1=D9BE3CEC82E26AA20176F764BB866FCE&amp;versionPK2=54765562462673621437091022161744#REF-Aisen1998">Aisen 1998</A>) through their well characterised anti-inflammatory action.</P>
<P>Anti-inflammatory medications such as non-selective and selective NSAIDs and corticosteroids have been the subject of epidemiological (Launer 2003) and clinical research in AD. The possibility of benefit from non-selective COX inhibitors (such as indomethacin, naproxen, ibuprofen and diclofenac) and/or selective COX-2 inhibitors (such as celecoxib and meloxicam) is supported by several lines of evidence. Less work has been carried out for corticosteroids such as prednisolone, but their potential usefulness is of  interest.</P>
<P>Epidemiological studies have found a lower prevalence of dementia in people who have regularly taken NSAIDs, usually for rheumatological disorders (<LINK REF="REF-McGeer-1996" TYPE="REFERENCE">McGeer 1996</LINK>, Stewart 1997). There has also been a cohort study reporting a lower incidence of AD in users of NSAIDs than in non-users (<LINK REF="REF-In_x0027_t-Veld-2001" TYPE="REFERENCE">In't Veld 2001</LINK>). There is <I>in vitro </I>evidence that, independently of their inhibition of prostaglandin synthesis, some NSAIDs can directly influence the processing of amyloid precursor protein (APP) which is thought to be implicated in the pathogenesis of AD (<LINK REF="REF-Avramovich-2002" TYPE="REFERENCE">Avramovich 2002</LINK>; <LINK REF="REF-Blasko-2001" TYPE="REFERENCE">Blasko 2001</LINK>). Likewise, an open-label pilot study of low-dose prednisolone showed the suppression of peripheral markers of the acute phase response and complement activation in AD without systemic toxicity (<A HREF="http://www.archie.cochrane.org/sections/documents/viewDiff?documentPK=4BC5AB7E82E26AA200618B080F91E8ED&amp;versionPK1=D9BE3CEC82E26AA20176F764BB866FCE&amp;versionPK2=54765562462673621437091022161744#REF-Aisen-1996">Aisen 1996</A>).</P>
<P>In recent years attempts have been made to determine whether anti-inflammatory agents may be efficacious in the treatment of AD. The purpose of this review is to establish the effectiveness, or otherwise, of such medication. It is now known that all anti-inflammatory drugs, including selective COX-2 inhibitors, can carry significant side effects profile and may occasionally be fatal. Hence, it is now important to ascertain whether there is a place for these drugs in the treatment of AD.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-01-02 08:03:56 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>To systematically review the evidence examining the efficacy and side effects of aspirin, steroidal and non-steroidal anti-inflammatory drugs in the treatment of AD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-01-11 14:23:45 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-01-02 08:04:20 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-06-05 03:08:41 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials assessing the efficacy of aspirin, steroidal and non-steroidal anti-inflammatory drugs in the treatment of AD.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-01-02 08:00:29 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Patients of any age diagnosed with probable AD according to internationally recognised criteria including the 'National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA), the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the World Health Organisation classification of mental and behavioural disorders (ICD-10) (<LINK REF="REF-APA-1995" TYPE="REFERENCE">APA 1995</LINK>; <LINK REF="REF-McKhann-1984" TYPE="REFERENCE">McKhann 1984</LINK>; <LINK REF="REF-WHO-1992" TYPE="REFERENCE">WHO 1992</LINK>) .</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-05-27 17:58:27 +0100" MODIFIED_BY="Darin   Jaturapatporn">
<P>Aspirin, steroidal and non-steroidal anti-inflammatory agents (traditional and selective COX-2 inhibitors) at any dose.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-01-02 08:04:20 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcomes</P>
<UL>
<LI>Cognition (using objective psychometric rating instruments, e.g. the Alzheimer's disease assessment scale - cognitive sub-scale or ADAS-COG) or Mini-Mental Status Examination (MMSE)</LI>
<LI>Adverse events</LI>
<LI>Death</LI>
</UL>
<P>Secondary outcome</P>
<UL>
<LI>Clinical global impression of change</LI>
<LI>Mood/depression</LI>
<LI>Behavioural disturbance</LI>
<LI>Activities of daily living</LI>
<LI>Quality of life</LI>
<LI>Caregiver burden</LI>
<LI>Institutionalization</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-06-05 17:35:36 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2011-06-05 17:35:36 +0100" MODIFIED_BY="[Empty name]">
<P>We searched ALOIS (<A HREF="http://www.medicine.ox.ac.uk/alois">www.medicine.ox.ac.uk/alois</A>) - the Cochrane Dementia and Cognitive Improvement Group&#8217;s Specialized Register on 12 April 2011. The search terms used were: aspirin OR "cyclooxygenase 2 inhibitor" OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflunisal OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indometacin OR indomethacin OR ketoprofen OR lumiracoxib OR mefenamic OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR "anti-inflammatory" OR prednisone OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR NSAIDS OR NSAID.</P>
<P>ALOIS is maintained by the Trials Search Co-ordinator for the Cochrane Dementia Group and contains studies in the areas of dementia prevention, dementia treatment and cognitive enhancement in healthy. The studies are identified from:  </P>
<OL>
<LI>Monthly searches of a number of major healthcare databases: Medline, Embase, Cinahl, Psycinfo and Lilacs</LI>
<LI>Monthly searches of a number of trial registers: ISRCTN; UMIN (Japan's Trial Register); the WHO portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register; the German Clinical Trials Register; the Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others)</LI>
<LI>Quarterly search of <I>The Cochrane Library</I>&#8217;s Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Six-monthly searches of a number of grey literature sources: ISI Web of Knowledge Conference Proceedings; Index to Theses; Australasian Digital Theses</LI>
</OL>
<P>To view a list of all sources searched for ALOIS see <A HREF="http://www.medicine.ox.ac.uk/alois/content/about-alois">About ALOIS</A> on the ALOIS website.</P>
<P>Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL and conference proceedings can be viewed in the &#8216;methods used in reviews&#8217; section within the editorial information about the <A HREF="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html">Dementia and Cognitive Improvement Group</A>.</P>
<P>Additional searches were performed in many of the sources listed above to cover the timeframe from the last searches performed for ALOIS to ensure that the search for the review was as up-to-date and as comprehensive as possible. The search strategies used can be seen in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>Details of the initial search carried out for this review can be viewed in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>The latest search (April 2011) retrieved a total of 1223 results. After a first-assess and a de-duplication of these results the authors were left with 116 references/records to further assess.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-04-26 13:39:48 +0100" MODIFIED_BY="[Empty name]">
<P>The first authors of important identified RCTs that were potentially suitable for inclusion were contacted to request additional information on related new, unpublished, or in press studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-01-11 14:23:45 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2012-01-02 08:25:30 +0000" MODIFIED_BY="Joey Kwong">
<P>Two authors (DJ, MI) independently examined the titles and abstracts of the trials identified in the search and considered them for inclusion according to the pre-determined eligibility criteria. Any disparity was resolved by retrieval of the cited articles and further discussion with the third author (NT).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-01-02 08:25:49 +0000" MODIFIED_BY="Joey Kwong">
<P>A double-check process was used for risk of bias and outcome data including clinical outcomes and side effects. As mentioned, there were 14 included studies with 15 interventions as one study was comprised  two interventions. Initially, the first author (DJ) extracted the data on all 14 included studies (15 interventions) and this was followed by verification by the other two authors (MI and NT). All authors had a data extraction form for this process. Any disagreements were resolved by discussion between DJ and the other author involved (either MI or NT depending on the study in question).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-01-02 08:26:03 +0000" MODIFIED_BY="Joey Kwong">
<P>The quality of the methods used in each study was examined by the two reviewers using the domain-based evaluation as shown in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. In conclusion, risk of bias are summarised for each study as described in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>. The Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE Working Group) approach was used to define the quality of data presented in this systematic review. The GRADE approach specifies four levels of quality as shown in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-01-02 08:27:18 +0000" MODIFIED_BY="Joey Kwong">
<P>The data presented in this review included dichotomous and continuous data. In dichotomous data (side effects, institutionalisation and death), each individual outcome comprised two possible categorical responses. Continuous data included the rest of clinical outcomes which were presented in a numerical quantity as a score format.</P>
<P>For dichotomous outcome, we used risk ratio (relative risk) to compare intervention and placebo. Risk ratio describes the probability with which side effects, institutionalisation and death will occur in the intervention group compared to placebo. In addition to risk ratio, 95% confidence interval was also calculated to determine the range of the effect.</P>
<P>For continuous data, we used both the mean difference (MD) and the standardized mean difference (SMD).</P>
<P>Mean difference was used for all outcomes that used the same scale. If an outcome was measured using more than one scale, then we calculated a standardised mean difference (SMD) where</P>
<P>SMD = <U>Difference in mean outcome between group</U>
</P>
<P>                      SD of outcome among participants</P>
<P>Heterogeneity may exist among studies in a meta-analysis and whenever possible the causes of the heterogeneity need to be explored. One way of exploring this is to carry out a subgroup analysis. However, this approach is problematic when there are very few included studies in each meta-analysis which is the case in this review Another approach to address the potential consequences of heterogeneity is to use the random-effects meta-analysis (Cochrane Handbook).  In this review, and in line with current guidelines, I<SUP>2 </SUP>was used to quantify inconsistency across studies which then move the focus away from testing whether heterogeneity is present to assessing its impact on the meta-analysis (Cochrane Handbook). Here, the intention was to use I<SUP>2 </SUP>level of &gt;30% (this is a conservative estimate and was preferred to 40%) as an indicator of potential heterogeneity. Hence, for I<SUP>2</SUP>&lt;30%, the fixed-effects meta-analysis method was determined to be appropriate.  For I<SUP>2</SUP>&gt;30% the random-effects meta-analysis method would be more fitting. This division is not ideal but is in line with current guidelines and does represent an effort to deal with the possible effects of heterogeneity on meta-analysis results.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-01-02 08:27:50 +0000" MODIFIED_BY="Joey Kwong">
<P>In this review only <LINK REF="STD-Aisen-2003a" TYPE="STUDY">Aisen 2003a</LINK> had two active interventions: a traditional NSAIDs and a selective COX-2 inhibitor group. The approach to overcome a potential unit-of-analysis error for such a study which included multiple groups but with clear separation of subgroups was to &#8220;split&#8221; the shared group (the placebo group) into two subgroups each with a smaller sample size.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-01-11 14:23:45 +0000" MODIFIED_BY="Joey Kwong">
<P>Missing data could be a source of bias and affect the validity of the study. For considered studies with potential missing data, the authors were contacted to request more information.</P>
<P>In studies where the SD for continuous outcomes was missing, then SD was calculated from available P value.</P>
<P>For included studies with high risk of bias because of missing data, a sensitivity analyses was conducted to take into account the high bias risk. This was applied to studies with both dichotomous and continuous outcome data.</P>
</MISSING_DATA>
<SUBGROUP_ANALYSIS MODIFIED="2012-01-02 08:26:58 +0000" MODIFIED_BY="Joey Kwong">
<P>For this review, interventions were grouped according to the established and accepted classification of the different groups of drugs studied (aspirin, steroid and NSAIDs). As aspirin, steroid and NSAID drugs differed significantly in chemical structure and mode of action, overall analyses under "anti-inflammatory drugs" would not have been useful. Therefore, separate analyses were needed to differentiate between the potential efficacy and adverse events of these three groups of drugs. As far as the NSAID drugs are concerned, a subgroup analysis was justified to differentiate between the traditional NSAIDs and selective COX-2 inhibitors subgroups. In essence, they were similar enough to be included as one group in the initial analysis and different enough to justify a further subgroup analyses. Hence, analyses undertaken included: aspirin VS Placebo; steroids VS Placebo; NSAIDs VS Placebo, then traditional NSAIDs VS Placebo and selective COX-2 inhibitors VS Placebo.</P>
<P>Heterogeneity was quantified using the I<SUP>2 </SUP>statistic which was interpreted as follows:</P>
<UL>
<LI>0%-40%: might not be important</LI>
<LI>30%-60%: may represent moderate heterogeneity</LI>
<LI>50%-90%: may represent substantial heterogeneity</LI>
<LI>70%-100%: considerable heterogeneity</LI>
</UL>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-01-08 03:03:04 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-01-08 03:02:10 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2012-01-02 08:28:20 +0000" MODIFIED_BY="[Empty name]">
<P>604 references were retrieved by the electronic searches, from which 14 relevant RCTs were selected. Kappa statistic for agreement among 2 authors was 0.793 as shown in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> which implied excellent agreement.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-01-02 08:29:06 +0000" MODIFIED_BY="[Empty name]">
<P>From 15 interventions (14 studies in total), there were three interventions for aspirin, one for steroids, six for traditional NSAIDs and five interventions for selective COX-2 inhibitors. One study had two interventions including both a traditional NSAIDs and a selective COX-2 inhibitor (<LINK REF="STD-Aisen-2003a" TYPE="STUDY">Aisen 2003a</LINK>). The 14 selected studies enrolled a total of 2445 AD patients. The characteristics of participants in each study are presented in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-01-08 03:02:10 +0000" MODIFIED_BY="[Empty name]">
<P>Studies were excluded if they were non-RCTs, did not include AD patients and did not use one of the drugs under investigation. In total:</P>
<UL>
<LI>529 studies were excluded because they were not RCTs; (Of these 470 studies were excluded at the begining if they were reviews or animal studies, therefore, there were only 59 studies included in the references for the excluded studies)</LI>
<LI>35 RCTs were excluded because participants were not diagnosed as suffering from AD;</LI>
<LI>18 RCTs were excluded because the interventions were not aspirin, steroidal or non-steroidal anti-inflammatory drugs;</LI>
<LI>6 RCTs were excluded because they were based on the same data used in other included RCTs;</LI>
<LI>2 RCTs identified from trial registers were excluded because there was no published data and no response from the authors to a request for information.</LI>
</UL>
<P>Flurbiprofen, a traditional NSAID, was included as a search term. Several studies were identified which proved on closer investigation to have used R-flurbiprofen. This enantiomer has little activity against cyclooxygenase, the target of traditional NSAIDs, and undergoes minimal chiral conversion in humans to the cyclooxygenase-inhibiting S-enantiomer. It cannot, therefore, be classed as an NSAID, but has been investigated as a potential modulator of AB-42 production in AD (<LINK REF="REF-Wilcock-2006a" TYPE="REFERENCE">Wilcock 2006a</LINK>). Trials using R-flurbiprofen were therefore excluded from this review.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-01-08 02:27:38 +0000" MODIFIED_BY="[Empty name]">
<P>Risk of bias assessment tool was used to assess the validity of each included study. A range from low (five studies) to high (seven studies) was observed. Two studies had unclear risk of bias (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<ALLOCATION MODIFIED="2012-01-08 02:27:38 +0000" MODIFIED_BY="[Empty name]">
<P>There were seven included studies that used proper allocation concealment method, while six studies were unclear and only <LINK REF="STD-Jhee-2004" TYPE="STUDY">Jhee 2004</LINK> did not apply allocation concealment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-01-02 08:30:27 +0000" MODIFIED_BY="[Empty name]">
<P>Eleven included studies properly blinded participants and outcome assessors. The remaining three studies were open-label studies (<LINK REF="STD-Bentham-2008" TYPE="STUDY">Bentham 2008</LINK>; <LINK REF="STD-Zhou-2004a" TYPE="STUDY">Zhou 2004a</LINK>; <LINK REF="STD-Zhou-2004b" TYPE="STUDY">Zhou 2004b</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-03-19 23:47:42 +0000" MODIFIED_BY="[Empty name]">
<P>All studies properly addressed the issue of incomplete outcome data and reasons for missing outcome data were unlikely to be related to true outcome.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-01-02 08:31:29 +0000" MODIFIED_BY="[Empty name]">
<P>Of all included studies, only <LINK REF="STD-H_x00fc_ll-1999" TYPE="STUDY">Hüll 1999</LINK> did not report all stated outcomes. In this particular study the data was presented in an abstract form and no full text article was available. This could have resulted from  negative findings or no measurement for these outcomes. This may represent a selective reporting bias.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-01-08 03:03:04 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Aspirin</HEADING>
<P>All three selected studies (<LINK REF="STD-Bentham-2008" TYPE="STUDY">Bentham 2008</LINK>; <LINK REF="STD-Zhou-2004a" TYPE="STUDY">Zhou 2004a</LINK>; <LINK REF="STD-Zhou-2004b" TYPE="STUDY">Zhou 2004b</LINK>) were open-label and unsuitable for meta-analysis due to clinical and methodological heterogeneity. Total numbers of participants from both <LINK REF="STD-Zhou-2004a" TYPE="STUDY">Zhou 2004a</LINK> and <LINK REF="STD-Zhou-2004b" TYPE="STUDY">Zhou 2004b</LINK> were 42, compared to 310 in <LINK REF="STD-Bentham-2008" TYPE="STUDY">Bentham 2008</LINK>. <LINK REF="STD-Bentham-2008" TYPE="STUDY">Bentham 2008</LINK>, <LINK REF="STD-Zhou-2004b" TYPE="STUDY">Zhou 2004b</LINK> and <LINK REF="STD-Zhou-2004a" TYPE="STUDY">Zhou 2004a</LINK> had different follow up time length which was 3 years, 36 weeks and 6 months respectively. Further, most patients (75%) in <A HREF="http://www.archie.cochrane.org/sections/documents/viewDiff?documentPK=4BC5AB7E82E26AA200618B080F91E8ED&amp;versionPK1=971B431C82E26AA2005DCF4315D96B9F&amp;versionPK2=54765562462673621437091022161744#STD-Bentham-2008">Bentham 2008</A> study took donepezil in the control group, while patients from <LINK REF="STD-Zhou-2004a" TYPE="STUDY">Zhou 2004a</LINK> and <LINK REF="STD-Zhou-2004b" TYPE="STUDY">Zhou 2004b</LINK> took hyperzine and nigocerline. All three studies also used different doses of aspirin, namely 75 mg, 150 mg and 50 mg per day.</P>
<P>In addition, an issue of lacking and missing data should be taken into account as neither <A HREF="http://www.archie.cochrane.org/sections/documents/viewDiff?documentPK=4BC5AB7E82E26AA200618B080F91E8ED&amp;versionPK1=971B431C82E26AA2005DCF4315D96B9F&amp;versionPK2=54765562462673621437091022161744#STD-Zhou-2004">Zhou 2004</A> nor <A HREF="http://www.archie.cochrane.org/sections/documents/viewDiff?documentPK=4BC5AB7E82E26AA200618B080F91E8ED&amp;versionPK1=971B431C82E26AA2005DCF4315D96B9F&amp;versionPK2=54765562462673621437091022161744#STD-Zhou-2004a">Zhou 2004a</A> provided data on side effects and detailed data on cognitive improvements. For example, there was no specific p-value or mean difference shown in the studies.</P>
<P>None of these studies reported significant cognitive improvement in the group treated with aspirin.</P>
<P>However, <LINK REF="STD-Bentham-2008" TYPE="STUDY">Bentham 2008</LINK> showed significant bleedings from various sites (RR 7.90, 95% CI 2.43 to 25.69; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), but there was no difference in terms of death (RR 1.01, 95% CI 0.70 to 1.46; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) and institutionalisation rate (RR 0.93, 95% CI 0.50 to 1.74; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), compared to aspirin avoidance group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Steroid</HEADING>
<P>Only one selected study assessed a steroidal anti-inflammatory agent, prednisone (<A HREF="http://www.archie.cochrane.org/sections/documents/viewDiff?documentPK=4BC5AB7E82E26AA200618B080F91E8ED&amp;versionPK1=971B431C82E26AA2005DCF4315D96B9F&amp;versionPK2=54765562462673621437091022161744#STD-Aisen-2000a">Aisen 2000a</A>).This study was classified as being at low risk of bias. A total of 138 subjects with probable AD were randomised to either the drug or the  placebo groups. This was a double-blind two-group parallel design comparing prednisone treatment with placebo. The primary outcome measure for this trial was the 1-year change in  the cognitive subscale of the AD Assessment Scale (ADAS-cog) score.</P>
<P>No significant effect on cognition or mood at 12 months was observed (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). Prednisone was associated with hyperglycaemia (RR 5.00, 95% CI 1.14 to 21.99; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>), abnormal lab results (RR 2.55, 95% CI 1.38 to 4.70; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>) and face edema (RR 1.87, 95% CI 1.10 to 3.17; <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">NSAIDs</HEADING>
<P>Ten studies investigated NSAIDs in AD. There were eleven interventions: six traditional NSAIDs and five selective COX-2 inhibitors. Analysis was initially undertaken on the NSAIDs group as a whole (all 11 interventions). Subsequently, subgroup analysis was carried out to establish whether any difference existed between traditional NSAIDs and selective COX-2 inhibitors.</P>
<P>All NSAIDs interventions used ADAS-cog scores as an outcome measure, but there was not enough data from <LINK REF="STD-Jhee-2004" TYPE="STUDY">Jhee 2004</LINK> to perform an analysis. In these studies, which included 1745 participants, the meta-analysis showed no significant difference between the scores of the treatment and placebo groups (MD -1.41, 95% CI -3.13 to 0.32; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). Six studies involving 1268 participants also used the MMSE as an outcome measure (<LINK REF="STD-De-Jong-2008" TYPE="STUDY">De Jong 2008</LINK>; <LINK REF="STD-Pasqualetti-2009" TYPE="STUDY">Pasqualetti 2009</LINK>; <LINK REF="STD-Reines-2004" TYPE="STUDY">Reines 2004</LINK>; <LINK REF="STD-Rogers-1993" TYPE="STUDY">Rogers 1993</LINK>; <LINK REF="STD-Scharf-1999" TYPE="STUDY">Scharf 1999</LINK>; <LINK REF="STD-Soininen-2007" TYPE="STUDY">Soininen 2007</LINK>). These studies showed no significant change in rate of MMSE scores decline in the treatment group (MD -1.08, 95%CI -2.21 to 0.12; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
<P>In the subgroup analyses, no significant difference in the rate of cognitive decline overall was observed in the traditional NSAIDs group for ADAScog (MD -3.81, 95% CI -7.94 to 0.33; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) and MMSE scores (MD -3.22, 95% CI -6.58 to 0.14; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). Similarly, for the selective COX-2 inhibitors studies, no overall significant change was reported for both ADAScog (MD 0.30, 95% CI -0.99 to 1.60; <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) and MMSE scores (MD 0.34, 95% CI -0.07 to 0.76; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). For all NSAIDs, no significant improvement was obtained for Clinician's Interview-Based Impression of Change (CIBIC+) (MD 0.04; 95% CI -0.09 to 0.16: <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). The same also applied for the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB), neuropsychiatric inventory (NPI) and other measures where no significant differences between the treatment and the placebo groups were observed (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK> to <LINK REF="CMP-003.12" TYPE="ANALYSIS">Analysis 3.12</LINK>). </P>
<P>Gastrointestinal side effects were more common in the NSAIDs group (RR 1.94, 95% CI 1.36 to 2.77; <LINK REF="CMP-003.13" TYPE="ANALYSIS">Analysis 3.13</LINK>) compared to placebo based on analysis of data from 1675 participants in 9 studies. Both traditional NSAIDs and selective COX-2 inhibitors had higher rate of gastrointestinal side effects (RR 1.43, 95% CI 0.68 to 3.00 and RR 2.03, 95% CI 1.37 to 3.03; from <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK> and <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>, respectively).</P>
<P>For traditional NSAIDs, common side effects compared to placebo included nausea and vomiting (RR 4.81, 95% CI 0.24 to 95.58; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>), elevated creatinine (RR 4.30, 95% CI 0.54 to 34.30; <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>), elevated liver function test (RR 4.04, 95% CI 0.48 to 33.98; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>), and hypertension (RR 3.36, 95% CI 0.84 to 13.34; <LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>). For selective COX-2 inhibitors, common side effects compared to placebo included hypertension (RR 8.65, 95% CI 0.51 to 146.03; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>), heart disease (RR 7.52, 95% CI 1.47 to 38.41; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>), and rash (RR 3.47, 95% CI 1.00 to 12.04; <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>). The hypertension results came from only 229 participants in Aisen 2003b resulting from the use of rofecoxib. For cardiac side effects, subgroup analysis was performed for rofecoxib and celecoxib separately. There was no direct comparison between the two products. The result showed that celecoxib caused significant heart problems in AD (RR 20.21, 95% CI 1.23 to 331.79; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>), while rofecoxib did not (RR 2.73, 95% CI 0.29 to 25.86; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
<P>Death rate was higher in the NSAIDs group although this did not reach statistical significant (RR 1.67, 95% CI 0.85 to 3.31; <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). Death rate for traditional NSAIDs (RR 0.72, 95% CI 0.18 to 2.87; <LINK REF="CMP-004.15" TYPE="ANALYSIS">Analysis 4.15</LINK>) and selective COX-2 inhibitor groups (RR 1.88, 95% CI 0.87 to 4.07; <LINK REF="CMP-005.14" TYPE="ANALYSIS">Analysis 5.14</LINK>). Data presented in this meta-analysis was from 1711 participants from 9 included studies.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-01-08 02:27:38 +0000" MODIFIED_BY="[Empty name]">
<P>Aspirin, steroids and NSAIDs (traditional NSAIDs and selective COX-2 inhibitors) do not slow down the decline in cognitive function in AD patients and do not improve non-cognitive and behavioural outcome measures such as depression, behavioral disturbance, activity of daily living, quality of life, clinical global impression of change and caregiver burden.</P>
<P>All anti-inflammatory agents are known to be associated with a host of side effects. In the selected studies aspirin significantly increased bleeding in AD patients. Steroid medication was associated with hyperglycaemia, abnormal laboratory parameters, and face edema. Traditional NSAIDs were associated with nausea, vomiting, elevated creatinine, elevated liver function tests, and hypertension. Selective COX-2 inhibitors were associated with hypertension, heart problems, and rash. Celecoxib tended to cause higher rate of heart problems compared to rofecoxib, however the baseline characteristic of celecoxib group had significantly higher rate of hypertension, diabetes and higher numbers of bypass patients. Gastrointestinal side effects were commonly found in both traditional NSAIDs and Selective COX-2 inhibitors. Significantly, death rate was higher in selective COX-2 inhibitors, compared to traditional NSAIDs. Meta-analysis of side effects that included more than 1000 participants included gastrointestinal, cerebrovascular and other side effects as well as death.</P>
<P>There is a wealth of epidemiological data supporting a role for anti-inflammatory treatment in the protection against the development of cognitive dysfunction. In addition, a role for inflammatory processes in the pathogenesis of AD is now widely recognised. Nevertheless, such data has not been translated into clinical benefit to patients with AD. Anti-inflammatory drugs do not seem, based on current evidence, to achieve any noticeable improvement in any of the various outcomes assessed, and foremost among them cognitive measures. It cannot be discounted that most, in fact all of the studies assessing the efficacy of anti-inflammatory agents have been for a relatively short duration not usually exceeding 12 months. Further, patients selected are likely to have well established disease. It is accepted that the disease pathological process begins many years before the start of any symptoms associated with AD. Hence, one cannot comment on any potential efficacy for anti-inflammatories such as NSAIDs in those with very early stages of asymptomatic and silent disease. In fact epidemiological studies showing a benefit for anti-inflammatories has tended to assess patients with mainly rheumatological disorders on long term treatment with anti-inflammatory drugs. This may explain the discrepancy between the widely observed data from epidemiological studies and RCTs.</P>
<P>It is tempting to speculate whether a potential difference may exist between traditional NSAIDs and selective COX-2 inhibitors. It remains unclear whether this may relate to mechanism of action beyond COX-2 inhibition. In recent years more interest has been directed at selective COX-2 inhibitors, in part, due to the earlier perceived supremacy of this class of NSAIDs when it comes to side effects. In recent years, however, the benefit/risk profile of these drugs has been evaluated and earlier enthusiasm about their use has been critically reassessed. It will be of benefit that future work continues to include traditional NSAIDs as well as the newer COX-2 inhibitors.</P>
<P> </P>
<SUMMARY_OF_RESULTS MODIFIED="2012-01-02 07:42:40 +0000" MODIFIED_BY="[Empty name]">
<P>Aspirin, steroid and NSAIDs (traditional NSAIDs and selective COX-2 inhibitors)  do not slow down cognitive decline in AD patients. They also  do not improve behavioural and all other non-cognitive outcome measures such as depression, behavioral disturbance, activity of daily living, quality of life, clinical global impression of change and caregiver burden.</P>
<P>All anti-inflammatory agents are known to be associated with a host of side effects. In the selected studies aspirin significantly increased bleeding in AD patients. Steroid medication was associated with hyperglycaemia, abnormal laboratory parameters, and face edema.Traditional NSAIDs were associated with nausea, vomiting, elevated creatinine, elevated liver function tests, and hypertension. Selective COX-2 inhibitors were associated with hypertension, heart problems and rash. Death rate was higher in selective COX-2 inhibitors, compared to traditional NSAIDs.</P>
<P>
<B> </B>
</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-01-02 08:51:04 +0000" MODIFIED_BY="[Empty name]">
<P>All patients in this review were diagnosed as having probable AD by NINCDS-ADRDA criteria or DSM 4. MMSE ranged from 10-26; hence patients in these studies had mild to moderate disease. Most recruitment took place in out-patient settings, except for two studies that were conducted in in-patient settings (42 participants) (<LINK REF="STD-Zhou-2004b" TYPE="STUDY">Zhou 2004b</LINK>; <LINK REF="STD-Zhou-2004a" TYPE="STUDY">Zhou 2004a</LINK>) and one study (<LINK REF="STD-H_x00fc_ll-1999" TYPE="STUDY">Hüll 1999</LINK>) in both out-patient and in-patient settings (10 participants). Minimum participants&#8217; age was 46 years. The studies were conducted in different countries including USA, UK, Netherlands, Australia, Belgium, Finland, France, Germany, Italy and China. Interventions included Aspirin, Steriods and NSAIDs.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-01-08 02:27:38 +0000" MODIFIED_BY="[Empty name]">
<P>The three aspirin studies were rated &#8216;moderate&#8217; in quality as they were not double-blind randomised controlled trials. The steroid study had low risk of bias and high quality rating. For NSAIDs, high rating for quality was obtained for four studies (<LINK REF="STD-Aisen-2003a" TYPE="STUDY">Aisen 2003a</LINK>; <LINK REF="STD-De-Jong-2008" TYPE="STUDY">De Jong 2008</LINK>; <LINK REF="STD-Pasqualetti-2009" TYPE="STUDY">Pasqualetti 2009</LINK>; <LINK REF="STD-Reines-2004" TYPE="STUDY">Reines 2004</LINK>). Moderate rating for quality was for three studies (<LINK REF="STD-Aisen-2002a" TYPE="STUDY">Aisen 2002a</LINK>; <LINK REF="STD-Rogers-1993" TYPE="STUDY">Rogers 1993</LINK>; <LINK REF="STD-Soininen-2007" TYPE="STUDY">Soininen 2007</LINK>) while low rating for quality was achieved by another three studies (<LINK REF="STD-H_x00fc_ll-1999" TYPE="STUDY">Hüll 1999</LINK>; <LINK REF="STD-Jhee-2004" TYPE="STUDY">Jhee 2004</LINK>; <LINK REF="STD-Scharf-1999" TYPE="STUDY">Scharf 1999</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-01-02 08:52:07 +0000" MODIFIED_BY="[Empty name]">
<P>There were 2 studies by <LINK REF="STD-Beck-2000" TYPE="STUDY">Beck 2000</LINK> and <LINK REF="STD-Taylor-1999" TYPE="STUDY">Taylor 1999</LINK> that met all inclusion criteria, but data could not be retrieved and the authors could not be contacted. Inability to include this unpublished data could have led to publication bias as the articles might not be published due to the nature and direction of the results. However, for this review thorough search of  multiple databases was performed and is expected to have identified all registered trials and possible unpublished articles.</P>
<SUBSECTION>
<HEADING LEVEL="3">Duplicate publication bias</HEADING>
<P>There were 15 studies in this review that were found to be repetitive or overlapped substantially with the included studies. It was crucial to identify all redundant and multiple publication as it can lead to overestimation of intervention effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Location bias</HEADING>
<P>It was found that trials published in low or non-impact factor journals were more likely to report significant results than those published in high-impact journals and that the quality of the trials was also associated with the journal of publication. In this systematic review, high risk of bias studies such as <LINK REF="STD-Zhou-2004b" TYPE="STUDY">Zhou 2004b</LINK>, <LINK REF="STD-H_x00fc_ll-1999" TYPE="STUDY">Hüll 1999</LINK> and <LINK REF="STD-Scharf-1999" TYPE="STUDY">Scharf 1999</LINK> tended to provided more significant positive outcome toward intervention group than those of low risk.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Language bias</HEADING>
<P>Reviews have often been exclusively based on studies published in English. Although the number of systematic reviews that restricted their search to studies reported in English had been decreased from 72% to 16%, it remained a challenge of the review process. In this review there was no language restriction which resulted in including 2 Chinese language studies. Although no total translation for the two Chinese language studies was done, data was extracted using a translation sheet from Cochrane as shown in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>. The process was done to help reduce language bias in the review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome reporting bias</HEADING>
<P>Of all included studies only one <LINK REF="STD-H_x00fc_ll-1999" TYPE="STUDY">Hüll 1999</LINK> did not report all stated outcomes. A reason for this may have been because the data was presented in an abstract form. For the remainder of the included studies, at least the stated primary outcomes were reported. For Jhee 2002, the ADAScog was not reported and data could not be retrieved although the author could be contacted. For side effects, <LINK REF="STD-Soininen-2007" TYPE="STUDY">Soininen 2007</LINK> study only reported side effects where more than 10% of participants complained. Hence, less common side effects were not reported. </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Selection bias</HEADING>
<P>In <LINK REF="STD-Soininen-2007" TYPE="STUDY">Soininen 2007</LINK> study the intervention group included higher number of subjects with pre-existing hypertension, diabetes and heart bypass. Hence, in this sponsored study the results obtained as far as side effects are concerned need to be interpreted with caution.</P>
</SUBSECTION>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-01-07 10:49:09 +0000" MODIFIED_BY="[Empty name]">
<P>Results from cross-sectional, cohort and case-control studies tended to be positive toward the use of NSAIDs in AD (Imbimbo 2004; <LINK REF="REF-In_x0027_t-Veld-2001" TYPE="REFERENCE">In't Veld 2001</LINK>; <LINK REF="STD-Landi-2003" TYPE="STUDY">Landi 2003</LINK>; <LINK REF="REF-McGeer-1996" TYPE="REFERENCE">McGeer 1996</LINK>; <LINK REF="REF-Rich-1995" TYPE="REFERENCE">Rich 1995</LINK>). There was also evidence from a systematic review that people who took NSAIDs had a lower risk of developing AD (<LINK REF="REF-Etminan-2003" TYPE="REFERENCE">Etminan 2003</LINK>). Theoretically, aspirin, steroid and NSAIDs should be able to decrease inflammatory process (<LINK REF="REF-Aisen-1994" TYPE="REFERENCE">Aisen 1994</LINK>; <LINK REF="REF-Aisen-1996" TYPE="REFERENCE">Aisen 1996</LINK>; <LINK REF="REF-Aisen-1998" TYPE="REFERENCE">Aisen 1998</LINK>; <LINK REF="REF-Harris-2002" TYPE="REFERENCE">Harris 2002</LINK>; <LINK REF="REF-Ho-1999" TYPE="REFERENCE">Ho 1999</LINK>; <LINK REF="REF-McGeer-1989" TYPE="REFERENCE">McGeer 1989</LINK>; <LINK REF="REF-Pasinetti-1998" TYPE="REFERENCE">Pasinetti 1998</LINK>; <LINK REF="REF-Thomas-2001" TYPE="REFERENCE">Thomas 2001</LINK>)<SUP> </SUP>which in turn would help improve AD.</P>
<P>In this systematic review, all three classes of drug were found to be associated with more side effects than placebo. The selective COX-2 inhibitor group experienced more hypertension and heart problems. Patients treated with NSAIDs, particularly COX-2 inhibitors had a higher death rate than the placebo group.</P>
<P>In patients with osteoarthritis and rheumatoid arthritis, selective COX-2 inhibitors have been associated with fewer gastrointestinal side effects than traditional NSAIDs (<LINK REF="REF-Deek-2002" TYPE="REFERENCE">Deek 2002</LINK>). Among the AD patients studied, gastrointestinal side effects occurred at a similar rate in both groups for AD.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-01-02 07:43:03 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-12-07 15:15:55 +0000" MODIFIED_BY="[Empty name]">
<P>There no evidence to support the use of aspirin, steroidal or NSAIDs (both traditional NSAIDs and selective COX-2 inhibitors) in AD. None of the assessed drugs can be recommended for the treatment of AD.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-01-02 07:43:03 +0000" MODIFIED_BY="[Empty name]">
<P>The results of this review show that currently available evidence does not support the use of aspirin, steroid and NSAIDs (traditional NSAIDs and COX-2 inhibitors) for treating AD. These results are not in line with the majority of epidemiological data supporting a protective role for anti-inflammatories in the development of cognitive impairment. However, all of the selected studies were of relatively short duration and in symptomatic people with well established disease. As it is now widely accepted that inflammatory processes contribute to the pathogenesis of AD, future clinical trials need to assess a prophylactic role for anti-inflammatories. Participants should include those with Mild cognitive impairment and those with normal cognition but with evidence of early disease pathology such as amyloid deposits as assessed on Pet imaging and tau/amyloid ratio in the cerebrospinal fluid. Agents used should not be restricted to COX-2 inhibitors but need to include traditional NSAIDs as well. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-01-09 10:52:29 +0000" MODIFIED_BY="[Empty name]">
<P>The authors wish to thank the consumer editor, Lynne Ramsay and Ruth Chandler, for their helpful comments. We wish to acknowledge the contribution of Rebecca Quinn as the writer of the protocol of this review. We also wish to thank Dr. Helen Collins. We want to express our thanks for the support of the Cochrane dementia and cognitive improvement group for their help coordinating this project.</P>
<P>We thank Dr. Wanruchada Katchamart, Dr. Paula A. Rochon, Dr. Sunila Kalkar and Wei Wu for their practical advice for the review. We also thank Wei Wu for extracting data and filling the translation sheet for the 2 Chinese studies. We thank Ms. Reem Malouf for statistical advice, Dr. Kittphon Nagaviroj for the PDF file for full text assessment form and Inez Kost and Rita Shaughnessy, the librarians at University of Toronto who helped with the article findings and search term respectively.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-12-07 15:15:19 +0000" MODIFIED_BY="[Empty name]">
<P>All authors declare no conflict of interest in this research project.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-12-12 10:58:31 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>DJ:</B> Wrote, coordinated, searched and selected trials for inclusion in this review. Also extracted, interpreted and entered data on to RevMan.</P>
<P>
<B>MI and NT</B>: contributed to trial searches, obtained copies of trial reports and assessed trials for inclusion/exclusion. They also were involved in data extraction and interpretation, and providing general advice on the review</P>
<P>
<B>JMcC</B>: contributed to design of analysis, data interpretation and drafting of review</P>
<P>
<B>Contact editors</B>: Leon Flicker and Gordon Wilcock<BR/>
<B>Consumer editor:</B> Lynne Ramsay</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-01-02 08:55:35 +0000" MODIFIED_BY="[Empty name]">
<P>1) Background about steroidal anti-inflammatory drugs was added in the review.</P>
<P>2) Inclusion criteria was adjusted to include any types of RCT and not only double-blinded</P>
<P>3) Two reviewers (DJ, MI) instead of 3 reviewers independently examined the titles and abstracts of the trials identified in the search and considered them for inclusion according to the pre-determined eligibility criteria. Any disparity was resolved by retrieval of the cited articles and further discussion with the third reviewer (NT).</P>
<P>4) Review topic was changed from aspirin and anti-inflammatory agents for Alzheimer&#8217;s disease to aspirin, steroidal and non-steroidal anti-inflammatory agents for Alzheimer&#8217;s disease.</P>
<P>5) Data was not extracted independently by two authors. The first author extracted the data and this was followed by verification by a second author.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-01-11 10:31:56 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-01-11 10:31:56 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aisen-2000a" MODIFIED="2012-01-07 12:04:24 +0000" MODIFIED_BY="[Empty name]" NAME="Aisen 2000a" YEAR="2000">
<REFERENCE MODIFIED="2012-01-07 12:04:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al</AU>
<TI>A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>3</NO>
<PG>588-93</PG>
<IDENTIFIERS MODIFIED="2012-01-07 12:04:24 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aisen-2002a" MODIFIED="2012-01-07 12:04:10 +0000" MODIFIED_BY="[Empty name]" NAME="Aisen 2002a" YEAR="2002">
<REFERENCE MODIFIED="2012-01-07 12:04:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisen PS, Schmeidler J, Pasinetti GM</AU>
<TI>Randomized pilot study of nimesulide treatment in Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>58</VL>
<NO>7</NO>
<PG>1050-4</PG>
<IDENTIFIERS MODIFIED="2012-01-02 08:56:07 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aisen-2003a" MODIFIED="2012-01-07 12:03:58 +0000" MODIFIED_BY="[Empty name]" NAME="Aisen 2003a" YEAR="2003">
<REFERENCE MODIFIED="2012-01-07 12:03:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al</AU>
<TI>Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>21</NO>
<PG>2819-26</PG>
<IDENTIFIERS MODIFIED="2012-01-02 08:56:14 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bentham-2008" MODIFIED="2012-01-07 12:03:43 +0000" MODIFIED_BY="[Empty name]" NAME="Bentham 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 12:03:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bentham P, Gray R, Sellwood E, Hills R, Crome P, Raftery J</AU>
<TI>Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial</TI>
<SO>Lancet Neurology</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>1</NO>
<PG>41-9</PG>
<IDENTIFIERS MODIFIED="2012-01-02 08:56:28 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Jong-2008" MODIFIED="2012-01-07 12:03:34 +0000" MODIFIED_BY="[Empty name]" NAME="De Jong 2008" YEAR="">
<REFERENCE MODIFIED="2012-01-07 12:03:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Jong D, Jansen R, Hoefnagels W, Jellesma-Eggenkamp M, Verbeek M, Borm G, et al</AU>
<TI>No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial</TI>
<SO>PLoS ONE</SO>
<YR>2008</YR>
<VL>3</VL>
<PG>e1475</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-H_x00fc_ll-1999" MODIFIED="2012-01-07 12:02:32 +0000" MODIFIED_BY="[Empty name]" NAME="Hüll 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-01-07 12:02:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hüll M, Bauer J</AU>
<TI>Treatment with the non-steroidal anti-inflammatory drug piroxicam-B-cyclodextrin in Alzheimer's disease</TI>
<SO>Ninth Congress of the International Psychogeriatric Association, August 15-20, 1999, Vancouver Convention &amp; Exhibition Centre Vancouver, British Columbia, Canada</SO>
<YR>1999</YR>
<PG>107</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jhee-2004" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Jhee 2004" YEAR="2002">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jhee SS, Frackiewicz E, Tolbert D, Sainati S, Karim A, Zolnouni PP, et al</AU>
<TI>A Pharmacokinetic, Pharmacodynamic, and Safety Study of Celecoxib in Subjects with Probable Alzheimer&#8217;s Disease</TI>
<SO>Clinical Research and Regulatory Affairs</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>1</NO>
<PG>49-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pasqualetti-2009" MODIFIED="2012-01-07 12:00:03 +0000" MODIFIED_BY="[Empty name]" NAME="Pasqualetti 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-01-07 12:00:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pasqualetti P, Bonomini C, Dal Forno G, Paulon L, Sinforiani E, Marra C, et al</AU>
<TI>A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease</TI>
<SO>Aging Clinical &amp; Experimental Research</SO>
<YR>2009</YR>
<VL>21</VL>
<NO>2</NO>
<PG>102-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reines-2004" MODIFIED="2012-01-02 09:06:07 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Reines 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-02 09:06:07 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al</AU>
<TI>Rofecoxib - no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>62</VL>
<PG>66-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rogers-1993" MODIFIED="2012-01-07 11:59:43 +0000" MODIFIED_BY="[Empty name]" NAME="Rogers 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-01-07 11:59:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al</AU>
<TI>Clinical trial of indomethacin in Alzheimers disease</TI>
<SO>Neurology</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>8</NO>
<PG>1609-11</PG>
<MD>Note</MD>
<IDENTIFIERS MODIFIED="2012-01-02 09:05:07 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scharf-1999" MODIFIED="2012-01-07 11:59:32 +0000" MODIFIED_BY="[Empty name]" NAME="Scharf 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-01-07 11:59:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N</AU>
<TI>A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<PG>197-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soininen-2007" MODIFIED="2012-01-07 11:59:25 +0000" MODIFIED_BY="[Empty name]" NAME="Soininen 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-07 11:59:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soininen H, West C, Robbins J, Niculescu L</AU>
<TI>Long-term efficacy and safety of celecoxib in Alzheimer's disease</TI>
<SO>Dementia and Geriatric Cognitive Disorders</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>1</NO>
<PG>8-21</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:59:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2004a" MODIFIED="2012-01-02 09:07:04 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Zhou 2004a" YEAR="2004">
<REFERENCE MODIFIED="2012-01-02 09:06:46 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou BR, Xu ZQ, Kuang YF, Deng YH, Liu ZF</AU>
<TI>Effectiveness of polydrug therapy for senile dementia</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2004</YR>
<VL>8</VL>
<PG>1214-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-01-02 09:07:04 +0000" MODIFIED_BY="Darin   Jaturapatporn"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2004b" MODIFIED="2012-01-07 11:59:06 +0000" MODIFIED_BY="[Empty name]" NAME="Zhou 2004b" YEAR="2004">
<REFERENCE MODIFIED="2012-01-07 11:59:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou BR, Xu ZQ, Kuang YF, Deng YH, Qian CY</AU>
<TI>Curative effect of aspirin for postponing the development of Alzheimer's disease</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2004</YR>
<VL>8</VL>
<PG>3020-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-01-02 09:07:10 +0000" MODIFIED_BY="Darin   Jaturapatporn"/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-01-11 10:31:56 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ADAPT-2008" MODIFIED="2012-01-08 01:54:14 +0000" MODIFIED_BY="[Empty name]" NAME="ADAPT 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-08 01:54:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cognitive function over time in the Alzheimer's Disease Anti-Inflammatory Prevention trial (ADAPT)</AU>
<TI>Results of a randomized, controlled trial of naproxen and celecoxib</TI>
<SO>Archives of Neurology</SO>
<YR>2008</YR>
<VL>65</VL>
<NO>7</NO>
<PG>896-905</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aisen-1996a" MODIFIED="2012-01-08 03:15:45 +0000" MODIFIED_BY="[Empty name]" NAME="Aisen 1996a" YEAR="1996">
<REFERENCE MODIFIED="2012-01-07 11:58:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, et al</AU>
<TI>A pilot study of prednisone in Alzheimer's disease</TI>
<SO>Dementia</SO>
<YR>1996</YR>
<VL>7</VL>
<PG>201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aisen-2000b" MODIFIED="2012-01-08 02:30:05 +0000" MODIFIED_BY="[Empty name]" NAME="Aisen 2000b" YEAR="2000">
<REFERENCE MODIFIED="2012-01-07 11:56:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al</AU>
<TI>A randomized controlled trial of prednisone in Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<PG>588-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aisen-2000c" MODIFIED="2012-01-08 02:30:11 +0000" MODIFIED_BY="[Empty name]" NAME="Aisen 2000c" YEAR="2000">
<REFERENCE MODIFIED="2012-01-07 11:56:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisen PS</AU>
<TI>Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial</TI>
<SO>Acta Neurologica Scandinavica Supplement</SO>
<YR>2000</YR>
<VL>102</VL>
<PG>85-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aisen-2002b" MODIFIED="2012-01-08 02:30:22 +0000" MODIFIED_BY="[Empty name]" NAME="Aisen 2002b" YEAR="2002">
<REFERENCE MODIFIED="2012-01-07 11:56:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisen PS</AU>
<TI>Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease</TI>
<SO>Journal of Pain and Symptom Management</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>4 Suppl</NO>
<PG>S35-40</PG>
<IDENTIFIERS MODIFIED="2012-01-02 09:29:42 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aisen-2003b" MODIFIED="2012-01-08 02:30:29 +0000" MODIFIED_BY="[Empty name]" NAME="Aisen 2003b" YEAR="2003">
<REFERENCE MODIFIED="2012-01-07 11:55:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisen PS, Berg JD, Craft S, Peskind ER, Sano M, Teri L, et al</AU>
<TI>Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognition</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2003</YR>
<VL>28</VL>
<PG>113-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aisen-2008a" MODIFIED="2012-01-08 02:30:39 +0000" MODIFIED_BY="[Empty name]" NAME="Aisen 2008a" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 11:55:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, et al</AU>
<TI>Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial</TI>
<SO>Current Alzheimer Research</SO>
<YR>2008</YR>
<VL>5</VL>
<PG>73-82</PG>
<IDENTIFIERS MODIFIED="2012-01-02 09:32:00 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aisen-2008b" MODIFIED="2012-01-08 02:30:45 +0000" MODIFIED_BY="[Empty name]" NAME="Aisen 2008b" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 11:54:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, et al</AU>
<TI>Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial</TI>
<SO>Current Alzheimer Research</SO>
<YR>2008</YR>
<VL>5</VL>
<NO>1</NO>
<PG>73-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aizen-2005" MODIFIED="2012-01-07 11:54:43 +0000" MODIFIED_BY="[Empty name]" NAME="Aizen 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-07 11:54:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aizen E, Kagan G, Assy B, Iobel R, Bershadsky Y, Gilhar A</AU>
<TI>Effect of non-steroidal anti-inflammatory drugs on natural killer cell activity in patients with dementia</TI>
<SO>The Israel Medical Association Journal</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>2</NO>
<PG>78-81</PG>
<IDENTIFIERS MODIFIED="2012-01-02 09:32:52 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allain-2007" MODIFIED="2012-01-07 11:54:31 +0000" MODIFIED_BY="[Empty name]" NAME="Allain 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-07 11:54:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allain H, Bentue-Ferrer D, Akwa Y</AU>
<TI>Treatment of the mild cognitive impairment (MCI)</TI>
<SO>Human Psychopharmacology</SO>
<YR>2007</YR>
<VL>22</VL>
<PG>189-97</PG>
<IDENTIFIERS MODIFIED="2012-01-02 09:34:28 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anthony-2000a" MODIFIED="2012-01-07 11:52:59 +0000" MODIFIED_BY="[Empty name]" NAME="Anthony 2000a" YEAR="2000">
<REFERENCE MODIFIED="2012-01-07 11:52:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anthony JC, Breitner JC, Zandi PP, Meyer MR, Jurasova I, Norton MC, et al</AU>
<TI>Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>11</NO>
<PG>2066-71</PG>
<IDENTIFIERS MODIFIED="2012-01-02 09:47:24 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anthony-2000b" MODIFIED="2012-01-08 01:56:56 +0000" MODIFIED_BY="[Empty name]" NAME="Anthony 2000b" YEAR="2000">
<REFERENCE MODIFIED="2012-01-07 11:52:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anthony JC, Breitner JCS, Zandi PP, Meyer MR, Jurasova I, Norton MC, et al</AU>
<TI>Alzheimer disease: current therapy and future therapeutic strategies</TI>
<SO>Alzheimer Disease and Associated Disorders</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>Suppl 1</NO>
<PG>S11-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asthana-1999" MODIFIED="2012-01-07 11:52:25 +0000" MODIFIED_BY="[Empty name]" NAME="Asthana 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-01-07 11:52:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asthana S, Raffaele KC, Greig NH, Schapiro MB, Blackman MR, Soncrant TT</AU>
<TI>Neuroendocrine responses to intravenous infusion of physostigmine in patients with Alzheimer disease</TI>
<SO>Alzheimer Disease and Associated Disorders</SO>
<YR>1999</YR>
<VL>13</VL>
<PG>102-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baum-2008" MODIFIED="2012-01-07 11:52:09 +0000" MODIFIED_BY="[Empty name]" NAME="Baum 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 11:52:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, et al</AU>
<TI>Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>1</NO>
<PG>110-3</PG>
<IDENTIFIERS MODIFIED="2012-01-02 09:49:49 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beck-2000" MODIFIED="2012-01-08 02:04:01 +0000" MODIFIED_BY="[Empty name]" NAME="Beck 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-01-08 02:04:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Beck K</AU>
<TI>The safety and efficacy of an Investigational Drug (VIOXX) in Delaying the progression of Alzheimer's Disease</TI>
<SO>ClinicalTrials.gov</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2012-01-08 02:03:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-08 02:03:53 +0000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="NCT00006187"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belanoff-2002a" MODIFIED="2012-01-08 02:31:55 +0000" MODIFIED_BY="[Empty name]" NAME="Belanoff 2002a" YEAR="2002">
<REFERENCE MODIFIED="2009-02-23 23:17:53 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belanoff JK, Jurik J, Schatzberg LD, DeBattista C, Schatzberg AF</AU>
<TI>Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone</TI>
<SO>Journal of Molecular Neuroscience</SO>
<YR>2002</YR>
<VL>19</VL>
<PG>201-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belanoff-2002b" MODIFIED="2012-01-08 02:31:50 +0000" MODIFIED_BY="[Empty name]" NAME="Belanoff 2002b" YEAR="2002">
<REFERENCE MODIFIED="2012-01-07 11:51:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belanoff JK, Jurik J, Schatzberg LD, DeBattista C, Schatzberg AF</AU>
<TI>Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County study</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>6</NO>
<PG>880-886</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernardi-2000" MODIFIED="2012-01-07 11:50:49 +0000" MODIFIED_BY="[Empty name]" NAME="Bernardi 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-01-07 11:50:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bernardi F, Lanzone A, Cento RM, Spada RS, Pezzani I, Genazzani AD, et al</AU>
<TI>Allopregnanolone and dehydroepiandrosterone response to corticotropin-releasing factor in patients suffering from Alzheimer's disease and vascular dementia</TI>
<SO>European Journal of Endocrinology</SO>
<YR>2000</YR>
<VL>142</VL>
<PG>466-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bertozzi-1996" MODIFIED="2012-01-07 11:50:39 +0000" MODIFIED_BY="[Empty name]" NAME="Bertozzi 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-01-07 11:50:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bertozzi B, Barbisoni P, Franzoni S, Frisoni GB, Rozzini R, Trabucchi M</AU>
<TI>Association of chronic non-steroidal anti-inflammatory drugs use and cognitive decline in non-demented elderly patients admitted to a Geriatric Evaluation and Rehabilitation Unit</TI>
<SO>Archives of Gerontology and Geriatrics</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>1</NO>
<PG>71-9</PG>
<MD>Article</MD>
<IDENTIFIERS MODIFIED="2012-01-02 09:53:48 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Black-2006" MODIFIED="2012-01-07 11:50:26 +0000" MODIFIED_BY="[Empty name]" NAME="Black 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-07 11:50:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Black S, Wilcock GK, Haworth J, Hendrix S, Zavitz K, Christensen D, et al</AU>
<TI>Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>5</NO>
<PG>A347</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:50:21 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breitner-1995" MODIFIED="2012-01-07 11:50:11 +0000" MODIFIED_BY="[Empty name]" NAME="Breitner 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-01-07 11:50:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breitner JCS, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, et al</AU>
<TI>Delayed onset of Alzheimers disease with non-steroidal anti-inflammatory and histamine (H2) blocking drugs</TI>
<SO>Neurobiology of Aging</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>4</NO>
<PG>523-30</PG>
<MD>Article</MD>
<IDENTIFIERS MODIFIED="2012-01-02 09:55:59 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breitner-2000" MODIFIED="2012-01-08 02:42:20 +0000" MODIFIED_BY="[Empty name]" NAME="Breitner 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-01-08 02:15:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Breitner J</AU>
<TI>Randomized controlled trial of two non-steroidal anti-inflammatory drugs for prevention of Alzheimer's disease</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breitner-2009" MODIFIED="2012-01-08 02:42:26 +0000" MODIFIED_BY="[Empty name]" NAME="Breitner 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-05-01 10:16:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Breitner JCS, Haneuse SJPA, Walker R, Dublin S, Crane PK, Gray SL, et al</AU>
<TI>Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort</TI>
<SO>Neurology</SO>
<YR>2009</YR>
<VL>72</VL>
<NO>22</NO>
<PG>1899-905</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Browne-1999" MODIFIED="2012-01-02 10:01:51 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Browne 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-01-02 10:01:51 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Browne SM, Halligan PW, Wade DT, Taggart DP</AU>
<TI>Cognitive performance after cardiac operation: implications of regression toward the mean</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1999</YR>
<VL>117</VL>
<NO>3</NO>
<PG>481-5</PG>
<IDENTIFIERS MODIFIED="2012-01-02 10:01:30 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruce_x002d_Jones-1994" MODIFIED="2012-01-07 11:49:34 +0000" MODIFIED_BY="[Empty name]" NAME="Bruce-Jones 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-01-07 11:49:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruce-Jones PN, Crome P, Kalra L</AU>
<TI>Indomethacin and cognitive function in healthy elderly volunteers</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1994</YR>
<VL>38</VL>
<PG>45-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brunner-2006" MODIFIED="2012-01-07 11:49:22 +0000" MODIFIED_BY="[Empty name]" NAME="Brunner 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-07 11:49:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brunner R, Schaefer D, Hess K, Parzer P, Resch F, Schwab S</AU>
<TI>Effect of high-dose cortisol on memory functions</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2006</YR>
<VL>1071</VL>
<PG>434-7</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:49:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Budge-2000" MODIFIED="2012-01-07 11:49:13 +0000" MODIFIED_BY="[Empty name]" NAME="Budge 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-01-07 11:49:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Budge M</AU>
<TI>A pilot study for the VITAL trial (Vitamins and Aspirin for the Treatment of Dementia)</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2012-01-07 11:49:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bullock-2004" MODIFIED="2012-01-07 11:48:58 +0000" MODIFIED_BY="[Empty name]" NAME="Bullock 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-07 11:48:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bullock R</AU>
<TI>DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled trial</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>62</VL>
<NO>6</NO>
<PG>1030</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bussiere-2005" MODIFIED="2012-01-02 10:05:41 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Bussiere 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-02 10:05:41 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bussiere M, Wiebe S</AU>
<TI>Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-to-severe dementia</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2005</YR>
<VL>53</VL>
<NO>11</NO>
<PG>1921-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canigueral-2008" MODIFIED="2012-01-02 10:06:59 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Canigueral 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-02 10:06:59 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canigueral S, Tschopp R, Ambrosetti L, Vignutelli A, Scaglione F, Petrini O</AU>
<TI>Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis</TI>
<SO>Circulation</SO>
<YR>2008</YR>
<VL>117</VL>
<NO>16</NO>
<PG>2104-2113</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2005" MODIFIED="2012-01-02 10:10:43 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Chang 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-02 10:10:43 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang J, Wei WS, Li YJ</AU>
<TI>A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type</TI>
<SO>Current Alzheimer Research</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>5</NO>
<PG>541-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-2003a" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Clarke 2003a" YEAR="2003">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke R, Harrison G, Richards S</AU>
<TI>Effect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia</TI>
<SO>Journal of Internal Medicine</SO>
<YR>2003</YR>
<VL>254</VL>
<NO>1</NO>
<PG>67-75</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:48:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clostre-1999" MODIFIED="2012-01-07 11:48:27 +0000" MODIFIED_BY="[Empty name]" NAME="Clostre 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-01-07 11:48:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clostre F</AU>
<TI>Ginkgo biloba extract (EGb 761) a state of art at the dawn of the year 2000</TI>
<SO>Annales Pharmaceutiques Francaises</SO>
<YR>1999</YR>
<VL>57</VL>
<NO>Suppl 1</NO>
<PG>1S8-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diener-2007" MODIFIED="2012-01-07 11:47:48 +0000" MODIFIED_BY="[Empty name]" NAME="Diener 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-07 11:47:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diener HC, Sacco R, Yusuf S</AU>
<TI>Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: The prevention regimen for effectively avoiding second strokes trial (PRoFESS)</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2007</YR>
<VL>23</VL>
<NO>5-6</NO>
<PG>368-80</PG>
<MD>Article</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:47:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diener-2008" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Diener 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al</AU>
<TI>Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study</TI>
<SO>Lancet Neurology</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>10</NO>
<PG>875-84</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:47:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doraiswamy-1996" MODIFIED="2012-01-07 11:46:07 +0000" MODIFIED_BY="[Empty name]" NAME="Doraiswamy 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-01-07 11:46:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doraiswamy PM, Krishen A, Stallone F, Martin WL, Potts NL, Metz A, et al</AU>
<TI>NSAIDs and cognition in Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>4</NO>
<PG>1194</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:46:04 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisk-2000" MODIFIED="2012-01-07 11:45:51 +0000" MODIFIED_BY="[Empty name]" NAME="Fisk 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-01-07 11:45:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Fisk J</AU>
<TI>AD2000, a reliable assessment of the efficacy and safety of donepezil and aspirin in Alzheimer's Disease</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Forssell-1989" MODIFIED="2012-01-07 11:45:42 +0000" MODIFIED_BY="[Empty name]" NAME="Forssell 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-01-07 11:45:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forssell LG, Sjokvist B, Winblad B</AU>
<TI>Early stages of late onset Alzheimer's disease III Double blind treatment with choline chloride and lecithin with and without L-dopa and L-tryptophan, alternatively placebo</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1989</YR>
<VL>79</VL>
<PG>43-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fotuhi-2008" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Fotuhi 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fotuhi M, Zandi PP, Hayden KM, Khachaturian AS, Szekely CA, Wengreen H, et al</AU>
<TI>Better cognitive performance in elderly taking antioxidant vitamins E and C supplements in combination with nonsteroidal anti-inflammatory drugs: the Cache County Study</TI>
<SO>Alzheimer's and Dementia</SO>
<YR>2008</YR>
<VL>4</VL>
<NO>3</NO>
<PG>223-7</PG>
<IDENTIFIERS MODIFIED="2012-01-02 10:23:46 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geldmacher-2004" MODIFIED="2012-01-11 10:31:56 +0000" MODIFIED_BY="[Empty name]" NAME="Geldmacher 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-11 10:31:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geldmacher DS, Landreth GE</AU>
<TI>Pioglitazone In Alzheimer's disease: rationale and clinical trial design</TI>
<SO>NeuroBiology of Aging</SO>
<YR>2004</YR>
<VL>25</VL>
<PG>211</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomez_x002d_Isla-2008" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Gomez-Isla 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomez-Isla T, Blesa R, Boada M, Clarimon J, Del Ser T, Domenech G, et al</AU>
<TI>A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study</TI>
<SO>Alzheimer Disease &amp; Associated Disorders</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>1</NO>
<PG>21-9</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:44:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-2009" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Green 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al</AU>
<TI>Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2009</YR>
<VL>302</VL>
<NO>23</NO>
<PG>2557-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Group-2007" MODIFIED="2012-01-02 10:34:52 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Group 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-02 10:34:52 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Group AR, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, et al</AU>
<TI>Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial</TI>
<SO>Neurology</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>21</NO>
<PG>1800-8</PG>
<IDENTIFIERS MODIFIED="2012-01-02 10:34:49 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollander-1987" MODIFIED="2012-01-07 11:44:33 +0000" MODIFIED_BY="[Empty name]" NAME="Hollander 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-01-07 11:44:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollander E, Davidson M, Mohs RC, Horvath TB, Davis BM, Zemishlany Z, et al</AU>
<TI>RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects</TI>
<SO>Biological Psychiatry</SO>
<YR>1987</YR>
<VL>22</VL>
<PG>1067-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jackson-2005" MODIFIED="2012-01-02 10:39:16 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Jackson 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-02 10:39:16 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jackson S, Ham RJ, Wilkinson D</AU>
<TI>Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: A placebo-controlled study</TI>
<SO>Alzheimer Disease and Associated Disorders</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>1</NO>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs-2009" MODIFIED="2012-01-07 11:44:14 +0000" MODIFIED_BY="[Empty name]" NAME="Jacobs 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-01-07 11:44:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L</AU>
<TI>Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study</TI>
<SO>American Journal of Geriatric Pharmacotherapy</SO>
<YR>2009</YR>
<VL>7</VL>
<NO>3</NO>
<PG>159-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacoby-2002" MODIFIED="2012-01-02 07:45:35 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Jacoby 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-02 07:45:35 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="OTHER">
<AU>Jacoby RJ</AU>
<TI>A pilot study for the VITAL trial (Vitamins and Aspirin for the treatment of Dementia)</TI>
<SO>National Research Register</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jeong-2004" MODIFIED="2012-01-07 11:43:50 +0000" MODIFIED_BY="[Empty name]" NAME="Jeong 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-07 11:43:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeong YH, Woo RS, Park CH, Suh YH</AU>
<TI>Therapeutic potentials of mefenamic acid for the treatment of Alzheimer's disease</TI>
<SO>Neurobiology of Aging</SO>
<YR>2004</YR>
<VL>25</VL>
<PG>S589</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:43:45 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2008" MODIFIED="2012-01-07 11:43:37 +0000" MODIFIED_BY="[Empty name]" NAME="Jiang 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 11:43:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang Q, Heneka M, Landreth G</AU>
<TI>The role of peroxisome proliferator-activated receptor- (PPAR) in Alzheimer's disease: therapeutic implications</TI>
<SO>CNS Drugs</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>1</NO>
<PG>1-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jin-2008" MODIFIED="2012-01-07 11:43:24 +0000" MODIFIED_BY="[Empty name]" NAME="Jin 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 11:43:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jin D-Q, Sung J-Y, Hwang YK, Kwon, Kyoung J, Han S-H, et al</AU>
<TI>Dexibuprofen (s(+)-isomer ibuprofen) reduces microglial activation and impairments of spatial working memory induced by chronic lipopolysaccharide infusion</TI>
<SO>Pharmacology, Biochemistry and Behavior</SO>
<YR>2008</YR>
<VL>89</VL>
<NO>3</NO>
<PG>404-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kimball-2008" MODIFIED="2012-01-07 11:43:10 +0000" MODIFIED_BY="[Empty name]" NAME="Kimball 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 11:43:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kimball AB, Gold MH, Zib B, Davis MW</AU>
<TI>Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2008</YR>
<VL>59</VL>
<NO>3</NO>
<PG>448-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Landi-2003" MODIFIED="2012-01-07 11:42:13 +0000" MODIFIED_BY="[Empty name]" NAME="Landi 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-07 11:42:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landi F, Cesari M, Onder G, Russo A, Torre S, Bernabei R</AU>
<TI>Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients</TI>
<SO>Am J Geriatr Psychiatry</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>2</NO>
<PG>179-85</PG>
<IDENTIFIERS MODIFIED="2012-01-02 10:42:34 +0000" MODIFIED_BY="Joey Kwong"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laughlin-2006" MODIFIED="2012-01-07 11:42:03 +0000" MODIFIED_BY="[Empty name]" NAME="Laughlin 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-07 11:42:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laughlin M, Black SE, Wilcock GK, Haworth J, Hendrix S, Zavitz KH, et al</AU>
<TI>Efficacy and safety of MPC-7869 (R-flurbiprofen), a Selective AB42-Lowering Agent, in Alzheimer's disease (AD): results of a 12-month phase 2 trial and 1-year follow-on study</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2006</YR>
<VL>54</VL>
<NO>4</NO>
<PG>S7</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:41:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leblhuber-2004" MODIFIED="2009-02-24 02:46:49 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Leblhuber 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-02-24 02:46:49 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="OTHER">
<AU>Leblhuber F, Haller H, Steiner K, Fuchs D</AU>
<TI>DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled trial</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>62</VL>
<PG>1030</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leuchtenberger-2006" MODIFIED="2012-01-07 11:41:37 +0000" MODIFIED_BY="[Empty name]" NAME="Leuchtenberger 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-07 11:41:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leuchtenberger S, Beher D, Weggen S</AU>
<TI>Selective modulation of A beta 42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond</TI>
<SO>Current Pharmaceutical Design</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>33</NO>
<PG>4337-55</PG>
<MD>Review</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:41:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucca-1994" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Lucca 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucca U, Tettamanti M, Forloni G, Spagnoli A</AU>
<TI>Nonsteroidal antiinflammatory drug use in Alzheimer's disease</TI>
<SO>Biological Psychiatry</SO>
<YR>1994</YR>
<VL>36</VL>
<NO>12</NO>
<PG>854-6</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:41:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-2006" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Martin 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin BK, Breitner JCS, Evans D, Lyketsos CG, Meinert CL</AU>
<TI>Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's disease Anti-inflammatory Prevention Trial (ADAPT)</TI>
<SO>PLoS Clinical Trials</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>7</NO>
<PG>e33</PG>
<MD>Article</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:41:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-2008" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Martin 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, et al</AU>
<TI>Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib</TI>
<SO>Archives of Neurology</SO>
<YR>2008</YR>
<VL>65</VL>
<NO>7</NO>
<PG>896-905</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:40:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McIntyre-2006" MODIFIED="2012-01-07 11:40:12 +0000" MODIFIED_BY="[Empty name]" NAME="McIntyre 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-07 11:40:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McIntyre JA, Castaner J, Fernandez-Forner D</AU>
<TI>MPC-7869 - prostate cancer therapy - treatment of Alzheimer's dementia</TI>
<SO>Drugs of the Future</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>1</NO>
<PG>22-7</PG>
<MD>Article</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:39:57 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meinert-2009" MODIFIED="2012-01-07 11:39:49 +0000" MODIFIED_BY="[Empty name]" NAME="Meinert 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-01-07 11:39:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meinert CL, Mccaffrey LD, Breitner JCS, Adapt RG</AU>
<TI>Alzheimer's disease anti-inflammatory prevention trial: design, methods, and baseline results</TI>
<SO>Alzheimers &amp; Dementia</SO>
<YR>2009</YR>
<VL>5</VL>
<NO>2</NO>
<PG>93-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meinerta-2008" MODIFIED="2012-01-07 11:39:09 +0000" MODIFIED_BY="[Empty name]" NAME="Meinerta 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 11:39:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meinert CL, Breitner JCS</AU>
<TI>Triflusal versus aspirin for the prevention of stroke</TI>
<SO>Progress in Neurotherapeutics and Neuropsychopharmacology</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>1</NO>
<PG>13-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-1989" MODIFIED="2012-01-08 03:07:06 +0000" MODIFIED_BY="[Empty name]" NAME="Meyer 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-01-08 03:07:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J</AU>
<TI>Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1989</YR>
<VL>37</VL>
<NO>6</NO>
<PG>549-55</PG>
<IDENTIFIERS MODIFIED="2012-01-08 03:07:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-2002" MODIFIED="2012-01-07 11:37:58 +0000" MODIFIED_BY="[Empty name]" NAME="Meyer 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-07 11:37:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Meyer JS, Chowdhury MH, Quach M</AU>
<TI>Randomized clinical trial of daily aspirin therapy in multi-infarct dementia</TI>
<SO>2nd International Congress on Vascular dementia, January, Salzburg, Austria, 2002</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nawata-2002" MODIFIED="2012-01-07 11:37:43 +0000" MODIFIED_BY="[Empty name]" NAME="Nawata 2002" YEAR="">
<REFERENCE MODIFIED="2012-01-07 11:37:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nawata H, Yanase T, Goto K, Okabe T, Ashida K</AU>
<TI>An open-label pilot study comparing rivastigmine and low-dose aspirin for the treatment of symptoms specific to patients with subcortical vascular dementia</TI>
<SO>Current Therapeutic Research - Clinical and Experimental</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>7</NO>
<PG>443-458</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nourhashemi-1998" MODIFIED="2012-01-07 11:37:08 +0000" MODIFIED_BY="[Empty name]" NAME="Nourhashemi 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-01-07 11:37:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nourhashemi F, Ousset PJ, Reyes G, Micas M, Adoue D, Vellas BJ, et al</AU>
<TI>Non steroidal anti-inflammatory drugs in Alzheimer disease</TI>
<SO>Presse Medicale</SO>
<YR>1998</YR>
<VL>27</VL>
<PG>25-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Shea-2007" MODIFIED="2012-01-07 11:36:57 +0000" MODIFIED_BY="[Empty name]" NAME="O'Shea 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-07 11:36:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Shea TM, Washburn LK, Nixon PA, Goldstein DJ</AU>
<TI>Followup of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: Neurodevelopmental outcomes at 4 to 11 years of age</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>120</VL>
<NO>3</NO>
<PG>594-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pasinetti-2002" MODIFIED="2012-01-07 11:36:21 +0000" MODIFIED_BY="[Empty name]" NAME="Pasinetti 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-07 11:36:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pasinetti GM</AU>
<TI>Cyclooxygenase as a target for the antiamyloidogenic activities of nonsteroidal anti-inflammatory drugs in Alzheimer's disease</TI>
<SO>Neurosignals</SO>
<YR>2002</YR>
<VL>11</VL>
<NO>5</NO>
<PG>293-7</PG>
<MD>Article</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:36:21 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfizer-2004" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Pfizer 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pfizer [Sponsor]</AU>
<TI>A double-blind, randomized, placebo-controlled, comparative study of celecoxib (SC-58635) for the inhibition of progression of Alzheimer's disease</TI>
<SO>http://www.clinicalstudyresults.org/documents/company-study_76_0.pdf</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfizer-2005" MODIFIED="2012-01-07 11:35:07 +0000" MODIFIED_BY="[Empty name]" NAME="Pfizer 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-07 11:35:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pfizer [Sponsor]</AU>
<TI>A placebo-controlled evaluation of the long-term efficacy and safety of celecoxib (SC-58635) In Alzheimer&#8217;s disease</TI>
<SO>http://www.clinicalstudyresults.org/documents/company-study_76_1.pdf</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pomara-1985" MODIFIED="2009-02-24 17:43:52 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Pomara 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-02-24 17:43:52 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pomara N, Roberts R, Rhiew HB, Stanley M, Gershon S</AU>
<TI>Multiple, single-dose naltrexone administrations fail to effect overall cognitive functioning and plasma cortisol in individuals with probable Alzheimer's disease</TI>
<SO>Neurobiology of Aging</SO>
<YR>1985</YR>
<VL>6</VL>
<PG>233-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pomara-2006" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Pomara 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pomara N, Hernando RT, de la Pena CB, Sidtis JJ, Cooper TB, Ferris S</AU>
<TI>The effect of mifepristone (RU 486) on plasma cortisol in Alzheimer's disease</TI>
<SO>Neurochemical Research</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>5</NO>
<PG>585-8</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:33:36 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reid-2005" MODIFIED="2012-01-07 11:33:21 +0000" MODIFIED_BY="[Empty name]" NAME="Reid 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-07 11:33:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reid MS, Angrist B, Baker S, Woo C, Schwartz M, Montgomery A, et al</AU>
<TI>A placebo-controlled screening trial of celecoxib for the treatment of cocaine dependence</TI>
<SO>Addiction</SO>
<YR>2005</YR>
<VL>100</VL>
<PG>32-42</PG>
<MD>Article</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:33:21 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Relkin-2003" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Relkin 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Relkin NR, Reichman WE, Orazem J, McRae T</AU>
<TI>A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease</TI>
<SO>Dementia and Geriatric Cognitive Disorders</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>1</NO>
<PG>15-24</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:32:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sainati-2000" MODIFIED="2012-01-07 11:32:11 +0000" MODIFIED_BY="[Empty name]" NAME="Sainati 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-01-07 11:32:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sainati SM, Ingram DM, Talwalker S, Geis GS</AU>
<TI>Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease</TI>
<SO>Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5-8, Stockholm, Sweden</SO>
<YR>2000</YR>
<PG>180</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simon-1998" MODIFIED="2012-01-07 11:31:56 +0000" MODIFIED_BY="[Empty name]" NAME="Simon 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-01-07 11:31:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al</AU>
<TI>Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor - Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>9</NO>
<PG>1591-602</PG>
<MD>Article</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:31:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Small-1999" MODIFIED="2012-01-07 10:05:52 +0000" MODIFIED_BY="[Empty name]" NAME="Small 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-01-07 10:05:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Small GW</AU>
<TI>Anti-inflammatory treatment for age-associated memory impairment: a double-blind placebo-controlled trial</TI>
<SO>Alzheimer's Disease Education and Referral Center (ADEAR)</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Small-2008" MODIFIED="2012-01-07 10:05:10 +0000" MODIFIED_BY="[Empty name]" NAME="Small 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 10:05:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Small GW, Siddarth P, Silverman DHS, Ercoli LM, Miller KJ, Lavretsky H, et al</AU>
<TI>Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study</TI>
<SO>The American Journal of Geriatric Psychiatry</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>12</NO>
<PG>999-1009</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solomon-2008" MODIFIED="2012-01-07 10:05:02 +0000" MODIFIED_BY="[Empty name]" NAME="Solomon 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 10:05:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, et al</AU>
<TI>Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis</TI>
<SO>Circulation</SO>
<YR>2008</YR>
<VL>117</VL>
<NO>16</NO>
<PG>2104-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Souza_x002d_Talarico-2008" MODIFIED="2012-01-07 10:04:03 +0000" MODIFIED_BY="[Empty name]" NAME="Souza-Talarico 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 10:04:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Souza-Talarico JN, Caramelli P, Nitrini R, Chaves EC</AU>
<TI>Effect of cortisol levels on working memory performance in elderly subjects with Alzheimer's disease</TI>
<SO>Arquivos de Neuro-Psiquiatria</SO>
<YR>2008</YR>
<VL>66</VL>
<NO>3B</NO>
<PG>619-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steiger-1991" MODIFIED="2012-01-07 11:30:31 +0000" MODIFIED_BY="[Empty name]" NAME="Steiger 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-01-07 11:30:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steiger A, Guldner J, Knisatschek H, Rothe B, et al.</AU>
<TI>Effects of an ACTH/MSH(4-9) analog (HOE 427) on the sleep EEG and nocturnal hormonal secretion in humans</TI>
<SO>Peptides</SO>
<YR>1991</YR>
<VL>12</VL>
<NO>5</NO>
<PG>1007-1010</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stevenson-2004" MODIFIED="2012-01-07 11:30:48 +0000" MODIFIED_BY="[Empty name]" NAME="Stevenson 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-07 11:30:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stevenson DD</AU>
<TI>A pharmacokinetic, pharmacodynamic, and safety study of celecoxib in subjects with probable Alzheimer's disease</TI>
<SO>Clinical Research and Regulatory Affairs</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>1</NO>
<PG>49-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stewart-1997" MODIFIED="2009-02-24 17:49:39 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Stewart 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-02-24 17:49:39 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stewart WF, Kawas C, Corrada M, Metter EJ</AU>
<TI>Risk of Alzheimer's disease and duration of NSAID use</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>48</VL>
<PG>626-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stoppe-1996" MODIFIED="2012-01-07 11:30:11 +0000" MODIFIED_BY="[Empty name]" NAME="Stoppe 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-01-07 11:30:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stoppe G, Sandholzer H, Staedt J, Winter S, Kiefer J, Ruther E</AU>
<TI>Prescribing practice with cognition enhancers in outpatient care: Are there differences regarding type of dementia? Results of a representation survey in lower Saxony, Germany</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1996</YR>
<VL>29</VL>
<NO>4</NO>
<PG>150-155</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:30:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szekely-2008" MODIFIED="2012-01-08 02:49:19 +0000" MODIFIED_BY="[Empty name]" NAME="Szekely 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 11:30:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szekely CA, Green RC, Breitner JCS, Ostbye T, Beiser AS, Corrada MM, et al</AU>
<TI>No advantage of A beta(42)-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies</TI>
<SO>Neurology</SO>
<YR>2008</YR>
<VL>70</VL>
<NO>24</NO>
<PG>2291-8</PG>
<MD>Article</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:30:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szekely-2010" MODIFIED="2012-01-07 11:29:47 +0000" MODIFIED_BY="[Empty name]" NAME="Szekely 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-01-07 11:29:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szekely CA, Zandi PP</AU>
<TI>Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence</TI>
<SO>CNS and Neurological Disorders - Drug Targets</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>2</NO>
<PG>132-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-1999" MODIFIED="2012-01-07 11:28:52 +0000" MODIFIED_BY="[Empty name]" NAME="Taylor 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-01-07 11:28:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Taylor D</AU>
<TI>52 week double-blind, randomised, placebo-controlled comparative study of celecoxib (SC-58635) for the inhibition of progression of Alzheimers disease</TI>
<SO>National Research Register</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thal-2005" MODIFIED="2012-01-07 11:28:38 +0000" MODIFIED_BY="[Empty name]" NAME="Thal 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-07 11:28:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al</AU>
<TI>A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>6</NO>
<PG>1204-15</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:28:38 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsartsalis-2011" MODIFIED="2012-01-07 11:28:26 +0000" MODIFIED_BY="[Empty name]" NAME="Tsartsalis 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-01-07 11:28:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsartsalis S, Panagopoulos PK, Mironidou-Tzouveleki M</AU>
<TI>Non-cholinergic pharmacotherapy approaches to Alzheimer's disease: the use of non-steroidal anti-inflammatory drugs</TI>
<SO>CNS &amp; Neurological Disorders-Drug Targets</SO>
<YR>2011</YR>
<VL>10</VL>
<NO>1</NO>
<PG>133-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tuppo-2005" MODIFIED="2012-01-07 11:28:04 +0000" MODIFIED_BY="[Empty name]" NAME="Tuppo 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-07 11:28:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tuppo EE, Arias HR</AU>
<TI>The role of inflammation in Alzheimer's disease</TI>
<SO>International Journal of Biochemistry &amp; Cell Biology</SO>
<YR>2005</YR>
<VL>37</VL>
<NO>2</NO>
<PG>289-305</PG>
<MD>Review</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:28:04 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turini-2002" MODIFIED="2012-01-07 11:27:50 +0000" MODIFIED_BY="[Empty name]" NAME="Turini 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-07 11:27:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turini ME, Dubois RN</AU>
<TI>Cyclooxygenase-2: a therapeutic target</TI>
<SO>Annual Review of Medicine</SO>
<YR>2002</YR>
<VL>53</VL>
<PG>35-57</PG>
<MD>Review</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:27:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Usui-2006" MODIFIED="2012-01-07 11:27:19 +0000" MODIFIED_BY="[Empty name]" NAME="Usui 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-07 11:27:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Usui T</AU>
<TI>Pharmaceutical prospects of phytoestrogens</TI>
<SO>Endocrine Journal</SO>
<YR>2006</YR>
<VL>53</VL>
<NO>1</NO>
<PG>7-20</PG>
<MD>Review</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:27:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uttner-2005" MODIFIED="2012-01-07 11:27:04 +0000" MODIFIED_BY="[Empty name]" NAME="Uttner 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-07 11:27:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uttner I, Muller S, Zinser C, Maier M, Sussmuth S, Claus A, et al</AU>
<TI>Reversible impaired memory induced by pulsed methylprednisolone in patients with MS</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>11</NO>
<PG>1971-1973</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Niekerk-2001" MODIFIED="2009-02-24 17:53:40 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Van Niekerk 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-02-24 17:53:40 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Niekerk JK, Huppert FA, Herbert J</AU>
<TI>Salivary cortisol and DHEA: Association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2001</YR>
<VL>26</VL>
<PG>591-612</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Reekum-1999" MODIFIED="2012-01-07 11:26:03 +0000" MODIFIED_BY="[Empty name]" NAME="van Reekum 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-01-07 11:26:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Reekum R, Simard M, Cohen T</AU>
<TI>The prediction and prevention of Alzheimer's disease - towards a research agenda</TI>
<SO>Journal of Psychiatry &amp; Neuroscience</SO>
<YR>1999</YR>
<VL>24</VL>
<NO>5</NO>
<PG>413-30</PG>
<MD>Review</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:26:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Visser-2005" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Visser 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Visser PJ, Scheltens P, Verhey FR</AU>
<TI>Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2005</YR>
<VL>76</VL>
<NO>10</NO>
<PG>1348-54</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:25:47 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vlad-2008" MODIFIED="2012-01-07 11:25:28 +0000" MODIFIED_BY="[Empty name]" NAME="Vlad 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 11:25:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vlad SC, Miller DR, Kowall NW, Felson DT</AU>
<TI>Protective effects of NSAIDs on the development of Alzheimer disease</TI>
<SO>Neurology</SO>
<YR>2008</YR>
<VL>70</VL>
<NO>19</NO>
<PG>1672-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walker-2005" MODIFIED="2012-01-07 11:23:20 +0000" MODIFIED_BY="[Empty name]" NAME="Walker 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-07 11:23:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walker PC, Alrawi A, Mitchell JF, Regal RE, Khanderia U</AU>
<TI>Medication use as a risk factor for falls among hospitalized elderly patients</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>23</NO>
<PG>2495-9</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:23:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walther-2011" MODIFIED="2012-01-07 11:23:05 +0000" MODIFIED_BY="[Empty name]" NAME="Walther 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-01-07 11:23:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walther S, Schupbach B, Seifritz E, Homan P, Strik W</AU>
<TI>Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>2</NO>
<PG>256-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watson-2004" MODIFIED="2012-01-07 11:22:52 +0000" MODIFIED_BY="[Empty name]" NAME="Watson 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-07 11:22:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watson GS, Reger MA, Cholerton BA, Asthana S, Baker LD, Rhoads KW, et al</AU>
<TI>Rosiglitazone preserves cognitive functions in patients with early Alzheimer's disease</TI>
<SO>Neurobiology of Aging</SO>
<YR>2004</YR>
<VL>25</VL>
<PG>83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whitehouse-1998" MODIFIED="2012-01-07 11:22:21 +0000" MODIFIED_BY="[Empty name]" NAME="Whitehouse 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-01-07 11:22:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whitehouse PJ, Kittner B, Roessner M, Rossor M, Sano M, Thal L, et al</AU>
<TI>Clinical trial designs for demonstrating disease course altering effects in dementia</TI>
<SO>Alzheimer Disease and Associated Disorders</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>281-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Widimsky-2008" MODIFIED="2012-01-07 11:22:06 +0000" MODIFIED_BY="[Empty name]" NAME="Widimsky 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-07 11:22:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Widimsky P, Motovska Z, Simek S, Kala P, Pudil R, Holm F, et al</AU>
<TI>Clopidogrel pre-treatment in stable angina: for all patients &gt; 6 H before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial Prague-8</TI>
<SO>European Heart Journal</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>12</NO>
<PG>1495-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilcock-1999" MODIFIED="2009-02-24 17:54:56 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Wilcock 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-02-24 17:54:56 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="OTHER">
<AU>Wilcock GK</AU>
<TI>A pilot study for a large simple randomised trial to assess the effects of aspirin, anti-oxidant vitamins (C &amp; E) and folic acid and Vitamin B12 in patients with dementia</TI>
<SO>National Research Register</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilcock-2004" MODIFIED="2012-01-07 11:21:55 +0000" MODIFIED_BY="[Empty name]" NAME="Wilcock 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-07 11:21:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wilcock GK</AU>
<TI>MPC-7869 effect on cognitive function in Alzheimer's</TI>
<SO>National Research Register</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilcock-2006" MODIFIED="2012-01-07 11:21:40 +0000" MODIFIED_BY="[Empty name]" NAME="Wilcock 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-07 11:21:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilcock GK</AU>
<TI>Disease-modifying treatments for Alzheimer's disease: a perspective based on experience with r-flurbiprofen</TI>
<SO>Alzheimer's and Dementia</SO>
<YR>2006</YR>
<VL>2</VL>
<PG>150-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilcock-2008" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Wilcock 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA</AU>
<TI>Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial</TI>
<SO>Lancet Neurology</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>6</NO>
<PG>483-93</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:21:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-2004" MODIFIED="2012-01-07 11:20:53 +0000" MODIFIED_BY="[Empty name]" NAME="Williams 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-07 11:20:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams B</AU>
<TI>Protection against stroke and dementia: an update on the latest clinical trial evidence</TI>
<SO>Current Hypertension Reports</SO>
<YR>2004</YR>
<VL>6</VL>
<NO>4</NO>
<PG>307-13</PG>
<MD>Article</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:20:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Windisch-2000" MODIFIED="2012-01-08 03:12:56 +0000" MODIFIED_BY="[Empty name]" NAME="Windisch 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-01-08 03:12:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Windisch M</AU>
<TI>Approach towards an integrative drug treatment of Alzheimer's disease</TI>
<SO>Journal of Neural Transmission, Supplement</SO>
<YR>2000</YR>
<VL>59</VL>
<PG>301-13</PG>
<MD>Review</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:20:32 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wisloff-1996" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Wisloff 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wisloff F, Hjorth M, Kaasa S, Westin J</AU>
<TI>Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group</TI>
<SO>British Journal of Haematology</SO>
<YR>1996</YR>
<VL>94</VL>
<NO>2</NO>
<PG>324-32</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:20:16 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolkowitz-2003" MODIFIED="2012-01-07 11:19:53 +0000" MODIFIED_BY="[Empty name]" NAME="Wolkowitz 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-07 11:19:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolkowitz OM, Kramer JH, Reus VI, Costa MM, Yaffe K, Walton P, et al</AU>
<TI>DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>60</VL>
<PG>1071-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wollheim-2000" MODIFIED="2012-01-07 11:19:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wollheim 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-01-07 11:19:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wollheim FA</AU>
<TI>Selective Cox-2 inhibition in man - therapeutic breakthrough or cosmetic advance?</TI>
<SO>Rheumatology</SO>
<YR>2000</YR>
<VL>39</VL>
<NO>9</NO>
<PG>935-8</PG>
<MD>Editorial Material</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:19:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Woodward-2002" MODIFIED="2012-01-07 11:19:28 +0000" MODIFIED_BY="[Empty name]" NAME="Woodward 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-07 11:19:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Woodward MC</AU>
<TI>The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease</TI>
<SO>Lancet Neurology</SO>
<YR>2002</YR>
<VL>1</VL>
<NO>5</NO>
<PG>279-284</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xia-2007" MODIFIED="2012-01-07 11:19:14 +0000" MODIFIED_BY="[Empty name]" NAME="Xia 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-07 11:19:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xia W, Han E</AU>
<TI>Follow-up of a randomized, placebo-controlled trial of dexamethasone to decrease the duration of ventilator dependency in very low birth weight infants: neurodevelopmental outcomes at 4 to 11 years of age</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>120</VL>
<NO>3</NO>
<PG>594-602</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yaqub-1999" MODIFIED="2012-01-07 11:19:02 +0000" MODIFIED_BY="[Empty name]" NAME="Yaqub 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-01-07 11:19:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yaqub BA</AU>
<TI>New horizons in management of Alzheimer's disease</TI>
<SO>Saudi Medical Journal</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>9</NO>
<PG>671-7</PG>
<MD>Review</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:19:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yip-2005" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" NAME="Yip 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yip AG, Green RC, Huyck M, Cupples LA, Farrer LA</AU>
<TI>Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study</TI>
<SO>BMC Geriatriatrics</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>2</PG>
<IDENTIFIERS MODIFIED="2012-01-07 11:18:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Young-1999" MODIFIED="2009-02-24 17:56:41 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Young 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-02-24 17:56:41 +0000" MODIFIED_BY="Darin   Jaturapatporn" PRIMARY="NO" TYPE="OTHER">
<AU>Young AH, Sahakian BJ, Robbins TW, Cowen PJ</AU>
<TI>The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers</TI>
<SO>Psychopharmacology</SO>
<YR>1999</YR>
<VL>145</VL>
<PG>260-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zandi-2005" MODIFIED="2012-01-07 11:18:22 +0000" MODIFIED_BY="[Empty name]" NAME="Zandi 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-07 11:18:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zandi P</AU>
<TI>Pharmacological strategies for prevention of Alzheimer's disease: the epidemiologic evidence</TI>
<SO>Research and Practice in Alzheimer's Disease</SO>
<YR>2005</YR>
<VL>10</VL>
<PG>200-4</PG>
<MD>Review</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:18:19 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zaragoza-2005" MODIFIED="2012-01-07 11:18:00 +0000" MODIFIED_BY="[Empty name]" NAME="Zaragoza 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-07 11:18:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zaragoza JL</AU>
<TI>Attitude before COX-2 selective inhibitors</TI>
<SO>Revista De Investigacion Clinica</SO>
<YR>2005</YR>
<VL>57</VL>
<NO>1</NO>
<PG>6-12</PG>
<MD>Editorial Material</MD>
<IDENTIFIERS MODIFIED="2012-01-07 11:17:58 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zerovnik-2010" MODIFIED="2011-05-01 10:18:20 +0100" MODIFIED_BY="[Empty name]" NAME="Zerovnik 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-05-01 10:18:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zerovnik E</AU>
<TI>Protein conformational pathology in Alzheimer's and other neurodegenerative diseases; new targets for therapy</TI>
<SO>Current Alzheimer Research</SO>
<YR>2010</YR>
<VL>7</VL>
<NO>1</NO>
<PG>74-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhai-2010" MODIFIED="2012-01-07 11:17:40 +0000" MODIFIED_BY="[Empty name]" NAME="Zhai 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-01-07 11:17:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhai Q-J, Yue X-Y, Hong Z, Xu G-L, Liu X-F</AU>
<TI>Efficacy observation of batroxobin for treatment of vascular cognitive impairment</TI>
<SO>Chinese Journal of Cerebrovascular Diseases</SO>
<YR>2010</YR>
<VL>7</VL>
<NO>2</NO>
<PG>73-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziebell-2010" MODIFIED="2012-01-07 11:17:32 +0000" MODIFIED_BY="[Empty name]" NAME="Ziebell 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-01-07 11:17:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ziebell JM, Morganti-Kossmann MC</AU>
<TI>Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury</TI>
<SO>Neurotherapeutics</SO>
<YR>2010</YR>
<VL>7</VL>
<NO>1</NO>
<PG>22-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-02-02 21:35:26 +0000" MODIFIED_BY="Darin   Jaturapatporn"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aisen-1994" NAME="Aisen 1994" TYPE="JOURNAL_ARTICLE">
<AU>Aisen</AU>
<TI>Inflammatory mechanisms in Alzheimer's disease: Implications for therapy</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>151</VL>
<PG>1105-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aisen-1996" MODIFIED="2009-10-04 03:54:24 +0100" MODIFIED_BY="Darin   Jaturapatporn" NAME="Aisen 1996" TYPE="JOURNAL_ARTICLE">
<AU> Aisen PS, Marin D, Altstiel L</AU>
<TI>A pilot study of prednisone in Alzheimer's disease</TI>
<SO>Dementia</SO>
<YR>1996</YR>
<VL>7</VL>
<PG>201-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aisen-1998" MODIFIED="2012-01-02 08:54:47 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Aisen 1998" TYPE="JOURNAL_ARTICLE">
<AU>Aisen PS, Pasinetti GM</AU>
<TI>Glucocorticoids in Alzheimer's disease: the story so far</TI>
<SO>Drugs Aging</SO>
<YR>1998</YR>
<VL>12</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1995" MODIFIED="2012-01-02 08:02:31 +0000" MODIFIED_BY="Joey Kwong" NAME="APA 1995" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders</SO>
<YR>1995</YR>
<EN>IV</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Avramovich-2002" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Avramovich 2002" TYPE="JOURNAL_ARTICLE">
<AU>Avramovich Y, Amit T, Youdim MB</AU>
<TI>Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein</TI>
<SO>Journal of Biological Chemistry</SO>
<YR>2002</YR>
<VL>277</VL>
<NO>35</NO>
<PG>31466-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bazan-2009" MODIFIED="2012-01-02 10:47:59 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Bazan 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bazan NG</AU>
<TI>Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease</TI>
<SO>Journal of Lipid Research</SO>
<YR>2009</YR>
<VL>50</VL>
<PG>S400-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blasko-2001" MODIFIED="2012-01-02 10:47:33 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Blasko 2001" TYPE="JOURNAL_ARTICLE">
<AU>Blasko I et al</AU>
<TI>Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells</TI>
<SO>Neurobiology of Disease</SO>
<YR>Dec 2001</YR>
<VL>8</VL>
<NO>6</NO>
<PG>1094-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Citron-1992" MODIFIED="2009-10-04 03:54:07 +0100" MODIFIED_BY="Darin   Jaturapatporn" NAME="Citron 1992" TYPE="JOURNAL_ARTICLE">
<AU>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ</AU>
<TI>Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production</TI>
<SO>Nature</SO>
<YR>1992</YR>
<VL>360</VL>
<NO>6405</NO>
<PG>672-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deek-2002" MODIFIED="2012-01-02 10:47:42 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Deek 2002" TYPE="JOURNAL_ARTICLE">
<AU>Deeks JJ, Smith LA, Bradley MD</AU>
<TI>Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials</TI>
<SO>BMJ</SO>
<YR>2002</YR>
<VL>325</VL>
<PG>619</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Etminan-2003" MODIFIED="2009-10-04 03:55:26 +0100" MODIFIED_BY="Darin   Jaturapatporn" NAME="Etminan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Etminan M, Gill S, Samii A</AU>
<TI>Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies </TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>128</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fiebich-1997" MODIFIED="2012-01-11 10:24:02 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Fiebich 1997" TYPE="JOURNAL_ARTICLE">
<AU>Fiebich BL et al</AU>
<TI>Prostaglandin E2 Induces Interleukin-6 Synthesis in Human Astrocytoma cells</TI>
<SO>Journal of Neurochemistry</SO>
<YR>1997</YR>
<VL>68</VL>
<NO>2</NO>
<PG>704-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haass-1994" MODIFIED="2012-01-02 10:46:59 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Haass 1994" TYPE="JOURNAL_ARTICLE">
<AU>Haass C, Hung AY, Selkoe DJ, Teplow DB</AU>
<TI>Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor</TI>
<SO>Journal of Biological Chemistry</SO>
<YR>1994</YR>
<VL>269</VL>
<NO>26</NO>
<PG>17741-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harris-2002" MODIFIED="2009-02-23 01:43:49 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Harris 2002" TYPE="JOURNAL_ARTICLE">
<AU>Harris JR</AU>
<TI>In vitro fibrillogenesis of the amyloid B1-42 peptide: cholesterol potentiation and aspirin inhibition</TI>
<SO>Micron</SO>
<YR>2002</YR>
<VL>33</VL>
<PG>609-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hebert-2003" MODIFIED="2012-01-02 10:46:41 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Hebert 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hebert LE, Scherr PA, Bienias JL, et al</AU>
<TI>Alzheimer disease in the US population: prevalence estimates using the 2000 census</TI>
<SO>Archives of Neurology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>8</NO>
<PG>1119-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ho-1999" MODIFIED="2012-01-02 10:46:21 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Ho 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM.</AU>
<TI>Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease</TI>
<SO>Journal of Neuroscience Research</SO>
<YR>1999</YR>
<VL>57</VL>
<PG>295-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-In_x0027_t-Veld-2001" MODIFIED="2012-01-07 12:06:02 +0000" MODIFIED_BY="[Empty name]" NAME="In't Veld 2001" TYPE="JOURNAL_ARTICLE">
<AU>In't Veld</AU>
<TI>Non-steroidal anti-inflammatory drugs and the risk of Alzheimer's disease</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<PG>1515-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joachim-1992" MODIFIED="2012-01-07 12:06:11 +0000" MODIFIED_BY="[Empty name]" NAME="Joachim 1992" TYPE="JOURNAL_ARTICLE">
<AU>Joachim CL, Selkoe DJ</AU>
<TI>The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease</TI>
<SO>Alzheimer Disease &amp; Associated Disorders</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>1</NO>
<PG>7-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jorm-2003" MODIFIED="2009-02-23 02:21:08 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Jorm 2003" TYPE="JOURNAL_ARTICLE">
<AU>Jorm</AU>
<TI>The incidence of dementia: a meta-analysis</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>51</VL>
<PG>728-733</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGeer-1989" MODIFIED="2012-01-02 10:45:44 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="McGeer 1989" TYPE="JOURNAL_ARTICLE">
<AU>Mcgeer PL, Akiyama H, Itagaki S, McGeer EG</AU>
<TI>Immune system response in Alzheimer's disease</TI>
<SO>Canadian Journal Neurological Sciences</SO>
<YR>1989</YR>
<VL>16</VL>
<PG>516-527</PG>
<IDENTIFIERS MODIFIED="2008-11-06 21:19:33 +0000" MODIFIED_BY="Darin   Jaturapatporn"/>
</REFERENCE>
<REFERENCE ID="REF-McGeer-1996" MODIFIED="2012-01-07 12:06:24 +0000" MODIFIED_BY="[Empty name]" NAME="McGeer 1996" TYPE="JOURNAL_ARTICLE">
<AU>McGeer</AU>
<TI>Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47(2)</VL>
<PG>425-432</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKhann-1984" MODIFIED="2012-01-02 08:02:26 +0000" MODIFIED_BY="Joey Kwong" NAME="McKhann 1984" TYPE="JOURNAL_ARTICLE">
<AU>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM</AU>
<TI>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services task force on Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>34</VL>
<PG>939-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pasinetti-1998" MODIFIED="2009-10-04 03:53:20 +0100" MODIFIED_BY="Darin   Jaturapatporn" NAME="Pasinetti 1998" TYPE="JOURNAL_ARTICLE">
<AU>Pasinetti GM, Aisen PS</AU>
<TI>Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain</TI>
<SO>Neuroscience</SO>
<YR>1998</YR>
<VL>87</VL>
<PG>319-424</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rich-1995" NAME="Rich 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rich</AU>
<TI>Nonsteroidal anti-inflammatory drugs in Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45</VL>
<PG>51-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruan-2009" MODIFIED="2012-01-02 10:45:26 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Ruan 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ruan L, Kang Z, Pei G, Le Y</AU>
<TI>Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease</TI>
<SO>Current Alzheimer Research</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>6</NO>
<PG>531-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salminen-2009" MODIFIED="2012-01-07 12:06:44 +0000" MODIFIED_BY="[Empty name]" NAME="Salminen 2009" TYPE="JOURNAL_ARTICLE">
<AU>Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T</AU>
<TI>Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors</TI>
<SO>Progress in Neurobiology</SO>
<YR>2009</YR>
<VL>87</VL>
<NO>3</NO>
<PG>181-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Selkoe-1991" MODIFIED="2012-01-02 10:44:45 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Selkoe 1991" TYPE="JOURNAL_ARTICLE">
<AU>Selkoe DJ</AU>
<TI>Alzheimer's disease. In the beginning</TI>
<SO>Nature</SO>
<YR>1991</YR>
<VL>354</VL>
<NO>6353</NO>
<PG>432-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2001" MODIFIED="2009-02-23 01:42:50 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Thomas 2001" TYPE="JOURNAL_ARTICLE">
<AU>Thomas T, Nadackal TG, Thomas K</AU>
<TI>Aspirin and non-steroidal anti-inflammatory drug inhibit amyloid-B aggregation</TI>
<SO>Neuroreport</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>3263-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1992" MODIFIED="2012-01-07 12:07:02 +0000" MODIFIED_BY="[Empty name]" NAME="WHO 1992" TYPE="BOOK">
<AU>World Health Organisation</AU>
<SO>The ICD-10 Classification of Mental and Behavioural disorders: clinical Descriptions and Diagnostic Guidelines</SO>
<YR>1992</YR>
<PB>Geneva: World Health Organisation, Division of Mental Health</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilcock-2006a" MODIFIED="2012-01-07 12:07:13 +0000" MODIFIED_BY="[Empty name]" NAME="Wilcock 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Wilcock G et al</AU>
<TI>Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective Ab42-lowering agent, in Alzheimers disease (AD): Results of a 12-month phase 2 trial and 1-year follow-on study.</TI>
<SO>Alzheimer and Dementia</SO>
<YR>2006</YR>
<VL>2</VL>
<NO>3</NO>
<PG>S81-S82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wimo-2005" MODIFIED="2009-02-23 01:39:04 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Wimo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wimo A, Winblad B, Jonsson L</AU>
<TI>An estimate of the total worldwide societal costs of dementia in 2005</TI>
<SO>Alzheimer's &amp; dementia</SO>
<YR>2007</YR>
<VL>3</VL>
<PG>81-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Younkin-1995" MODIFIED="2012-01-02 10:44:33 +0000" MODIFIED_BY="Darin   Jaturapatporn" NAME="Younkin 1995" TYPE="JOURNAL_ARTICLE">
<AU>Younkin SG</AU>
<TI>Evidence that A beta 42 is the real culprit in Alzheimer's disease</TI>
<SO>Annals of Neurology</SO>
<YR>1995</YR>
<VL>37</VL>
<NO>3</NO>
<PG>287-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2011-05-01 10:18:21 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-01-11 14:31:49 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-01-11 14:31:49 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-12-07 15:28:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aisen-2000a">
<CHAR_METHODS MODIFIED="2011-12-07 15:17:41 +0000" MODIFIED_BY="[Empty name]">
<P>Double blind randomised controlled trial, 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-21 15:08:01 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>138 participants (69 intervention, 69 control) who had MMSE 13-26, aged&gt;50 years, were out-patient in USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-21 15:08:21 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Intervention: Prednisone 20 mg oral x 4 weeks then 10 mg x1year, follow by gradual taper over an additional 16 weeks of observation</P>
<P>Control: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-07 15:28:51 +0000" MODIFIED_BY="[Empty name]">
<P>Cognition (ADAScog 0-70 lower score = improvement) at 12 months</P>
<P>(CDR-sob lower score = improvement) at 12 months</P>
<P>Mood and depression (BPRS 7-126 lower score = improvement at 12 months</P>
<P>(Ham-D 0-54 lower score = improvement) at 12 months</P>
<P>(BDRS lower score = improvement) at 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-21 15:32:25 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Supported by a grant from the national institutes of health. Prednisone and matching placebo were provided by Pharmacia and Upjohn, Inc</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-03 12:36:45 +0100" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Aisen-2002a">
<CHAR_METHODS MODIFIED="2009-02-22 22:51:35 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Double blind randomised controlled trial, 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-03 12:36:45 +0100" MODIFIED_BY="Darin   Jaturapatporn">
<P>40 participants (21 intervention, 19 placebo) who has probable AD with stable medical condition, were out-patient in USA, age-not limited</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-22 22:51:44 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Intervention: Nimesulide 100 mg oral twice</P>
<P>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-01 22:38:55 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Cognition (ADAScog 0-70 lower score = improvement)</P>
<P> (CDR-sob lower score = improvement)</P>
<P> (MMSE 0-30 higher score = improvement)</P>
<P>Mood and depression (BPRS 7-126 lower score = improvement)</P>
<P> (Ham-D 0-54 lower score = improvement)</P>
<P>Activity of daily living (Blessed ADL score higher score = improvement)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-01 22:40:23 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Sources of funding not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-21 15:33:14 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Aisen-2003a">
<CHAR_METHODS MODIFIED="2009-02-21 15:11:11 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Double blind randomised controlled trial, 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-21 15:11:41 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>351 participants (240 intervention, 111 control) who had MMSE 13-26, aged &gt; 50 years, were out-patient in USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-21 15:11:56 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Intervention 1: Naproxen sodium 220 mg oral twice (118 participants)</P>
<P>Intervention 2: Rofecoxib 25 mg oral once (122 participants)</P>
<P>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-21 15:12:44 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Cognition (ADAScog 0-70 lower score = improvement) at 6, 12 months</P>
<P>(CDR-sob lower score = improvement) at 6, 12 months</P>
<P>(NPI 0-144 lower score = improvement) at 6, 12 months</P>
<P>Activity of daily living (ADCS-ADL 0-78 higher score = improvement) at 6, 12 months</P>
<P>Qulity of life (QoL-AD higher score = improvement) at 6, 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-21 15:33:14 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>source of funding: a grant from the national institute on aging and the general clinical research centre program of the national centre for research resources</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-21 16:20:50 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Bentham-2008">
<CHAR_METHODS MODIFIED="2009-02-21 15:33:58 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Open-label randomised controlled trial, 3 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-21 16:20:50 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>310 participants (156 intervention, 154 control) who had a DSM-4 diagnosis of probable dementia of AD without a coexisting diagnosis of vascular dementia, aged 46-90, were out-patient in the UK. 75% took Donepezil.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-21 15:15:28 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Intervention: aspirin 75 mg oral once</P>
<P>Control: avoid aspirin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-21 15:34:12 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Cognition (MMSE 0-30 higher score = improvement) at 12 wk, 1,2,3 years</P>
<P>(NPI 0-144 lower score = improvement) at 12 wk, 1,2,3 years</P>
<P>Activity of daily living (BALDS 0-60 higher score = improvement ) at 12 wk, 1,2,3 years</P>
<P>Caregiver burden (GHQ for care give 0-30 lower score = improvement) at 12 wk, 1,2,3 years</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-01 23:27:05 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>funding from research and development directorate of the west midlands region or national health service executive</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-03 12:37:31 +0100" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-De-Jong-2008">
<CHAR_METHODS MODIFIED="2009-02-21 15:16:30 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Double blind randomised controlled trial, 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-03 12:37:31 +0100" MODIFIED_BY="Darin   Jaturapatporn">
<P>51 participants (26 intervention, 25 control) who had a diagnosis of</P>
<P>probable AD by NINCDS/ADRDA with MMSE 10-26, were out-patient in Netherlands, aged-not limited</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-21 15:16:50 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Intervention: Indomethacin 50 mg oral twice</P>
<P>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-21 15:17:20 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Cognition (ADAScog 0-70 lower score = improvement) at 6,12 months</P>
<P>(MMSE higher score = improvement) at 6,12 months</P>
<P>(CIBIC+ 1-7 lower score = improvement) at 6,12 months</P>
<P>(NPI 0-144 lower score = improvement) at 6,12 months</P>
<P>Activity of daily living (IDDD lower score = improvement) at 6,12 months</P>
<P>Caregiver burden (NPI-D lower score = improvement) at 6,12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-09 20:07:39 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Funding from grants from Zon-MW Innovational Research, Hersenstichting Nederland</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-02 07:43:06 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-H_x00fc_ll-1999">
<CHAR_METHODS MODIFIED="2009-02-21 15:17:37 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Double blind randomised controlled trial, 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-02 07:43:06 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>10 Participants (7 intervention, 3 control) who had AD diagnosis, unclear if they were out-patient or in-patient, in Germany, aged 55-75</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-21 15:18:48 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Intervention: Piroxicam-B-cyclodextrin 10 mg oral once</P>
<P>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-21 15:18:55 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Cognition (ADAScog 0-70 lower score = improvement) at 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-09 20:13:41 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Sources of funding not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-21 15:35:09 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Jhee-2004">
<CHAR_METHODS MODIFIED="2009-02-21 15:35:09 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Double blind randomised controlled trial, 4 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-21 15:19:56 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>21 participants (16 intervention, 5 control) who had a diagnosis of probable AD. Subjects had to meet the NINCDS-ADRDA and DSM4 criteria for probable AD, had modified Hachinski Ischemia Scale score of less than or equal to 4, MMSE score between 10-24 inclusive and had been diagnosed with probable AD for at least a six month period. They were out-patient, aged&gt;/=60 y in USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-21 15:20:02 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Interventions: Celecoxib dose 50. 200 and 400 mg oral twice</P>
<P>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-21 15:20:18 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Cognition (ADAScog 0-70 lower score = improvement) at 4 weeks</P>
<P>(MMSE higher score = improvement) at 4 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-09 20:22:27 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Sources of funding not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-02 07:43:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pasqualetti-2009">
<CHAR_METHODS MODIFIED="2011-06-01 12:54:01 +0100" MODIFIED_BY="[Empty name]">
<P>Double blind randomised control trial, 52 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-01 14:49:53 +0100" MODIFIED_BY="[Empty name]">
<P>132 participants (66 intervention, 66 control) who had a diagnosis of probable AD by ADRdA-NINCDS criteria with MMSE 16-25 and Clinical Dementia Rating =0.5-1, in Italy, aged 65 years or older and be cared for by a reliable caregiver, Out-patient setting</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-02 07:43:15 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: Ibuprofen 400 mg twice a day plus esomeprazole 20 mg</P>
<P>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-01 12:58:44 +0100" MODIFIED_BY="[Empty name]">
<P>Cognition (MMSE 0-30 higher score = improvement) at 52 weeks</P>
<P>(ADAScog 0-70 lower score = improvement) at 52 weeks</P>
<P>(CDR-sob lower score = improvement) at 52 weeks</P>
<P>(CIBIC+ 1-7 lower score = improvement) at 52 weeks</P>
<P>(NPI 0-144 lower score = improvement) at 52 weeks</P>
<P>Mood (GDS 0-15 lower score = improvement) at 52 weeks</P>
<P>Basic and instrumental activities of Daily LIving Scales (lower score = improvement) at 52 weeks</P>
<P>Caregiver burden (NPI-stress CG subscale lower score = improvement) at 52 weeks</P>
<P>(STAI-Y1, STAI-Y2) at 52 weeks</P>
<P>(Beck Depression Inventory) at 52 weeks</P>
<P>(CBI) at 52 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-01 14:41:57 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by a grant from the Italian Health Department. Active drug tablets and relative placebos were supplied by Angelini SpA for Ibuprofen and by Astra-Zeneca Pharmaceuticals.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-21 15:26:23 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Reines-2004">
<CHAR_METHODS MODIFIED="2009-02-21 15:24:21 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Double blind randomised controlled trial, 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-21 15:25:49 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>692 participants (346 intervention, 346 control) who aged at least 50 years, met standard research criteria for possible or probable AD and had mild or moderate dementia as measured by MMSE score from 14-26 inclusive, unclear if they were out-patient or in-patient, in USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-21 15:24:28 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Intervention: Rofecoxib 25 mg oral once</P>
<P>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-21 15:26:23 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Cognition (ADAScog 0-70 lower score = improvement) at 6, 12 months</P>
<P>(CDR-sob lower score = improvement) at 6, 12 months</P>
<P>(MMSE 0-30 higher score = improvement) at 6, 12 months</P>
<P>(CIBIC+ 1-7 lower score = improvement) at 6, 12 months</P>
<P>Activity of daily living (ADCS-ADL 0-78 higher score = improvement) at 6, 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-09 21:13:43 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Funding from Merck Research Laboratories </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-03 12:38:50 +0100" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Rogers-1993">
<CHAR_METHODS MODIFIED="2009-02-21 15:26:41 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Double blind randomised control trial, 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-03 12:38:50 +0100" MODIFIED_BY="Darin   Jaturapatporn">
<P>28 participants (14 intervention, 14 control) who had a diagnosis of probable AD and MMSE of 16 or more, unclear if they are out-patient or in-patient, in USA, aged, not limited</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-21 15:27:14 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Intervention: Indomethacin oral once 100 mg/day for weight &lt; 100 pounds, 125 mg/day for weight 101-150 pounds, 150 mg/day for weight &gt; 150 pounds</P>
<P>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-21 15:28:04 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Cognition (MMSE 0-30 higher score = improvement) at 6 months</P>
<P>(ADAScog 0-70 lower score = improvement) at 6 months</P>
<P>(BNT 0-60 higher score = improvement) at 6 months</P>
<P>(TK higher score = improvement) at 6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-02 01:30:47 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Sources of funding not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-21 15:35:24 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Scharf-1999">
<CHAR_METHODS MODIFIED="2009-02-21 15:28:16 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Double blind randomised control trial, 25 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-21 15:28:36 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>27 participants (12 intervention, 15 placebo) who had a diagnosis of AD according to DSM-4 criteria that was of mild to moderate severity, defined by a MMSE score of 11-25, aged &gt;/= 50 years, were out-patient in Australia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-21 15:28:41 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Intervention: Unknown dose of diclofenac and misoprostol oral</P>
<P>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-21 15:35:24 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Cognition (ADAScog 0-70 lower score = improvement) at 12, 25 weeks</P>
<P>(MMSE 0-30 higher score = improvement) at 12, 25 weeks</P>
<P>Clinical global impression of change at 12, 25 weeks</P>
<P>(GDS lower score = improvement) at 12, 25 weeks</P>
<P>(CGIC lower score = improvement) at 12, 25 weeks</P>
<P>Behavioral disturbance</P>
<P>(ADAS-noncog lower score = improvement) at 12, 25 weeks</P>
<P>(ADAS-total lower score = improvement) at 12, 25 weeks</P>
<P>Activity of daily living</P>
<P>(IADL lower score = improvement) at 12, 25 weeks</P>
<P>Quality of life</P>
<P>(PSMS lower score = improvement) at 12, 25 weeks</P>
<P>Caregiver burden</P>
<P>(CGIC lower score = improvement) at 12, 25 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-02 01:47:46 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>source of funding from postgraduate medical research scholarship</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-21 15:31:30 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Soininen-2007">
<CHAR_METHODS MODIFIED="2009-02-21 15:30:03 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Double blind randomised control trial, 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-21 15:30:36 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>461 participants (308 intervention, 153 control) who aged &gt;/= 50 years with early to moderate AD by MMSE and global deterioration scale (GDS) scores of 3-5, meeting NINCDS or DSM 4 criteria for probable AD with symptoms present for at least one year, were out-patient in USA, Australia, Belgium, Finland, France, Germany, Netherlands and the UK.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-21 15:30:41 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Intervention: Celecoxib 200 mg oral twice</P>
<P>Control: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-21 15:31:27 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Cognition (ADAScog 0-70 lower score = improvement) at 6, 12 months</P>
<P>(CIBIC+ 1-7 lower score = improvement) at 6, 12 months</P>
<P>Clinical global impression of change (NOSGER 30-150 lower score = improvement ) at 6, 12 months</P>
<P>Behavioral disturbance (Behave-AD 0-75 lower score = improvement) at 6, 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-21 15:31:30 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Funding from Pfizer</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-03 12:40:56 +0100" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Zhou-2004a">
<CHAR_METHODS MODIFIED="2009-02-21 15:38:33 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Open-label randomised controlled trial, 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-03 12:40:56 +0100" MODIFIED_BY="Darin   Jaturapatporn">
<P>16 participants (8 intervention, 8 control) who had a diagnosis of AD, were in-patient. in China, aged-not limited</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-21 15:39:30 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Intervention: Hyperzine A 0.15 mg oral twice, Nicegoline 20 mg oral twice and enteric-coated aspirin oral 50 mg once</P>
<P>Control: Hyperzine A 0.15 mg oral twice, Nicegoline 20 mg oral twice</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-21 15:38:48 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Cognition (MMSE 0-30 higher score = improvement) at 3,6 months</P>
<P>Activity of daily living (Blessed ADL score higher score = improvement) at 3,6 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-09 22:51:20 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Sources of funding not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-10-03 12:39:30 +0100" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Zhou-2004b">
<CHAR_METHODS MODIFIED="2009-02-21 15:39:46 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Open-label randomised controlled trial, 36 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-03 12:39:30 +0100" MODIFIED_BY="Darin   Jaturapatporn">
<P>26 participants (13 intervention, 13 control) who had a diagnosis of AD, were in-patient in China, aged-not limited</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-21 15:40:57 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Intervention: Hyperzine A 0.15 mg oral twice and aspirin oral 150 mg once</P>
<P>Control: Hyperzine A 0.15 mg oral twice</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-21 15:41:18 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Cognition (MMSE 0-30 higher score = improvement) at 36 weeks</P>
<P>Activity of daily living (Blessed ADL score higher score = improvement) at 36 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-02-09 23:11:10 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Sources of funding not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-01-08 02:52:11 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-01-08 01:53:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ADAPT-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-08 01:53:07 +0000" MODIFIED_BY="[Empty name]">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 05:43:20 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Aisen-1996a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 05:43:20 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>no comparison group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 05:37:43 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Aisen-2000b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 05:37:43 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Repeat study to Aisen2000a</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 05:44:28 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Aisen-2000c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 05:44:28 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 05:45:56 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Aisen-2002b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 05:45:56 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 21:55:13 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Aisen-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 21:55:13 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 21:58:40 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Aisen-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 21:58:40 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:26:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aisen-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:26:01 +0100" MODIFIED_BY="[Empty name]">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:01:26 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Aizen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:01:26 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:01:32 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Allain-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:01:32 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:02:21 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Anthony-2000a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:02:21 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:02:18 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Anthony-2000b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:02:18 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:05:33 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Asthana-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:05:33 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is physostigmine which is not aspirin, steroids or NSAIDS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:05:20 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Baum-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:05:20 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is curcurmin which is not aspirin, steroids or NSAIDS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:51:14 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Beck-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:51:14 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>This study met all inclusion criteria, but information of the study from the authors could not be obtained.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:07:44 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Belanoff-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:07:44 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is mifepristone which is not aspirin, steroids or NSAIDS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:07:24 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Belanoff-2002b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:07:24 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:08:55 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Bernardi-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:08:55 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:08:58 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Bertozzi-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:08:58 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:10:32 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Black-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:10:32 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is R-flurbiprofen which is not aspirin, steroids or NSAIDS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:11:03 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Breitner-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:11:03 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:12:23 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Breitner-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:12:23 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but for AD prevention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:29:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Breitner-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:29:36 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, but in MCI and normal elderly</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:14:40 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Browne-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:14:40 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:14:49 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Bruce_x002d_Jones-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:14:49 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but for healthy elderly</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:15:02 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Brunner-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:15:02 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:15:19 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Budge-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:15:19 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but for non-specified dementia, not AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:15:44 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Bullock-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:15:44 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:16:06 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Bussiere-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:16:06 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but for non-specified dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:16:55 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Canigueral-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:16:55 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but not in AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:19:29 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Chang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:19:29 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is Ginko biloba which is not aspirin, steroids or NSAIDS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:22:14 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Clarke-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:22:14 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but for non-specified dementia, not AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:22:29 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Clostre-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:22:29 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:32:10 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Diener-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:32:10 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but for ischemic stroke, not AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:32:23 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Diener-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:32:23 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but ofr ischemic stroke, not AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:33:14 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Doraiswamy-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:33:14 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 21:51:46 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Fisk-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 21:51:46 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Repeat study to Bentham2008</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:37:59 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Forssell-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:37:59 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is choline chloride and lecithin which is not aspirin, steroids or NSAIDS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:38:26 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Fotuhi-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:38:26 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:40:03 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Geldmacher-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:40:03 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is pioglitazone which is not aspirin, steroids or NSAIDS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:40:43 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Gomez_x002d_Isla-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:40:43 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in MCI, not AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:32:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Green-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:32:00 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, AD, but intervention is Tarenflurbil</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 22:42:08 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Group-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 22:42:08 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in elderly with family history of AD, not AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 23:00:27 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Hollander-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 23:00:27 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is RS 86 (Cholinomimetic drug) which is not aspirin, steroids or NSAIDS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 23:13:06 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Jackson-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 23:13:06 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is propranolol which is not aspirin, steroid, or NSAIDS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:33:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jacobs-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:33:39 +0100" MODIFIED_BY="[Empty name]">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 23:13:41 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Jacoby-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 23:13:41 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but for non-specified dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 23:14:00 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Jeong-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 23:14:00 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:33:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:33:50 +0100" MODIFIED_BY="[Empty name]">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:33:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jin-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:33:51 +0100" MODIFIED_BY="[Empty name]">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:34:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kimball-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:34:10 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, but in atopic dermatitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 23:21:44 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Landi-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 23:21:44 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 23:22:21 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Laughlin-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 23:22:21 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is R-flurbiprofen which is not aspirin, steroid, or NSAIDS</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 23:22:46 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Leblhuber-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 23:22:46 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 23:22:57 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Leuchtenberger-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 23:22:57 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 23:23:08 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Lucca-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 23:23:08 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 23:24:45 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Martin-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 23:24:45 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in patients with family history of AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 23:25:01 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Martin-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 23:25:01 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in patients with family history of AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 23:58:05 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-McIntyre-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 23:58:05 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:35:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meinert-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:35:36 +0100" MODIFIED_BY="[Empty name]">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 23:59:28 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Meinerta-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 23:59:28 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in TIA or Stroke patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:07:47 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Meyer-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:07:47 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:08:17 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Meyer-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:08:17 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in multi-infarct dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:11:36 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Nawata-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:11:36 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in vascular dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:17:26 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Nourhashemi-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:17:26 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:20:08 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-O_x0027_Shea-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:20:08 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in premature infact</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:20:57 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Pasinetti-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:20:57 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 21:50:07 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Pfizer-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 21:50:07 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Repeat study to Soininen2007</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 21:50:17 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Pfizer-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 21:50:17 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Repeat study to Soininen2007</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:23:11 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Pomara-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:23:11 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is naltrexone which is not aspirin, steroid or NSAIDs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:23:25 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Pomara-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:23:25 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is mifepristone which is not aspirin, steroid or NSAIDs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:26:41 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Reid-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:26:41 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in cocaine dependent subjects</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:27:52 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Relkin-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:27:52 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is donepezil which is not aspirin, steroid or NSAIDs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-02 21:48:47 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Sainati-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-02 21:48:47 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>Repeat study to Soininen2007</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:33:05 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Simon-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:33:05 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in osteoarthritis and rheumatoid arthritis patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:33:17 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Small-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:33:17 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in MCI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:49:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Small-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:49:28 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, but in non demented volunteer with mild age-related memory decline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:49:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Solomon-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:49:35 +0100" MODIFIED_BY="[Empty name]">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:49:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Souza_x002d_Talarico-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:49:40 +0100" MODIFIED_BY="[Empty name]">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:34:20 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Steiger-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:34:20 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in healthy men</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-08 02:48:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stevenson-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-08 02:48:43 +0000" MODIFIED_BY="[Empty name]">
<P>Repeat study to Jhee2004</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:35:21 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Stewart-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:35:21 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:35:27 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Stoppe-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:35:27 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:35:40 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Szekely-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:35:40 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:50:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Szekely-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:50:05 +0100" MODIFIED_BY="[Empty name]">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:51:30 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Taylor-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:51:30 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>This study met all inclusion criteria, but information of the study from the authors could not be obtained.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:36:24 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Thal-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:36:24 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in MCI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:50:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsartsalis-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:50:54 +0100" MODIFIED_BY="[Empty name]">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:38:59 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Tuppo-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:38:59 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:39:07 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Turini-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:39:07 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:39:10 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Usui-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:39:10 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:38:53 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Uttner-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:38:53 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in multiple sclerosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:40:34 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Van-Niekerk-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:40:34 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in men aged 62-76</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:41:19 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-van-Reekum-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:41:19 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:41:14 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Visser-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:41:14 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:51:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vlad-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:51:20 +0100" MODIFIED_BY="[Empty name]">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:41:43 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Walker-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:41:43 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:52:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Walther-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:52:21 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, but in 2 patients with unspecified dementia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:42:42 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Watson-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:42:42 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in both AD and MCI and intervention is rosiglitasone which is not aspirin, steroid or NSAIDs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:43:08 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Whitehouse-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:43:08 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:52:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Widimsky-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:52:35 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, but in stable angina group A</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:43:26 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Wilcock-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:43:26 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in non-specified AD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:44:12 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Wilcock-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:44:12 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is R-flurbiprofen which is not aspirin, steroid and NSAIDs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:44:30 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Wilcock-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:44:30 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:45:18 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Wilcock-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:45:18 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, AD, but intervention is tarenflurbil which is not aspirin, steroid and NSAIDs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:45:44 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Williams-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:45:44 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:45:45 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Windisch-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:45:45 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:45:59 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Wisloff-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:45:59 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in multiple myeloma</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-08 02:52:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wolkowitz-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-08 02:52:11 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, AD, but intervention is a steroid that does not have anti-inflammatory effect</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:46:12 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Wollheim-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:46:12 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:46:41 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Woodward-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:46:41 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:46:53 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Xia-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:46:53 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in premature infant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:47:02 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Yaqub-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:47:02 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:47:04 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Yip-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:47:04 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:47:35 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Young-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:47:35 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>RCT, but in normal male volunteers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:48:14 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Zandi-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:48:14 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-03 00:48:16 +0000" MODIFIED_BY="Darin   Jaturapatporn" STUDY_ID="STD-Zaragoza-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-03 00:48:16 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:52:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zerovnik-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:52:59 +0100" MODIFIED_BY="[Empty name]">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:53:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhai-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:53:11 +0100" MODIFIED_BY="[Empty name]">
<P>RCT, but in vascular cognitive impairment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-01 10:53:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ziebell-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-01 10:53:17 +0100" MODIFIED_BY="[Empty name]">
<P>not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-02-02 21:35:26 +0000" MODIFIED_BY="Darin   Jaturapatporn" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-01-11 14:31:49 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-01-11 14:31:49 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-11 14:31:49 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2000a">
<DESCRIPTION>
<P>
<B>Quote</B> &#8220;Codes were randomised at the packaging centre (supposed it is computer), the randomisation scheme was approved by the Alzheimer&#8217;s disease Cooperative study (ADCS) statistic core. Randomization was stratified by site and utilized a block size of eight&#8221;</P>
<P>
<B>Comment:</B>
</P>
<P>Codes were generated at the packaging centre, probably using computer.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-21 15:32:59 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="UNKNOWN" STUDY_ID="STD-Aisen-2002a">
<DESCRIPTION>
<P>
<B>Quote</B>:  The randomisation schedule was generated in the research pharmacy</P>
<P>
<B>Comment:</B>
</P>
<P>Insufficient information about the sequence generation process to permit judgement of yes or no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-21 15:33:23 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2003a">
<DESCRIPTION>
<P>
<B>Quote</B>: The randomisation process used a permuted block design with block size of 3 stratified by site. The randomisation sequence was generated by the ADCS data centre</P>
<P>
<B>Comment:</B>
</P>
<P>done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-21 15:34:20 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Bentham-2008">
<DESCRIPTION>
<P>
<B>Quote</B>: Eligible patients were randomly assigned to take open-label aspirin or to take no aspirin. Treatment allocation was obtained by telephone from the central trial office and used minimised randomisation generated by a computer program to balance allocations by age, severity of dementia, the presence of absence of vascular dementia, parkinsonian and psychotic symptoms.</P>
<P>
<B>Comment:</B>
</P>
<P>done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-21 15:34:39 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-De-Jong-2008">
<DESCRIPTION>
<P>
<B>Quote</B>:  the statistician provided computer-generated lists of random numbers allocating patients in a 1:1 ratio to receive indomethacin or placebo. For each centre, a separate randomisation list was provided</P>
<P>
<B>Comment:</B>
</P>
<P>done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 20:09:01 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="UNKNOWN" STUDY_ID="STD-H_x00fc_ll-1999">
<DESCRIPTION>
<P>
<B>No information</B>
</P>
<P>
<B>Comment:</B>
</P>
<P>probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 20:15:08 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-Jhee-2004">
<DESCRIPTION>
<P>
<B>Quote</B>: Subjects with AD were randomly allocated a treatment arm in the order in which they were enrolled in the study</P>
<P>
<B>Comment:</B>
</P>
<P>Sequence generated by some rule based on the number they enrolled in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-01-02 07:43:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pasqualetti-2009">
<DESCRIPTION>
<P>
<B>Quote</B>: Randomization was performed with a permuted block design with a block size of 10, allocation rate 1:1, stratified by recruitment site. The randomisation sequence was provided by the Statistical Analysis Center, according to a pseudo-random computerized generator.</P>
<P>
<B>Comment:</B>
</P>
<P>Sequence generated by some rule based on the number they enrolled in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 21:09:05 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Reines-2004">
<DESCRIPTION>
<P>
<B>Quote</B>:  Randomization of patients at each study site was determined by a computer-generated allocation schedule and was stratified according to MMSE score (14-20 and &gt; 20) to try to ensure equal distributions of dementia severity in each treatment group</P>
<P>
<B>Comment:</B>
</P>
<P>done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 01:20:26 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="UNKNOWN" STUDY_ID="STD-Rogers-1993">
<DESCRIPTION>
<P>Patients were then randomly assigned to one of two treatment conditions in a double-blind protocol, no information about sequence generation</P>
<P>
<B>Comment:</B>
</P>
<P>probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 01:42:18 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-Scharf-1999">
<DESCRIPTION>
<P>
<B>Quote</B>: Randomization was performed by the manufacturer of the medication before delivery to the study centre. For patients 1 to 20, 50% received diclofenac/misoprostol (D/M) and 50% placebo; for patients 21-41, two thirds received D/M and one third placebo.</P>
<P>
<B>Comment:</B>
</P>
<P>Sequence generated by some rule based on hospital or clinic record number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-21 15:31:44 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Soininen-2007">
<DESCRIPTION>
<P>
<B>Quote:</B> Patients were assigned to receive the study medication in the order of enrolment according to a computer-generated randomisation schedule prepared by the sponsor prior to the start of the study.</P>
<P>
<B>Comment:</B>
</P>
<P>done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 22:47:05 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2004a">
<DESCRIPTION>
<P>
<B>No information</B>
</P>
<P>
<B>Comment:</B>
</P>
<P>probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 23:13:46 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2004b">
<DESCRIPTION>
<P>
<B>No information</B>
</P>
<P>
<B>Comment:</B>
</P>
<P>probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-06-01 12:54:24 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-21 15:32:53 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2000a">
<DESCRIPTION>
<P>
<B>Quote 1</B> &#8220;Scratch-off code breakers were used so that instances of unbinding would be documented. All code breakers were collected at the end of the trial&#8221;</P>
<P>
<B>Quote 2</B> &#8220;Randomization codes were broken in two instances. In each case, the code was broken by investigators at local sites to determine whether stress-dose glucocorticoid treatment was necessary for subjects who required surgical procedures&#8221;</P>
<P>
<B>Comment:</B>
</P>
<P>It mentioned about using the code as a number. Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 22:43:09 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="UNKNOWN" STUDY_ID="STD-Aisen-2002a">
<DESCRIPTION>
<P>
<B>Comment </B>
</P>
<P>Insufficient information to permit judgement of Yes or No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-21 15:33:32 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2003a">
<DESCRIPTION>
<P>
<B>Quote 1: </B>Scratch-off code-breakers were used so that instances of unbinding would be documented. All code breakers were collected at the end of the trial.</P>
<P>
<B>Comment:</B> Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 23:22:55 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="UNKNOWN" STUDY_ID="STD-Bentham-2008">
<DESCRIPTION>
<P>No statement</P>
<P>
<B>Comment:</B> Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 19:53:20 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-De-Jong-2008">
<DESCRIPTION>
<P>
<B>Quote 1: </B> Randomization codes were held by the pharmacy of the Radboud University Nijmegen Medical Centerthat labelled and dispensed all trial medication. Allocation was concealed from all investigators and patients.</P>
<P>
<B>Comment:</B>  done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 20:09:19 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="UNKNOWN" STUDY_ID="STD-H_x00fc_ll-1999">
<DESCRIPTION>
<P>
<B>No information</B>
</P>
<P>
<B>Comment:</B> Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 20:15:25 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-Jhee-2004">
<DESCRIPTION>
<P>
<B>No information</B>
</P>
<P>
<B>Comment:</B> Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-01 12:54:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pasqualetti-2009">
<DESCRIPTION>
<P>
<B>Quote</B>: Randomization was performed with a permuted block design with a block size of 10, allocation rate 1:1, stratified by recruitment site.</P>
<P>
<B>Comment:</B> Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 21:09:36 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Reines-2004">
<DESCRIPTION>
<P>
<B>Quote</B>: A statistician at Merck Research Laboratories generated the allocation schedule according to in-house blinding conditions. The rofecoxib and placebo tables were visually identical.</P>
<P>
<B>Comment: </B>done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 01:22:18 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="UNKNOWN" STUDY_ID="STD-Rogers-1993">
<DESCRIPTION>
<P>No information</P>
<P>
<B>Comment:</B> Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-21 15:35:28 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Scharf-1999">
<DESCRIPTION>
<P>
<B>Quote: </B>The identity code was concealed in sequentially numbered opaque envelopes.</P>
<P>
<B>Quote 2</B>: The medication and envelopes were stored in a pharmacy separate from the study site. The medication was supervised and dispensed by independent pharmacist trained in the conduct of randomised double-blind clinical trials.</P>
<P>
<B>Quote 3:</B> Medication codes were broken after completion of the trial or if a patient was withdrawn prematurely due to an adverse event.</P>
<P>
<B>Comment:</B>
</P>
<P>Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-21 15:31:48 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Soininen-2007">
<DESCRIPTION>
<P>
<B>Quote</B>: Patients and study personnel were blinded to the allocation of treatments throughout, and the randomisation code was only to be broken for a specific patient in an emergency situation when the investigator&#8217;s opinion required this action.</P>
<P>
<B>Comment:</B> Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 22:48:12 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2004a">
<DESCRIPTION>
<P>
<B>No information</B>
</P>
<P>
<B>Comment:</B> Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 23:14:03 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="UNKNOWN" STUDY_ID="STD-Zhou-2004b">
<DESCRIPTION>
<P>
<B>No information</B>
</P>
<P>
<B>Comment:</B> Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-06-01 12:54:25 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-01 22:03:23 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2000a">
<DESCRIPTION>
<P>
<B>Quote 1</B>&#8220;Matching placebo tablets were assembled into identical containers with coded labels to blind participants&#8221;</P>
<P>
<B>Quote 2</B> &#8220;Adequacy of masking was assesses by questionnaires completed by subjects, caregivers, psychometrists, and site investigators&#8221;</P>
<P>
<B>Comment: </B>
</P>
<P>Blinding of participants ensured and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-21 15:33:04 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2002a">
<DESCRIPTION>
<P>
<B>Quote 1</B> : All investigators and study personnel remained blind to group assignment of participants until completion of data collection</P>
<P>
<B>Quote 2</B>  : Participants were treated twice daily with Nimesulide or identical placebo tablets</P>
<P>
<B>Comment: </B>
</P>
<P>done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-21 15:33:37 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2003a">
<DESCRIPTION>
<P>
<B>Quote 1</B>: Rofecoxib tablets were over-encapsulated to allow preparation of an identical placebo capsule.</P>
<P>Naproxen sodium tablets and identical placebo tables were supplied by?..</P>
<P>
<B>Quote 2</B>: Adequacy of masking was assessed by questionnaires completed by participants, caregivers, psychometrists, and site investigators.</P>
<P>The results of questionnaires at 12 months indicated that the percentage of participants and informants who believed they were taking active study medication and active study medication also did not differ significantly across the treatment group, indicating that blinding was adequately maintained.</P>
<P>
<B>Quote3</B>: the randomisation  code was broken in 1 instance, based on clinical need for the management of an acute medical problem</P>
<P>
<B>Comment: </B>
</P>
<P>acceptable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-01 23:23:17 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-Bentham-2008">
<DESCRIPTION>
<P>
<B>Quote 1</B>: No blinding and the outcome or outcome measurement is likely to be influenced by lack of blinding. This is an open-label study</P>
<P>
<B>Quote 2:</B> The potential for biased assessment by patients or raters was judged insufficient to justify the cost of packaging aspirin and placebo for this long-term study.</P>
<P>
<B>Comment: </B>
</P>
<P>Not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-09 19:53:43 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-De-Jong-2008">
<DESCRIPTION>
<P>
<B>Quote 1</B>: The indomethacin and placebo tablets were of identical appearance. Neither the patients nor the investigators knew which treatment they received or dispensed. The blinding process remained complete until all data was entered in the trial database and the accuracy of the data and the database was confirmed. Afterward, the database was forwarded to the statistician for analysis</P>
<P>
<B>Comment: </B>
</P>
<P>done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-21 15:35:03 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-H_x00fc_ll-1999">
<DESCRIPTION>
<P>
<B>Quote 1</B>: all patients received either 10 mg piroxicam B Cyclodextrin or placebo</P>
<P>
<B>Comment: </B>
</P>
<P>Probably done, but there is only information for participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-09 20:15:44 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Jhee-2004">
<DESCRIPTION>
<P>
<B>Quote 1</B>: All study medication had the same appearance and was provided as celecoxib 50 mg and 200 mg capsules and matching placebo.</P>
<P>
<B>Comment: </B>
</P>
<P>Probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-06-01 12:54:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pasqualetti-2009">
<DESCRIPTION>
<P>
<B>Quote 1</B>: Tablets of the active drug and the placebo were undistinguishable, as were the gastroprotective agent and the relative placebo. Code-breaking was possible only at the level of the statistical Analysis Center an upon motivated request, resulting in simultaneous discontinuation of the patient from the study.</P>
<P>
<B>Comment: </B>
</P>
<P>Done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-09 21:10:07 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Reines-2004">
<DESCRIPTION>
<P>
<B>Quote 1</B>: A The rofecoxib and placebo tables were visually identical.</P>
<P>
<B>Quote 2</B>: Any adverse events occurring during the study were recorded and rated by the investigator, while still blinded. Any serious vascular events including cardiac, peripheral vascular and cerebrovascular events were reviewed by independent blinded adjudication committees  </P>
<P>
<B>Comment: </B>
</P>
<P>done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-01 23:53:10 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Rogers-1993">
<DESCRIPTION>
<P>
<B>Quote 1</B>:  Patients were then randomly assigned to one of two treatment conditions in a double-blind protocol</P>
<P>
<B>Comment: </B>
</P>
<P>probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-02 01:43:37 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Scharf-1999">
<DESCRIPTION>
<P>
<B>Quote 1</B>: Patients were randomly assigned in a double-blind fashion to receive either D/M as a single table twice a day or identical placebo twice daily for 25 weeks.</P>
<P>
<B>Comment: </B>
</P>
<P>Blinding of participants ensured and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-21 15:31:51 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Soininen-2007">
<DESCRIPTION>
<P>
<B>Quote 1: </B>Eligible patients were randomised to receive the 52-week dosing regimen of either celecoxib 200 mg bid or matching placebo in the ration of 2:1</P>
<P>
<B>Quote 2: </B>Patients and study personnel were blinded to the allocation of treatments throughout.</P>
<P>
<B>Comment: </B>
</P>
<P>Blinding of participants and unlikely to introduce bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-09 22:48:26 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-Zhou-2004a">
<DESCRIPTION>
<P>
<B>Quote 1</B>: This is an open-label trial</P>
<P>
<B>Comment: </B>
</P>
<P>Only outcome assessors were blinded, incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-09 23:14:24 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-Zhou-2004b">
<DESCRIPTION>
<P>
<B>Quote 1</B>: This is an open-label trial</P>
<P>
<B>Comment: </B>
</P>
<P>Only outcome assessors were blinded, incomplete blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-06-01 12:54:27 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-19 23:45:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aisen-2000a">
<DESCRIPTION>
<P>The reasons for early discontinuation of study medication were caregiver issues and perceived lack of efficacy. No subjects discontinued medication because of serious adverse events attributed to the treatment</P>
<P>1 year: 19/69 missing from intervention group, 11/69 missing from placebo</P>
<P>
<B>Comment:</B>
</P>
<P>Reasons for missing outcome data likely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-15 20:57:02 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2002a">
<DESCRIPTION>
<P>
<B>Comment: </B>Reasons for missing outcome data unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-21 15:33:43 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2003a">
<DESCRIPTION>
<P>
<B>Quote 1: </B>Reason for loss follow up are caregiver issue and adverse event</P>
<P>
<B>Comment: </B>Reasons for missing outcome data unlikely to be related to true outcome</P>
<P>Missing outcome data balanced in  numbers across intervention groups, with similar reasons for missing data across group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-01 23:23:47 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Bentham-2008">
<DESCRIPTION>
<P>
<B>Quote 1</B>
</P>
<P>
<B>Comment: </B>Reasons for missing outcome data unlikely to be related to true outcome</P>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-09 19:54:01 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-De-Jong-2008">
<DESCRIPTION>
<P>
<B>Quote 1: </B> </P>
<P>
<B>Comment: </B>Reasons for missing outcome data unlikely to be related to true outcome</P>
<P>Missing outcome data balanced in  numbers across intervention groups, with similar reasons for missing data across group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-09 20:09:58 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-H_x00fc_ll-1999">
<DESCRIPTION>
<P>
<B>Comment: </B>
</P>
<P>Reasons for missing outcome data unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-09 20:15:58 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Jhee-2004">
<DESCRIPTION>
<P>
<B>Comment: </B>
</P>
<P>Reasons for missing outcome data unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-01 12:54:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pasqualetti-2009">
<DESCRIPTION>
<P>
<B>Comment: </B>
</P>
<P>Reasons for missing outcome data unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-09 21:10:41 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Reines-2004">
<DESCRIPTION>
<P>
<B>Comment: </B>Reasons for missing outcome data unlikely to be related to true outcome</P>
<P>Reason for missing outcome data unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-01 23:53:22 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Rogers-1993">
<DESCRIPTION>
<P>
<B>Comment: </B>
</P>
<P>Reasons for missing outcome data unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-02 01:44:14 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Scharf-1999">
<DESCRIPTION>
<P>Side effects are more significant in D/M group.</P>
<P>
<B>Comment:</B>
</P>
<P>Reasons for missing outcome data unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-09 22:10:58 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Soininen-2007">
<DESCRIPTION>
<P>
<B>Comment: </B>
</P>
<P>Reasons for missing outcome data unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-09 22:48:33 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Zhou-2004a">
<DESCRIPTION>
<P>
<B>Comment: </B>
</P>
<P>Reasons for missing outcome data unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-09 23:14:34 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Zhou-2004b">
<DESCRIPTION>
<P>
<B>Comment: </B>
</P>
<P>Reasons for missing outcome data unlikely to be related to true outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-06-01 12:54:28 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 22:04:12 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2000a">
<DESCRIPTION>
<P>Report all outcome state in methodology</P>
<P>
<B>Comment:</B>
</P>
<P>The study protocol is not available, but all of the study&#8217;s pre-specified outcomes have been reported in the pre-specified way in methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 22:44:19 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2002a">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study protocol is not available, but all of the study&#8217;s pre-specified outcomes have been reported in the pre-specified way in methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-21 15:33:53 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2003a">
<DESCRIPTION>
<P>All primary outcomes were reported, but not all secondary outcome such as institutionalisation</P>
<P>
<B>Comment:</B>
</P>
<P>The study protocol is not available, but all of the study&#8217;s pre-specified outcomes have been reported in the pre-specified way in methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 23:23:55 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Bentham-2008">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study protocol is not available, but all of the study&#8217;s pre-specified outcomes have been reported in the pre-specified way in methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 19:54:24 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-De-Jong-2008">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study protocol is not available, but all of the study&#8217;s pre-specified outcomes have been reported in the pre-specified way in methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 20:10:23 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-H_x00fc_ll-1999">
<DESCRIPTION>
<P>Only report ADAS-cog</P>
<P>
<B>Comment:</B>
</P>
<P>not all of the study&#8217;s pre-specified primary outcomes have been reported. The study report fails to include results for a key outcome that would be expected to have been reported for such a study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 20:16:14 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Jhee-2004">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study protocol is not available, but all of the study&#8217;s pre-specified outcomes have been reported in the pre-specified way in methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-01 12:54:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pasqualetti-2009">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study protocol is not available, but all of the study&#8217;s pre-specified outcomes have been reported in the pre-specified way in methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 21:10:57 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Reines-2004">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study protocol is not available, but all of the study&#8217;s pre-specified outcomes have been reported in the pre-specified way in methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 23:53:31 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Rogers-1993">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 01:44:36 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Scharf-1999">
<DESCRIPTION>
<P>Report all outcome state in methodology</P>
<P>
<B>Comment:</B>
</P>
<P>The study protocol is not available, but all of the study&#8217;s pre-specified outcomes have been reported in the pre-specified way in methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 22:11:11 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Soininen-2007">
<DESCRIPTION>
<P>All primary outcomes were reported, but not all secondary outcomes were reported</P>
<P>
<B>Comment:</B>
</P>
<P>The study protocol is not available, but all of the study&#8217;s pre-specified outcomes have been reported in the pre-specified way in methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 22:48:43 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Zhou-2004a">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 23:14:44 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Zhou-2004b">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-06-01 12:54:30 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 22:04:31 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2000a">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 22:44:36 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2002a">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 23:11:54 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Aisen-2003a">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 23:24:20 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-Bentham-2008">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>Had a potential source of bias related to the specific study design used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 19:54:42 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-De-Jong-2008">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-15 21:01:18 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-H_x00fc_ll-1999">
<DESCRIPTION>
<P>
<B>Comment:</B>  had a potential source of bias related to the specific study design used</P>
<P>Selection bias due to baseline imbalance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-21 17:19:19 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-Jhee-2004">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study appears to have some degrees of selective bias as patients' age in each group were difference.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-01 12:54:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pasqualetti-2009">
<DESCRIPTION>
<P>
<B>Comment: </B>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 21:11:14 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Reines-2004">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-01 23:53:42 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="YES" STUDY_ID="STD-Rogers-1993">
<DESCRIPTION>
<P>
<B>Comment: </B>
</P>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 01:44:59 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-Scharf-1999">
<DESCRIPTION>
<P>
<B>Comment:</B>
</P>
<P>Selection bias: baseline are different between intervention and placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-21 15:35:51 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-Soininen-2007">
<DESCRIPTION>
<P>Celecoxib group has more hypertension, diabetes and by pass patients, trans cerebral ischemias, coronary artery disease and aspirin use, compared to placebo</P>
<P>
<B>Comment:</B>
</P>
<P>Selection bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 22:48:52 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-Zhou-2004a">
<DESCRIPTION>
<P>
<B>Comment:</B> </P>
<P>Performance bias due to the nature of open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-09 23:14:53 +0000" MODIFIED_BY="Darin   Jaturapatporn" RESULT="NO" STUDY_ID="STD-Zhou-2004b">
<DESCRIPTION>
<P>
<B>Comment:</B> </P>
<P>Performance bias due to the nature of open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-10-01 10:03:50 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2012-01-02 08:13:25 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-01-02 08:13:20 +0000" MODIFIED_BY="Joey Kwong" NO="1">
<TITLE MODIFIED="2012-01-02 08:11:21 +0000" MODIFIED_BY="Joey Kwong">The Cochrane Collaboration&#8217;s tool for assessing risk of bias</TITLE>
<TABLE COLS="3" ROWS="7">
<TR>
<TD VALIGN="TOP">
<P>
<B>Domain</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Description</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Review authors&#8217; judgment</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Sequence generation.</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
</TD>
<TD VALIGN="TOP">
<P>Was the allocation sequence adequately generated?</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Allocation concealment.</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment.</P>
</TD>
<TD VALIGN="TOP">
<P>Was allocation adequately concealed?</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Blinding of participants, personnel and outcome assessors</B>
<B>
<I> </I>
</B>
<I>Assessments should be made for each main outcome (or class of outcomes).</I>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Describe all measures used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.</P>
</TD>
<TD VALIGN="TOP">
<P>Was knowledge of the allocated intervention adequately prevented during the study?</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Incomplete outcome data </B>
<I>Assessments should be made for each main outcome (or class of outcomes).</I>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomised participants), reasons for attrition/exclusions where reported, and any re-inclusions in analyses performed by the review authors.</P>
</TD>
<TD VALIGN="TOP">
<P>Were incomplete outcome data adequately addressed?</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Selective outcome reporting.</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>State how the possibility of selective outcome reporting was examined by the review authors, and what was found.</P>
</TD>
<TD VALIGN="TOP">
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Other sources of bias.</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>State any important concerns about bias not addressed in the other domains in the tool.</P>
<P>If particular questions/entries were pre-specified in the review&#8217;s protocol, responses should be provided for each question/entry.</P>
</TD>
<TD VALIGN="TOP">
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2012-01-02 08:13:23 +0000" MODIFIED_BY="Joey Kwong" NO="2">
<TITLE MODIFIED="2012-01-02 08:12:18 +0000" MODIFIED_BY="Joey Kwong">Risk of bias within a study and across studies</TITLE>
<TABLE COLS="4" ROWS="4">
<TR>
<TD VALIGN="TOP">
<P>
<B>Risk of bias</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Interpretation</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Within a study</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Across studies</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Low risk of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Plausible bias unlikely to seriously alter the results.</P>
</TD>
<TD VALIGN="TOP">
<P>Low risk of bias for all key domains.</P>
</TD>
<TD VALIGN="TOP">
<P>Most information is from studies at low risk of bias.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Unclear risk of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Plausible bias that raises some doubt about the results.</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear risk of bias for one or more key domains.</P>
</TD>
<TD VALIGN="TOP">
<P>Most information is from studies at low or unclear risk of bias.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>High risk of bias.</P>
</TD>
<TD VALIGN="TOP">
<P>Plausible bias that seriously weakens confidence in the results.</P>
</TD>
<TD VALIGN="TOP">
<P>High risk of bias for one or more key domains.</P>
</TD>
<TD VALIGN="TOP">
<P>The proportion of information from studies at high risk of bias is sufficient to affect the interpretation of results.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2012-01-02 08:13:25 +0000" MODIFIED_BY="Joey Kwong" NO="3">
<TITLE MODIFIED="2012-01-02 08:12:47 +0000" MODIFIED_BY="Joey Kwong">Levels of quality of a body of evidence in the GRADE approach for RCT</TITLE>
<TABLE COLS="5" ROWS="5">
<TR>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>
<B>Underlying methodology</B>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>
<B>Quality rating</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>Randomised trials</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>High</P>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>Downgraded randomised trials</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>Moderate</P>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>Double-downgraded randomised trials</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>Low</P>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>Triple-downgraded randomised trials</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>Very low</P>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2012-01-02 08:13:25 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-06-05 17:27:39 +0100" MODIFIED_BY="[Empty name]">Characteristics of participants from each study</TITLE>
<TABLE COLS="8" ROWS="16">
<TR>
<TD>
<P>Study</P>
</TD>
<TD>
<P>Mean age (SD)</P>
</TD>
<TD>
<P>Female (%)</P>
</TD>
<TD>
<P>year of education (SD)</P>
</TD>
<TD>
<P>Duration of disease, yr (SD)</P>
</TD>
<TD>
<P>ApoE (% &gt;/=1allele)</P>
</TD>
<TD>
<P>MMSE (SD)</P>
</TD>
<TD>
<P>Hypertension (%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Bentham 2008</P>
<P>(Aspirin, N=156)</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>63</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>19</P>
</TD>
<TD>
<P>19</P>
</TD>
</TR>
<TR>
<TD>
<P>Zhou 2004a</P>
<P>(Aspirin, N=13)</P>
</TD>
<TD>
<P>71.1 (10.6)</P>
</TD>
<TD>
<P>57.14</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>2.65 (3.15)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>14.65 (5.93)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Zhou 2004</P>
<P>(Aspirin, N=8)</P>
</TD>
<TD>
<P>69.5 (9.8)</P>
</TD>
<TD>
<P>37.50</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>14.5 (6.8)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Aisen 2000</P>
<P>(Prednisone, N=69)</P>
</TD>
<TD>
<P>73.4 (7.2)</P>
</TD>
<TD>
<P>49.3</P>
</TD>
<TD>
<P>14.1 (3)</P>
</TD>
<TD>
<P>3.5 (2.4)</P>
</TD>
<TD>
<P>65.6</P>
</TD>
<TD>
<P>21.2 (4.4)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Aisen 2002</P>
<P>(Nimesulide, N=21)</P>
</TD>
<TD>
<P>73(2)</P>
</TD>
<TD>
<P>38.09</P>
</TD>
<TD>
<P>13.1 (11.2)</P>
</TD>
<TD>
<P>2 (0.5)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>21.1 (1.1)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Aisen 2003</P>
<P>(Naproxen, N=118)</P>
</TD>
<TD>
<P>74.1 (7.8)</P>
</TD>
<TD>
<P>48.3</P>
</TD>
<TD>
<P>13.8 (3.2)</P>
</TD>
<TD>
<P>4.1 (2.3)</P>
</TD>
<TD>
<P>70.4</P>
</TD>
<TD>
<P>20.7 (3.6)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Aisen 2003</P>
<P>(Rofecoxib, N=122)</P>
</TD>
<TD>
<P>73.7 (7.2)</P>
</TD>
<TD>
<P>54.9</P>
</TD>
<TD>
<P>13.8 (3.2)</P>
</TD>
<TD>
<P>4.1 (2.3)</P>
</TD>
<TD>
<P>68.1</P>
</TD>
<TD>
<P>21.2 (3.8)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>de Jong 2008 (Indomethacin, N=26)</P>
</TD>
<TD>
<P>72.7 (6.9)</P>
</TD>
<TD>
<P>53.85</P>
</TD>
<TD>
<P>2.4 (1.3)</P>
</TD>
<TD>
<P>2.74 (1.75)</P>
</TD>
<TD>
<P>50</P>
</TD>
<TD>
<P>19.1 (4.1)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Pasqualetti 2009 (Ibuprofen, N=66)</P>
</TD>
<TD>
<P>73.7 (7.3)</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>7.4 (3.7)</P>
</TD>
<TD>
<P>2 (0.5-5.41)</P>
</TD>
<TD>
<P>20.4</P>
</TD>
<TD>
<P>19.7 (3.0)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Rogers 1993</P>
<P>(Indoethacin, N=14)</P>
</TD>
<TD>
<P>78 (2)</P>
</TD>
<TD>
<P>35.71</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Hull 1999</P>
<P>(Piroxicam, N=6)</P>
</TD>
<TD>
<P>range of 55-75</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Scharf 1999</P>
<P>(Diclofenac, N=12)</P>
</TD>
<TD>
<P>71.8 (2.3)</P>
</TD>
<TD>
<P>66.67</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>18.5 (0.99)</P>
</TD>
</TR>
<TR>
<TD>
<P>Jhee 2004 (Celecoxib, N=15)</P>
</TD>
<TD>
<P>71.17</P>
</TD>
<TD>
<P>26.67</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
</TR>
<TR>
<TD>
<P>Reines 2004</P>
<P>(Rofecoxib, N=346)</P>
</TD>
<TD>
<P>76 (8)</P>
</TD>
<TD>
<P>54</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>2.17 (1.83)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>21 (4)</P>
</TD>
</TR>
<TR>
<TD>
<P>Soininen 2007 (Celecoxib, N=285)</P>
</TD>
<TD>
<P>73.7 (8.2)</P>
</TD>
<TD>
<P>53</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>1.37 (1.7)</P>
</TD>
<TD>
<P>N/A</P>
</TD>
<TD>
<P>19.8 (4.2)</P>
</TD>
<TD>
<P>31.9</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-01-02 08:42:48 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-01-02 08:42:18 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Aspirin vs. aspirin avoidance</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="25.68572394282542" CI_START="2.4281773756090814" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="7.897435897435898" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.4096918106655172" LOG_CI_START="0.3852804082823732" LOG_EFFECT_SIZE="0.897486109473945" METHOD="MH" MODIFIED="2009-02-02 05:14:52 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="5.942043652097072E-4" Q="0.0" RANDOM="NO" SCALE="66.51252935470144" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="154" WEIGHT="100.0" Z="3.4342461380296108">
<NAME>Bleeding</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin avoidance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="25.68572394282542" CI_START="2.4281773756090814" EFFECT_SIZE="7.897435897435898" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="3" LOG_CI_END="1.4096918106655172" LOG_CI_START="0.3852804082823732" LOG_EFFECT_SIZE="0.897486109473945" MODIFIED="2009-02-02 05:14:36 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="9" O_E="0.0" SE="0.6017443286780833" STUDY_ID="STD-Bentham-2008" TOTAL_1="156" TOTAL_2="154" VAR="0.3620962370962371" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4614324834331145" CI_START="0.6997523346024126" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0112570356472796" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.16477875623143082" LOG_CI_START="-0.1550556439110978" LOG_EFFECT_SIZE="0.004861556160166479" METHOD="MH" MODIFIED="2009-02-02 05:16:13 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9524871185927208" Q="0.0" RANDOM="NO" SCALE="63.33324048591118" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="154" WEIGHT="100.0" Z="0.05958380323379186">
<NAME>Death</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin avoidance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4614324834331145" CI_START="0.6997523346024126" EFFECT_SIZE="1.0112570356472796" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="41" LOG_CI_END="0.16477875623143082" LOG_CI_START="-0.1550556439110978" LOG_EFFECT_SIZE="0.004861556160166479" MODIFIED="2009-02-02 05:16:07 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="10" O_E="0.0" SE="0.18787230984953565" STUDY_ID="STD-Bentham-2008" TOTAL_1="156" TOTAL_2="154" VAR="0.03529600480819993" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.740701965698582" CI_START="0.49936794122269956" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9323361823361823" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.24072441974888265" LOG_CI_START="-0.301579342234944" LOG_EFFECT_SIZE="-0.030427461243030682" METHOD="MH" MODIFIED="2009-02-02 05:17:02 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8259190799963239" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="154" WEIGHT="100.0" Z="0.21993846385711432">
<NAME>Institutionaliation</NAME>
<GROUP_LABEL_1>Aspirin</GROUP_LABEL_1>
<GROUP_LABEL_2>Aspirin avoidance</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.740701965698582" CI_START="0.49936794122269956" EFFECT_SIZE="0.9323361823361823" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="18" LOG_CI_END="0.24072441974888265" LOG_CI_START="-0.301579342234944" LOG_EFFECT_SIZE="-0.030427461243030682" MODIFIED="2009-02-02 05:17:02 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="11" O_E="0.0" SE="0.31855191423621576" STUDY_ID="STD-Bentham-2008" TOTAL_1="156" TOTAL_2="154" VAR="0.10147532206355735" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-01-02 08:42:25 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Steroids vs. placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.280660327184431" CI_START="-0.48066032718443186" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.8999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2011-10-01 09:46:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.1177604810801201" Q="0.0" RANDOM="NO" SCALE="31.61" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="69" UNITS="" WEIGHT="100.00000000000001" Z="1.5642431337654692">
<NAME>ADAScog</NAME>
<GROUP_LABEL_1>Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.280660327184431" CI_START="-0.48066032718443186" EFFECT_SIZE="1.8999999999999995" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="6.3" MODIFIED="2009-02-05 00:52:52 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="212" SD_1="7.8" SD_2="6.4" SE="1.2146449352961464" STUDY_ID="STD-Aisen-2000a" TOTAL_1="69" TOTAL_2="69" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.010705881785138" CI_START="0.8841560537931271" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.3033485483394093" LOG_CI_START="-0.05347107512280942" LOG_EFFECT_SIZE="0.12493873660829993" METHOD="MH" MODIFIED="2011-10-01 09:46:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.1698939640462088" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="69" WEIGHT="100.0" Z="1.372544601948621">
<NAME>Confusion</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.010705881785138" CI_START="0.8841560537931272" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="24" LOG_CI_END="0.3033485483394093" LOG_CI_START="-0.05347107512280937" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2009-02-15 18:30:14 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="719" O_E="0.0" SE="0.20959761310732963" STUDY_ID="STD-Aisen-2000a" TOTAL_1="69" TOTAL_2="69" VAR="0.04393115942028984" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.987948657584383" CI_START="1.136986464236474" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="1.3421847142062897" LOG_CI_START="0.05575529446574778" LOG_EFFECT_SIZE="0.6989700043360189" METHOD="MH" MODIFIED="2011-10-01 09:46:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.03318333348979786" Q="0.0" RANDOM="YES" SCALE="63.33" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="69" WEIGHT="100.0" Z="2.1298580610022224">
<NAME>hyperglycemia</NAME>
<GROUP_LABEL_1>Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.987948657584383" CI_START="1.136986464236474" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3421847142062897" LOG_CI_START="0.05575529446574778" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2009-02-02 05:04:13 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="3" O_E="0.0" SE="0.7556550090839227" STUDY_ID="STD-Aisen-2000a" TOTAL_1="69" TOTAL_2="69" VAR="0.5710144927536233" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.696137391626833" CI_START="1.3797166272281138" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5454545454545454" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.671740794277153" LOG_CI_START="0.13978989809083528" LOG_EFFECT_SIZE="0.4057653461839942" METHOD="MH" MODIFIED="2011-10-01 09:46:30 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.002789126405373923" Q="0.0" RANDOM="NO" SCALE="72.76042583509388" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="69" WEIGHT="100.00000000000001" Z="2.990070964807639">
<NAME>Abnormal lab results</NAME>
<GROUP_LABEL_1>Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.696137391626833" CI_START="1.3797166272281136" EFFECT_SIZE="2.5454545454545454" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="11" LOG_CI_END="0.671740794277153" LOG_CI_START="0.13978989809083522" LOG_EFFECT_SIZE="0.4057653461839942" MODIFIED="2009-02-02 05:07:26 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="5" O_E="0.0" SE="0.31247058961924695" STUDY_ID="STD-Aisen-2000a" TOTAL_1="69" TOTAL_2="69" VAR="0.09763786937699984" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.1744671427509736" CI_START="1.097647034212125" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8666666666666667" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.5016708362786048" LOG_CI_START="0.04046270829447122" LOG_EFFECT_SIZE="0.27106677228653797" METHOD="MH" MODIFIED="2011-10-01 09:46:13 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.0212301062785654" Q="0.0" RANDOM="NO" SCALE="76.41139630306112" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="69" TOTAL_2="69" WEIGHT="100.0" Z="2.303867078012171">
<NAME>Face edema</NAME>
<GROUP_LABEL_1>Steroid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1744671427509736" CI_START="1.097647034212125" EFFECT_SIZE="1.8666666666666667" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="15" LOG_CI_END="0.5016708362786048" LOG_CI_START="0.04046270829447122" LOG_EFFECT_SIZE="0.27106677228653797" MODIFIED="2009-02-02 05:09:41 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="7" O_E="0.0" SE="0.2709159373949336" STUDY_ID="STD-Aisen-2000a" TOTAL_1="69" TOTAL_2="69" VAR="0.07339544513457558" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-01-02 08:42:32 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>NSAIDs vs. placebo</NAME>
<CONT_OUTCOME CHI2="61.815851021876" CI_END="0.31984424298909797" CI_START="-3.1311943759465275" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.4056750664787148" ESTIMABLE="YES" I2="85.44062752316555" I2_Q="71.02775789444414" ID="CMP-003.01" MODIFIED="2011-10-12 03:09:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.981141137922918E-10" P_Q="0.06319146052513014" P_Z="0.11034089048912306" Q="3.451579606288858" RANDOM="YES" SCALE="25.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="5.2135295949975475" TOTALS="YES" TOTAL_1="982" TOTAL_2="763" UNITS="" WEIGHT="99.99999999999999" Z="1.5966628070444202">
<NAME>Cognition:ADAScog all studies</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="55.742800371025496" CI_END="0.32924661551789614" CI_START="-7.942703667936243" DF="5" EFFECT_SIZE="-3.8067285262091732" ESTIMABLE="YES" I2="91.03023176675755" ID="CMP-003.01.01" MODIFIED="2011-10-05 12:22:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="9.180456395085912E-11" P_Z="0.07124072052198117" STUDIES="6" TAU2="20.852108902990338" TOTAL_1="240" TOTAL_2="171" WEIGHT="50.79780370419614" Z="1.803939954816965">
<NAME>traditional NSAIDs vs placebo</NAME>
<CONT_DATA CI_END="2.6876625694206386" CI_START="-2.4876625694206393" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="5.7" MODIFIED="2011-06-13 12:43:50 +0100" MODIFIED_BY="[Empty name]" ORDER="695" SD_1="8.0" SD_2="8.2" SE="1.3202602648986363" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="56" WEIGHT="11.141544170505911"/>
<CONT_DATA CI_END="4.147675551441752" CI_START="-7.147675551441754" EFFECT_SIZE="-1.5000000000000009" ESTIMABLE="YES" MEAN_1="7.8" MEAN_2="9.3" MODIFIED="2009-02-12 16:23:22 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="692" SD_1="7.6" SD_2="10.0" SE="2.881520066689948" STUDY_ID="STD-De-Jong-2008" TOTAL_1="19" TOTAL_2="19" WEIGHT="5.734204699984736"/>
<CONT_DATA CI_END="3.7956019921912425" CI_START="-20.795601992191244" EFFECT_SIZE="-8.5" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="10.0" MODIFIED="2011-10-05 12:22:12 +0100" MODIFIED_BY="[Empty name]" ORDER="690" SD_1="4.46" SD_2="8.49" SE="6.273381597405555" STUDY_ID="STD-H_x00fc_ll-1999" TOTAL_1="6" TOTAL_2="2" WEIGHT="1.7390500188587485"/>
<CONT_DATA CI_END="0.3435417170422188" CI_START="-0.543541717042219" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="3.1" MODIFIED="2011-06-01 13:07:01 +0100" MODIFIED_BY="[Empty name]" ORDER="464" SD_1="1.3" SD_2="1.3" SE="0.2263009527424072" STUDY_ID="STD-Pasqualetti-2009" TOTAL_1="66" TOTAL_2="66" WEIGHT="14.721985827570858"/>
<CONT_DATA CI_END="-10.802183991535099" CI_START="-18.597816008464903" EFFECT_SIZE="-14.700000000000001" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="13.3" MODIFIED="2011-10-05 12:22:11 +0100" MODIFIED_BY="[Empty name]" ORDER="694" SD_1="4.9" SD_2="5.6" SE="1.9887181801351341" STUDY_ID="STD-Rogers-1993" TOTAL_1="14" TOTAL_2="14" WEIGHT="8.453640480601027"/>
<CONT_DATA CI_END="1.9293975591864305" CI_START="-5.289397559186431" EFFECT_SIZE="-1.68" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="1.93" MODIFIED="2009-02-13 02:28:39 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="693" SD_1="4.5" SD_2="5.55" SE="1.8415632060879168" STUDY_ID="STD-Scharf-1999" TOTAL_1="17" TOTAL_2="14" WEIGHT="9.007378506674861"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.400691823475883" CI_END="1.5986404761344768" CI_START="-0.994807362246486" DF="3" EFFECT_SIZE="0.30191655694399533" ESTIMABLE="YES" I2="44.45156105816826" ID="CMP-003.01.02" MODIFIED="2011-03-21 04:31:41 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1447005576512409" P_Z="0.6481462904540358" STUDIES="4" TAU2="0.7686907984068311" TOTAL_1="742" TOTAL_2="592" WEIGHT="49.202196295803844" Z="0.45633890852879627">
<NAME>Selective COX-2 inhibitor</NAME>
<CONT_DATA CI_END="4.171753297447129" CI_START="-1.3717532974471287" EFFECT_SIZE="1.4" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="-0.5" MODIFIED="2011-03-21 04:31:41 +0000" MODIFIED_BY="[Empty name]" ORDER="241" SD_1="4.5825" SD_2="4.3588" SE="1.414185831632808" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" WEIGHT="10.744850307815812"/>
<CONT_DATA CI_END="3.9479038689103576" CI_START="-0.14790386891035867" EFFECT_SIZE="1.8999999999999995" ESTIMABLE="YES" MEAN_1="7.6" MEAN_2="5.7" MODIFIED="2009-02-12 17:41:48 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="697" SD_1="7.7" SD_2="8.2" SE="1.044868112406127" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="111" WEIGHT="12.292470060971013"/>
<CONT_DATA CI_END="0.719744994051958" CI_START="-1.919744994051959" EFFECT_SIZE="-0.6000000000000005" ESTIMABLE="YES" MEAN_1="4.84" MEAN_2="5.44" MODIFIED="2009-02-14 16:37:55 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="696" SD_1="8.57" SD_2="8.57" SE="0.6733516556742566" STUDY_ID="STD-Reines-2004" TOTAL_1="321" TOTAL_2="327" WEIGHT="13.677145285375259"/>
<CONT_DATA CI_END="1.3432482322444959" CI_START="-2.5632482322444963" EFFECT_SIZE="-0.6100000000000003" ESTIMABLE="YES" MEAN_1="4.39" MEAN_2="5.0" MODIFIED="2009-02-14 16:37:55 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="699" SD_1="9.5" SD_2="9.5" SE="0.9965735328054336" STUDY_ID="STD-Soininen-2007" TOTAL_1="278" TOTAL_2="135" WEIGHT="12.487730641641758"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="65.21114775104331" CI_END="0.04293302207998151" CI_START="-2.2069295091898793" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.081998243554949" ESTIMABLE="YES" I2="92.33259929868356" I2_Q="76.4851163204288" ID="CMP-003.02" MODIFIED="2011-10-01 09:58:39 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0126344207606053E-12" P_Q="0.039189852845214035" P_Z="0.05940797978576974" Q="4.252625756634129" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="1.4136966612489672" TOTALS="YES" TOTAL_1="694" TOTAL_2="574" UNITS="" WEIGHT="100.0" Z="1.8851619236543764">
<NAME>Cognition:MMSE all</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="47.255144011965726" CI_END="0.14115319894345335" CI_START="-6.583360275022189" DF="3" EFFECT_SIZE="-3.221103538039368" ESTIMABLE="YES" I2="93.65148480080738" ID="CMP-003.02.01" MODIFIED="2011-06-14 15:48:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.067344156448826E-10" P_Z="0.06042476318316054" STUDIES="4" TAU2="10.548572170945938" TOTAL_1="117" TOTAL_2="117" WEIGHT="56.619505598296556" Z="1.8776813964233456">
<NAME>traditional NSAIDs vs placebo</NAME>
<CONT_DATA CI_END="1.9325859026575412" CI_START="-2.1325859026575413" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="2.4" MODIFIED="2009-02-13 03:36:34 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="702" SD_1="3.2" SD_2="3.6" SE="1.037052679891222" STUDY_ID="STD-De-Jong-2008" TOTAL_1="20" TOTAL_2="23" WEIGHT="13.234281740120522"/>
<CONT_DATA CI_END="-0.42940703190683893" CI_START="-0.7705929680931612" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.7" MODIFIED="2011-06-01 13:17:45 +0100" MODIFIED_BY="[Empty name]" ORDER="466" SD_1="0.5" SD_2="0.5" SE="0.08703882797784893" STUDY_ID="STD-Pasqualetti-2009" TOTAL_1="66" TOTAL_2="66" WEIGHT="23.178133750741402"/>
<CONT_DATA CI_END="-9.089115594396679" CI_START="-15.910884405603321" EFFECT_SIZE="-12.5" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="13.4" MODIFIED="2011-06-14 15:48:55 +0100" MODIFIED_BY="[Empty name]" ORDER="701" SD_1="4.8" SD_2="4.4" SE="1.740279123753264" STUDY_ID="STD-Rogers-1993" TOTAL_1="14" TOTAL_2="14" WEIGHT="7.415680808469871"/>
<CONT_DATA CI_END="0.842455769113096" CI_START="-3.382455769113096" EFFECT_SIZE="-1.27" ESTIMABLE="YES" MEAN_1="-0.41" MEAN_2="0.86" MODIFIED="2009-02-13 02:40:14 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="705" SD_1="2.69" SD_2="3.21" SE="1.0778033605596213" STUDY_ID="STD-Scharf-1999" TOTAL_1="17" TOTAL_2="14" WEIGHT="12.79140929896476"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.09236165824325566" CI_END="0.7626053826850807" CI_START="-0.07490606398189648" DF="1" EFFECT_SIZE="0.3438496593515921" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.02" MODIFIED="2009-02-18 01:40:18 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="2" P_CHI2="0.761196013046195" P_Z="0.10753543498842667" STUDIES="2" TAU2="0.0" TOTAL_1="577" TOTAL_2="457" WEIGHT="43.380494401703444" Z="1.6093701193160297">
<NAME>Selective COX-2 inhibitor</NAME>
<CONT_DATA CI_END="1.1882412755547478" CI_START="-0.3082412755547479" EFFECT_SIZE="0.43999999999999995" ESTIMABLE="YES" MEAN_1="2.57" MEAN_2="2.13" MODIFIED="2009-02-14 16:56:33 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="707" SD_1="4.87" SD_2="4.87" SE="0.3817627678145004" STUDY_ID="STD-Reines-2004" TOTAL_1="322" TOTAL_2="329" WEIGHT="21.12454045721149"/>
<CONT_DATA CI_END="0.8053000718829176" CI_START="-0.205300071882918" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="2.0" MODIFIED="2009-02-14 16:50:55 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="708" SD_1="2.38" SD_2="2.38" SE="0.2578108964596596" STUDY_ID="STD-Soininen-2007" TOTAL_1="255" TOTAL_2="128" WEIGHT="22.255953944491957"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5265741235250907" CI_END="0.16232361272327164" CI_START="-0.08507039398484226" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0386266093692147" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2011-10-05 12:41:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7685212664044632" P_Q="0.5562055481834066" P_Z="0.5405153117445145" Q="0.3463171304592649" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="617" TOTAL_2="482" UNITS="" WEIGHT="100.0" Z="0.6120339309422345">
<NAME>CIBIC+</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.37798086657281876" CI_START="-0.5779808665728199" DF="0" EFFECT_SIZE="-0.10000000000000053" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" MODIFIED="2009-03-06 02:05:44 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="1" P_CHI2="1.0" P_Z="0.6817687426907766" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="6.697262673900112" Z="0.4100507199363949">
<NAME>traditional NSAIDs vs placebo</NAME>
<CONT_DATA CI_END="0.37798086657281876" CI_START="-0.5779808665728199" EFFECT_SIZE="-0.10000000000000053" ESTIMABLE="YES" MEAN_1="5.6" MEAN_2="5.7" MODIFIED="2009-02-12 16:37:54 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="292" SD_1="0.8" SD_2="0.7" SE="0.24387227027795988" STUDY_ID="STD-De-Jong-2008" TOTAL_1="19" TOTAL_2="19" WEIGHT="6.697262673900112"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.18025699306582585" CI_END="0.17663677009766407" CI_START="-0.07948233853001432" DF="1" EFFECT_SIZE="0.04857721578382487" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.02" MODIFIED="2009-02-18 01:40:57 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="2" P_CHI2="0.671152483492527" P_Z="0.4571917177762561" STUDIES="2" TAU2="0.0" TOTAL_1="598" TOTAL_2="463" WEIGHT="93.30273732609989" Z="0.7434790314215411">
<NAME>Selective COX-2 inhibitor</NAME>
<CONT_DATA CI_END="0.1841231824149805" CI_START="-0.12412318241498044" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.87" MODIFIED="2009-02-14 16:53:08 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="294" SD_1="1.0" SD_2="1.0" SE="0.07863572169217621" STUDY_ID="STD-Reines-2004" TOTAL_1="319" TOTAL_2="328" WEIGHT="64.41431925062504"/>
<CONT_DATA CI_END="0.3201427500779327" CI_START="-0.140142750077933" EFFECT_SIZE="0.08999999999999986" ESTIMABLE="YES" MEAN_1="4.92" MEAN_2="4.83" MODIFIED="2009-02-14 16:53:55 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="296" SD_1="1.12" SD_2="1.12" SE="0.11742192810340879" STUDY_ID="STD-Soininen-2007" TOTAL_1="279" TOTAL_2="135" WEIGHT="28.88841807547485"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.693580491755894" CI_END="0.30389171483792066" CI_START="-0.24605066674086085" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.028920524048529902" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2011-10-05 12:41:28 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6383620259832246" P_Q="0.7922209900360412" P_Z="0.8366797809447546" Q="0.0693941242809116" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="564" TOTAL_2="560" UNITS="" WEIGHT="100.0" Z="0.20614227034627272">
<NAME>CDR sum score</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.082352829478378E-33" CI_END="0.6960616424485754" CI_START="-0.4960616424485761" DF="0" EFFECT_SIZE="0.09999999999999966" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-003.04.01" MODIFIED="2011-03-21 04:32:58 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.7422924949128971" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="111" WEIGHT="21.2810003335759" Z="0.32881900880061077">
<NAME>traditional NSAIDs vs placebo</NAME>
<CONT_DATA CI_END="0.6960616424485754" CI_START="-0.4960616424485761" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="2.3" MEAN_2="2.2" MODIFIED="2009-02-12 17:42:33 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="280" SD_1="2.3" SD_2="2.3" SE="0.30411867113387486" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="111" WEIGHT="21.2810003335759"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6241863674749821" CI_END="0.31962323841744533" CI_START="-0.3002136327381888" DF="2" EFFECT_SIZE="0.009704802839628244" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" MODIFIED="2011-03-21 04:32:55 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4439280748307569" P_Z="0.951061024310695" STUDIES="3" TAU2="0.0" TOTAL_1="446" TOTAL_2="449" WEIGHT="78.7189996664241" Z="0.06137441939286451">
<NAME>Selective COX-2 inhibitor</NAME>
<CONT_DATA CI_END="1.3315172269576265" CI_START="-0.3315172269576267" EFFECT_SIZE="0.49999999999999994" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="0.2" MODIFIED="2011-03-21 04:32:55 +0000" MODIFIED_BY="[Empty name]" ORDER="242" SD_1="1.3747" SD_2="1.30766" SE="0.4242512788584527" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" WEIGHT="10.935329826348806"/>
<CONT_DATA CI_END="0.603690455040665" CI_START="-0.603690455040665" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.2" MODIFIED="2009-02-12 17:42:51 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="283" SD_1="2.4" SD_2="2.3" SE="0.308010993978715" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="111" WEIGHT="20.746544423285382"/>
<CONT_DATA CI_END="0.30092838815892986" CI_START="-0.50092838815893" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.69" MEAN_2="1.79" MODIFIED="2009-02-14 17:02:33 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="284" SD_1="2.55" SD_2="2.55" SE="0.20455905890179713" STUDY_ID="STD-Reines-2004" TOTAL_1="303" TOTAL_2="319" WEIGHT="47.037125416789905"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.0181810646065097" CI_END="1.493726946037485" CI_START="0.13567444597382605" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8147006960056555" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" MODIFIED="2011-10-05 12:41:37 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5686417819526193" P_Q="0.7762759246042887" P_Z="0.01869390826510703" Q="0.08075569644385068" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="325" TOTAL_2="307" UNITS="" WEIGHT="100.0" Z="2.3515792243318288">
<NAME>NPI</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.937425368162659" CI_END="1.5359730936916125" CI_START="0.1401743940019442" DF="2" EFFECT_SIZE="0.8380737438467784" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.01" MODIFIED="2011-06-01 13:40:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3795714353769075" P_Z="0.018591284472670562" STUDIES="3" TAU2="0.0" TOTAL_1="203" TOTAL_2="196" WEIGHT="94.66458600420074" Z="2.3536264286440947">
<NAME>traditional NSAIDs vs placebo</NAME>
<CONT_DATA CI_END="3.4602973147922897" CI_START="-2.860297314792289" EFFECT_SIZE="0.30000000000000027" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="3.4" MODIFIED="2009-02-13 02:20:20 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="300" SD_1="12.5" SD_2="11.9" SE="1.6124262178898752" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="111" WEIGHT="4.616546806157472"/>
<CONT_DATA CI_END="4.089049501146076" CI_START="-16.489049501146077" EFFECT_SIZE="-6.2" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="9.4" MODIFIED="2009-02-12 16:32:27 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="302" SD_1="18.1" SD_2="14.0" SE="5.249611514448625" STUDY_ID="STD-De-Jong-2008" TOTAL_1="19" TOTAL_2="19" WEIGHT="0.4355345518084994"/>
<CONT_DATA CI_END="1.6173023534653366" CI_START="0.1826976465346637" EFFECT_SIZE="0.9000000000000001" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="1.3" MODIFIED="2011-06-01 13:40:06 +0100" MODIFIED_BY="[Empty name]" ORDER="468" SD_1="2.0" SD_2="2.2" SE="0.3659773134217393" STUDY_ID="STD-Pasqualetti-2009" TOTAL_1="66" TOTAL_2="66" WEIGHT="89.61250464623477"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.3396965443364537" CI_START="-2.539696544336454" DF="0" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.02" MODIFIED="2009-02-18 01:41:18 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="2" P_CHI2="1.0" P_Z="0.789708398478189" STUDIES="1" TAU2="0.0" TOTAL_1="122" TOTAL_2="111" WEIGHT="5.335413995799256" Z="0.26668929326274465">
<NAME>Selective COX-2 inhibitor</NAME>
<CONT_DATA CI_END="3.3396965443364537" CI_START="-2.539696544336454" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="3.4" MODIFIED="2009-02-13 02:21:01 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="303" SD_1="10.9" SD_2="11.9" SE="1.4998727361953612" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="111" WEIGHT="5.335413995799256"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.2885840069454001" CI_START="-0.962258994232419" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.33683749364350946" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" MODIFIED="2011-10-01 10:11:32 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.2911550942299611" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="19" UNITS="" WEIGHT="100.0" Z="1.0555910782766027">
<NAME>Mood/depression</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2885840069454001" CI_START="-0.962258994232419" DF="0" EFFECT_SIZE="-0.33683749364350946" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.01" MODIFIED="2011-03-21 04:33:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2911550942299611" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="19" WEIGHT="100.0" Z="1.0555910782766027">
<NAME>selective COX-2 inhibitor vs placebo</NAME>
<CONT_DATA CI_END="0.2885840069454001" CI_START="-0.962258994232419" EFFECT_SIZE="-0.33683749364350946" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="1.0" MODIFIED="2009-10-07 16:03:01 +0100" MODIFIED_BY="[Empty name]" ORDER="442" SD_1="4.1243" SD_2="2.6153" SE="0.319098465850472" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.2872232146420665" CI_START="-1.1458729821647766" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.4293248837613551" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" MODIFIED="2011-10-01 10:11:58 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.24026435521642242" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="1.1743263455921593">
<NAME>Clinical global impression: GDS</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2872232146420665" CI_START="-1.1458729821647766" DF="0" EFFECT_SIZE="-0.4293248837613551" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.01" MODIFIED="2009-02-24 21:19:23 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="1" P_CHI2="1.0" P_Z="0.24026435521642242" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0" Z="1.1743263455921593">
<NAME>traditional NSAIDs vs placebo</NAME>
<CONT_DATA CI_END="0.28722321464206657" CI_START="-1.1458729821647766" EFFECT_SIZE="-0.429324883761355" ESTIMABLE="YES" MEAN_1="0.35" MEAN_2="0.57" ORDER="441" SD_1="0.49" SD_2="0.51" SE="0.36559248233919683" STUDY_ID="STD-Scharf-1999" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6765532569536208" CI_END="0.3450386523238246" CI_START="-0.48852434108363074" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.07174284437990305" ESTIMABLE="YES" I2="40.35381841570313" I2_Q="40.35381841570312" ID="CMP-003.08" MODIFIED="2011-10-01 10:11:58 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.19538315139053997" P_Q="0.19538315139053997" P_Z="0.7358310934190946" Q="1.6765532569536206" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.04902365477662269" TOTALS="YES" TOTAL_1="292" TOTAL_2="149" UNITS="" WEIGHT="100.0" Z="0.3373791596919859">
<NAME>Clinical global impression: CGIC and NOSGER 6 months</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.27433483105692025" CI_START="-1.1599245815013852" DF="0" EFFECT_SIZE="-0.4427948752222325" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.01" MODIFIED="2009-02-24 21:19:23 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="1" P_CHI2="1.0" P_Z="0.22620665399772766" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="14" WEIGHT="24.72352220908089" Z="1.2101883388395789">
<NAME>traditional NSAIDs vs placebo</NAME>
<CONT_DATA CI_END="0.27433483105692025" CI_START="-1.1599245815013852" EFFECT_SIZE="-0.4427948752222325" ESTIMABLE="YES" MEAN_1="4.29" MEAN_2="4.57" ORDER="439" SD_1="0.69" SD_2="0.51" SE="0.3658892265040482" STUDY_ID="STD-Scharf-1999" TOTAL_1="17" TOTAL_2="14" WEIGHT="24.72352220908089"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.358544247386278E-33" CI_END="0.256124268095252" CI_START="-0.15587610015854947" DF="0" EFFECT_SIZE="0.05012408396835129" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-003.08.02" MODIFIED="2009-02-24 21:19:23 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="2" P_CHI2="0.0" P_Z="0.6334336394591058" STUDIES="1" TAU2="0.0" TOTAL_1="275" TOTAL_2="135" WEIGHT="75.2764777909191" Z="0.47689957051451537">
<NAME>Selective COX-2 inhibitor</NAME>
<CONT_DATA CI_END="0.256124268095252" CI_START="-0.15587610015854944" EFFECT_SIZE="0.050124083968351295" ESTIMABLE="YES" MEAN_1="3.89" MEAN_2="3.31" ORDER="440" SD_1="11.55" SD_2="11.55" SE="0.10510406607050124" STUDY_ID="STD-Soininen-2007" TOTAL_1="275" TOTAL_2="135" WEIGHT="75.2764777909191"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.5139550289204737" CI_END="0.45941038738771167" CI_START="-0.28511597619055207" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.08714720559857977" ESTIMABLE="YES" I2="43.084075250262316" I2_Q="0.0" ID="CMP-003.09" MODIFIED="2011-10-01 10:12:35 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.17256570169656338" P_Q="0.6599076458288439" P_Z="0.6463565045183274" Q="0.19363580848090384" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.051269042922562326" TOTALS="YES" TOTAL_1="311" TOTAL_2="168" UNITS="" WEIGHT="100.0" Z="0.45882964709434065">
<NAME>Behavioral disturbance</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.1353015336479855" CI_END="0.8183901605314625" CI_START="-0.8879595744658637" DF="1" EFFECT_SIZE="-0.034784706967200645" ESTIMABLE="YES" I2="68.10514110786403" ID="CMP-003.09.01" MODIFIED="2009-03-06 02:05:44 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="1" P_CHI2="0.07661452421073645" P_Z="0.9363092380098753" STUDIES="2" TAU2="0.25843241616034174" TOTAL_1="36" TOTAL_2="33" WEIGHT="42.13703736830187" Z="0.07990949507030526">
<NAME>traditional NSAIDs vs placebo</NAME>
<CONT_DATA CI_END="1.0276411209237388" CI_START="-0.25724256830197795" EFFECT_SIZE="0.3851992763108804" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="1.6" ORDER="425" SD_1="6.7" SD_2="4.2" SE="0.3277824744129778" STUDY_ID="STD-De-Jong-2008" TOTAL_1="19" TOTAL_2="19" WEIGHT="22.7299572899058"/>
<CONT_DATA CI_END="0.23314911630910223" CI_START="-1.2050730391155668" EFFECT_SIZE="-0.4859619614032323" ESTIMABLE="YES" MEAN_1="-0.59" MEAN_2="1.36" ORDER="424" SD_1="3.89" SD_2="3.93" SE="0.3669001488724236" STUDY_ID="STD-Scharf-1999" TOTAL_1="17" TOTAL_2="14" WEIGHT="19.407080078396067"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.36855799219689533" CI_START="-0.04398905434330966" DF="0" EFFECT_SIZE="0.16228446892679282" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.02" MODIFIED="2009-02-24 21:19:23 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="2" P_CHI2="1.0" P_Z="0.12307601871169281" STUDIES="1" TAU2="0.0" TOTAL_1="275" TOTAL_2="135" WEIGHT="57.86296263169813" Z="1.5419900203586874">
<NAME>Selective COX-2 inhibitor</NAME>
<CONT_DATA CI_END="0.36855799219689533" CI_START="-0.04398905434330966" EFFECT_SIZE="0.16228446892679282" ESTIMABLE="YES" MEAN_1="1.01" MEAN_2="0.28" ORDER="426" SD_1="4.49" SD_2="4.49" SE="0.10524352737966702" STUDY_ID="STD-Soininen-2007" TOTAL_1="275" TOTAL_2="135" WEIGHT="57.86296263169813"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="37.10674598667684" CI_END="0.03512225435324892" CI_START="-0.47713629331308094" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.221007019479916" ESTIMABLE="YES" I2="81.13550565033823" I2_Q="65.24872702614442" ID="CMP-003.10" MODIFIED="2011-10-01 10:12:35 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="4.4772694306471905E-6" P_Q="0.08982035281511447" P_Z="0.09079863293107564" Q="2.8775924287790264" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0973625235615077" TOTALS="YES" TOTAL_1="953" TOTAL_2="784" UNITS="" WEIGHT="100.0" Z="1.6911998852318966">
<NAME>Activity of daily living</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="12.756078212940782" CI_END="0.006221513238138132" CI_START="-0.965513642711479" DF="3" EFFECT_SIZE="-0.47964606473667043" ESTIMABLE="YES" I2="76.48179989241082" ID="CMP-003.10.01" MODIFIED="2011-06-13 12:45:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.005194931454673313" P_Z="0.05300665170509352" STUDIES="4" TAU2="0.1782276282846077" TOTAL_1="220" TOTAL_2="155" WEIGHT="42.423585325154114" Z="1.9348667308255407">
<NAME>traditional NSAIDs vs placebo</NAME>
<CONT_DATA CI_END="0.05940093103965116" CI_START="-0.5790809505805906" EFFECT_SIZE="-0.2598400097704697" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="11.5" MODIFIED="2011-06-13 12:45:42 +0100" MODIFIED_BY="[Empty name]" ORDER="428" SD_1="10.5" SD_2="11.2" SE="0.1628810240026106" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="56" WEIGHT="13.784034646586507"/>
<CONT_DATA CI_END="0.7183005643857563" CI_START="-0.5540896987609898" EFFECT_SIZE="0.08210543281238328" ESTIMABLE="YES" MEAN_1="19.4" MEAN_2="18.2" ORDER="429" SD_1="13.8" SD_2="14.8" SE="0.3245953173586857" STUDY_ID="STD-De-Jong-2008" TOTAL_1="19" TOTAL_2="19" WEIGHT="8.42394860968971"/>
<CONT_DATA CI_END="-0.631957845806139" CI_START="-1.356481460552242" EFFECT_SIZE="-0.9942196531791905" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.7" MODIFIED="2011-06-01 14:39:17 +0100" MODIFIED_BY="[Empty name]" ORDER="471" SD_1="0.2" SD_2="0.2" SE="0.18483084905157768" STUDY_ID="STD-Pasqualetti-2009" TOTAL_1="66" TOTAL_2="66" WEIGHT="12.984165877084115"/>
<CONT_DATA CI_END="0.05031405417268153" CI_START="-1.4100512883216565" EFFECT_SIZE="-0.6798686170744875" ESTIMABLE="YES" MEAN_1="0.06" MEAN_2="1.86" ORDER="427" SD_1="2.95" SD_2="2.03" SE="0.3725490248834962" STUDY_ID="STD-Scharf-1999" TOTAL_1="17" TOTAL_2="14" WEIGHT="7.231436191793787"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.884009139505987" CI_END="0.17221859104416276" CI_START="-0.22343364121099296" DF="3" EFFECT_SIZE="-0.025607525083415097" ESTIMABLE="YES" I2="61.94829373082157" ID="CMP-003.10.02" MODIFIED="2011-06-13 12:45:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.048470800655567636" P_Z="0.799722096073936" STUDIES="4" TAU2="0.023514970505268705" TOTAL_1="733" TOTAL_2="629" WEIGHT="57.576414674845886" Z="0.253706779868904">
<NAME>Selective COX-2 inhibitor</NAME>
<CONT_DATA CI_END="0.5989087143545467" CI_START="-0.4071061168197535" EFFECT_SIZE="0.09590129876739664" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.3" MODIFIED="2011-06-13 12:45:45 +0100" MODIFIED_BY="[Empty name]" ORDER="243" SD_1="1.37477" SD_2="0.8717" SE="0.2566411523654559" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="55" WEIGHT="10.462361242928365"/>
<CONT_DATA CI_END="-0.04687510447189963" CI_START="-0.564089227500655" EFFECT_SIZE="-0.3054821659862773" ESTIMABLE="YES" MEAN_1="8.3" MEAN_2="11.5" ORDER="431" SD_1="9.7" SD_2="11.2" SE="0.13194480284037727" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="111" WEIGHT="14.87943623759226"/>
<CONT_DATA CI_END="0.13043105922724618" CI_START="-0.17881726321883817" EFFECT_SIZE="-0.024193101995796006" ESTIMABLE="YES" MEAN_1="7.85" MEAN_2="8.13" ORDER="433" SD_1="11.56" SD_2="11.56" SE="0.07889132782168337" STUDY_ID="STD-Reines-2004" TOTAL_1="315" TOTAL_2="328" WEIGHT="16.486165693314923"/>
<CONT_DATA CI_END="0.36855799219689533" CI_START="-0.04398905434330966" EFFECT_SIZE="0.16228446892679282" ESTIMABLE="YES" MEAN_1="1.01" MEAN_2="0.28" ORDER="432" SD_1="4.49" SD_2="4.49" SE="0.10524352737966702" STUDY_ID="STD-Soininen-2007" TOTAL_1="275" TOTAL_2="135" WEIGHT="15.748451501010335"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.20139309709042538" CI_END="0.2919184441243736" CI_START="-0.1371202380867198" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.07739910301882691" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.11" MODIFIED="2011-10-01 10:12:51 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.9042074536422912" P_Q="0.907594154823614" P_Z="0.4794671823562866" Q="0.013473097850856732" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="257" TOTAL_2="125" UNITS="" WEIGHT="100.00000000000001" Z="0.7071598000012863">
<NAME>Quality of life</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.18791999923956862" CI_END="0.35606235437017475" CI_START="-0.22442047553467245" DF="1" EFFECT_SIZE="0.06582093941775116" ESTIMABLE="YES" I2="0.0" ID="CMP-003.11.01" MODIFIED="2011-06-13 12:46:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6646534588635258" P_Z="0.6566951720045204" STUDIES="2" TAU2="0.0" TOTAL_1="135" TOTAL_2="70" WEIGHT="54.62785443697583" Z="0.44448057389925505">
<NAME>traditional NSAIDs vs placebo</NAME>
<CONT_DATA CI_END="0.35511325861597215" CI_START="-0.2810241919907111" EFFECT_SIZE="0.037044533312630516" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="2.4" MODIFIED="2011-06-13 12:46:35 +0100" MODIFIED_BY="[Empty name]" ORDER="434" SD_1="5.5" SD_2="5.1" SE="0.16228294387663605" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="56" WEIGHT="45.48738513656423"/>
<CONT_DATA CI_END="0.9185749171559959" CI_START="-0.5005224779150542" EFFECT_SIZE="0.20902621962047083" ESTIMABLE="YES" MEAN_1="0.53" MEAN_2="0.21" ORDER="435" SD_1="1.84" SD_2="0.89" SE="0.3620212938259859" STUDY_ID="STD-Scharf-1999" TOTAL_1="17" TOTAL_2="14" WEIGHT="9.140469300411603"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4098115552398941" CI_START="-0.22713323782560302" DF="0" EFFECT_SIZE="0.09133915870714555" ESTIMABLE="YES" I2="0.0" ID="CMP-003.11.02" MODIFIED="2011-06-13 12:46:36 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5740305047522376" STUDIES="1" TAU2="0.0" TOTAL_1="122" TOTAL_2="55" WEIGHT="45.37214556302418" Z="0.562125519803989">
<NAME>Selective COX-2 inhibitor</NAME>
<CONT_DATA CI_END="0.4098115552398941" CI_START="-0.22713323782560302" EFFECT_SIZE="0.09133915870714555" ESTIMABLE="YES" MEAN_1="2.9" MEAN_2="2.4" MODIFIED="2011-06-13 12:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="436" SD_1="5.6" SD_2="5.1" SE="0.1624889023700528" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="55" WEIGHT="45.37214556302418"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5992832130208416" CI_END="-0.07233804106754343" CI_START="-0.6307702797167409" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.35155416039214216" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.12" MODIFIED="2011-10-01 10:13:10 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.7410838058174001" P_Q="1.0" P_Z="0.013596807801614619" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="99" UNITS="" WEIGHT="99.99999999999997" Z="2.4677425309489034">
<NAME>Caregiver burden</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.5992832130208416" CI_END="-0.07233804106754343" CI_START="-0.6307702797167409" DF="2" EFFECT_SIZE="-0.35155416039214216" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.01" MODIFIED="2011-06-01 13:23:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7410838058174001" P_Z="0.013596807801614619" STUDIES="3" TAU2="0.0" TOTAL_1="102" TOTAL_2="99" WEIGHT="99.99999999999997" Z="2.4677425309489034">
<NAME>traditional NSAIDs vs placebo</NAME>
<CONT_DATA CI_END="0.06710166314403554" CI_START="-1.2345575556013395" EFFECT_SIZE="-0.583727946228652" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="6.5" ORDER="437" SD_1="8.3" SD_2="8.8" SE="0.332062024866961" STUDY_ID="STD-De-Jong-2008" TOTAL_1="19" TOTAL_2="19" WEIGHT="18.405446936840253"/>
<CONT_DATA CI_END="0.044869882877340395" CI_START="-0.6414016747848548" EFFECT_SIZE="-0.2982658959537572" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.5" MODIFIED="2011-06-01 13:23:41 +0100" MODIFIED_BY="[Empty name]" ORDER="467" SD_1="1.0" SD_2="1.0" SE="0.17507249191194776" STUDY_ID="STD-Pasqualetti-2009" TOTAL_1="66" TOTAL_2="66" WEIGHT="66.21386892649863"/>
<CONT_DATA CI_END="0.4088280128483372" CI_START="-1.0150823664257944" EFFECT_SIZE="-0.30312717678872864" ESTIMABLE="YES" MEAN_1="4.47" MEAN_2="4.79" ORDER="438" SD_1="1.01" SD_2="1.05" SE="0.3632491184801749" STUDY_ID="STD-Scharf-1999" TOTAL_1="17" TOTAL_2="14" WEIGHT="15.38068413666109"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="11.403729281953902" CI_END="2.76832316074843" CI_START="1.3631299633785614" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9425715556269816" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="35" I2="29.84751038715215" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="0.4422167861957675" LOG_CI_START="0.13453726426270868" LOG_EFFECT_SIZE="0.2883770252292381" METHOD="MH" MODIFIED="2011-10-01 17:09:35 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.1798557574042381" P_Q="1.0" P_Z="2.3877482025742996E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="989" TOTAL_2="686" WEIGHT="99.99999999999997" Z="3.6740084609275776">
<NAME>Gastrointestinal side effects</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.381865820367336" CI_START="1.368920590865392" EFFECT_SIZE="2.7142857142857144" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.7309328658170937" LOG_CI_START="0.13637825606005063" LOG_EFFECT_SIZE="0.43365556093857216" ORDER="754" O_E="0.0" SE="0.349244320864071" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="0.12197159565580618" WEIGHT="16.24964493218745"/>
<DICH_DATA CI_END="22.775052429998958" CI_START="0.3381166749744493" EFFECT_SIZE="2.775" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.357459385426947" LOG_CI_START="-0.47093341050955684" LOG_EFFECT_SIZE="0.443262987458695" MODIFIED="2009-02-14 15:27:06 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="757" O_E="0.0" SE="1.07400697902341" STUDY_ID="STD-Aisen-2003a" TOTAL_1="240" TOTAL_2="111" VAR="1.1534909909909912" WEIGHT="3.52725978720661"/>
<DICH_DATA CI_END="2.2948312108828905" CI_START="0.27978220039100604" EFFECT_SIZE="0.8012820512820513" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3607507478785395" LOG_CI_START="-0.5531799185713498" LOG_EFFECT_SIZE="-0.09621458534640516" ORDER="756" O_E="0.0" SE="0.5368473975024265" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="0.2882051282051283" WEIGHT="15.779300401003686"/>
<DICH_DATA CI_END="4.816917538103997" CI_START="0.03813091420702448" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.6827692115930425" LOG_CI_START="-1.4187227821822312" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2011-10-01 17:09:35 +0100" MODIFIED_BY="[Empty name]" ORDER="759" O_E="0.0" SE="1.2344267996967353" STUDY_ID="STD-H_x00fc_ll-1999" TOTAL_1="7" TOTAL_2="3" VAR="1.523809523809524" WEIGHT="3.6110322071527667"/>
<DICH_DATA CI_END="1.8043006754171937" CI_START="0.2946759567414343" EFFECT_SIZE="0.7291666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.25630891169462433" LOG_CI_START="-0.5306552977452476" LOG_EFFECT_SIZE="-0.1371731930253116" MODIFIED="2011-10-01 17:09:35 +0100" MODIFIED_BY="[Empty name]" ORDER="752" O_E="0.0" SE="0.4622666721606438" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="0.21369047619047615" WEIGHT="11.791125574376382"/>
<DICH_DATA CI_END="3.576791602279195" CI_START="1.1183206752809218" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="16" LOG_CI_END="0.5534936372088661" LOG_CI_START="0.048566354119096225" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="753" O_E="0.0" SE="0.2965967855172924" STUDY_ID="STD-Reines-2004" TOTAL_1="346" TOTAL_2="346" VAR="0.08796965317919075" WEIGHT="41.26893951031734"/>
<DICH_DATA CI_END="32.80285982197966" CI_START="0.5292560223507785" EFFECT_SIZE="4.166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5159117080642133" LOG_CI_START="-0.27633419148742516" LOG_EFFECT_SIZE="0.619788758288394" ORDER="755" O_E="0.0" SE="1.052774113156917" STUDY_ID="STD-Rogers-1993" TOTAL_1="24" TOTAL_2="20" VAR="1.1083333333333332" WEIGHT="2.8137913302489093"/>
<DICH_DATA CI_END="112.95106309578426" CI_START="0.37175745715993386" EFFECT_SIZE="6.48" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.0528903228567366" LOG_CI_START="-0.42974031111555" LOG_EFFECT_SIZE="0.8115750058705934" ORDER="758" O_E="0.0" SE="1.4583095236151573" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.126666666666667" WEIGHT="1.499598092671415"/>
<DICH_DATA CI_END="31.11175407662241" CI_START="0.4963886332276794" EFFECT_SIZE="3.9298245614035086" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.492924497265015" LOG_CI_START="-0.3041781719416721" LOG_EFFECT_SIZE="0.5943731626616714" ORDER="751" O_E="0.0" SE="1.0556270036936903" STUDY_ID="STD-Soininen-2007" TOTAL_1="285" TOTAL_2="140" VAR="1.1143483709273183" WEIGHT="3.4593081648354236"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2757894374947357" CI_END="34.30282088073016" CI_START="0.5388412141977496" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.299275945293644" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="1.5353298355693386" LOG_CI_START="-0.2685391939176497" LOG_EFFECT_SIZE="0.6333953208258445" METHOD="MH" MODIFIED="2011-10-01 10:13:08 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.5994744008431871" P_Q="1.0" P_Z="0.1686946200605738" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="42" WEIGHT="100.0" Z="1.3764103673844943">
<NAME>Elevated creatinine</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="124.2142564295905" CI_START="0.3658000863985998" EFFECT_SIZE="6.7407407407407405" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.094171443935422" LOG_CI_START="-0.4367561962832468" LOG_EFFECT_SIZE="0.8287076238260874" ORDER="761" O_E="0.0" SE="1.4866794241583188" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="2.21021571021571" WEIGHT="46.70152855993564"/>
<DICH_DATA CI_END="50.04129972983788" CI_START="0.09323498840335014" EFFECT_SIZE="2.16" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6993285811605914" LOG_CI_START="-1.0304210788587294" LOG_EFFECT_SIZE="0.3344537511509309" ORDER="765" O_E="0.0" SE="1.6034684627740925" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.571111111111111" WEIGHT="53.29847144006436"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07455944023313776" CI_END="18.76358745500805" CI_START="0.9739697819157991" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="4.2749464536426895" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" I2_Q="100.0" ID="CMP-003.15" LOG_CI_END="1.2733158757788972" LOG_CI_START="-0.011454517198184876" LOG_EFFECT_SIZE="0.6309306792903561" METHOD="MH" MODIFIED="2011-10-01 10:13:08 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.9634066140269414" P_Q="0.0" P_Z="0.05422742928903173" Q="8.656736674482511E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="61" WEIGHT="100.0" Z="1.9250154189575075">
<NAME>Elevated liver function test</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="35.3305429822976" CI_START="0.5792396855594232" EFFECT_SIZE="4.523809523809524" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5481503120004707" LOG_CI_START="-0.23714169089061377" LOG_EFFECT_SIZE="0.6555043105549285" ORDER="774" O_E="0.0" SE="1.0486893598361642" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="1.099749373433584" WEIGHT="49.04641367507353"/>
<DICH_DATA CI_END="67.75150586967578" CI_START="0.12318071613639271" EFFECT_SIZE="2.888888888888889" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.830918952441243" LOG_CI_START="-0.909457275378257" LOG_EFFECT_SIZE="0.4607308385314931" ORDER="773" O_E="0.0" SE="1.6097105613022769" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="2.591168091168091" WEIGHT="23.796103669846996"/>
<DICH_DATA CI_END="91.65147041627819" CI_START="0.2771543095230956" EFFECT_SIZE="5.04" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9621394369856662" LOG_CI_START="-0.5572783640946156" LOG_EFFECT_SIZE="0.7024305364455253" ORDER="775" O_E="0.0" SE="1.4799184876738076" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.19015873015873" WEIGHT="27.157482655079477"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.932397007963319" CI_END="3.443341538946619" CI_START="0.3400153808386309" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.082030075701416" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="0.5369801017413883" LOG_CI_START="-0.4685014368922769" LOG_EFFECT_SIZE="0.034239332424555693" METHOD="MH" MODIFIED="2011-10-01 10:13:07 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.5865560893305761" P_Q="1.0" P_Z="0.8938106021803623" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="374" TOTAL_2="203" WEIGHT="100.0" Z="0.13348401900648638">
<NAME>Headache</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8230354467494423" CI_START="0.009702213656709344" EFFECT_SIZE="0.1925925925925926" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5824083247666914" LOG_CI_START="-2.0131291658150676" LOG_EFFECT_SIZE="-0.7153604205241881" ORDER="785" O_E="0.0" SE="1.5246315700855155" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="2.3245014245014244" WEIGHT="48.22500839527239"/>
<DICH_DATA CI_END="12.08896337218474" CI_START="0.2908127762293526" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.082389061734073" LOG_CI_START="-0.5363865176065977" LOG_EFFECT_SIZE="0.27300127206373764" ORDER="787" O_E="0.0" SE="0.9508767883730609" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="0.9041666666666668" WEIGHT="28.849952112304045"/>
<DICH_DATA CI_END="58.665164940986045" CI_START="0.10824822543988676" EFFECT_SIZE="2.52" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7683802960571493" LOG_CI_START="-0.9655792144940613" LOG_EFFECT_SIZE="0.4014005407815441" ORDER="783" O_E="0.0" SE="1.605941349815621" STUDY_ID="STD-Rogers-1993" TOTAL_1="24" TOTAL_2="20" VAR="2.579047619047619" WEIGHT="10.28955493135844"/>
<DICH_DATA CI_END="36.488133652671934" CI_START="0.06126540971869944" EFFECT_SIZE="1.4951456310679612" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5621516500164712" LOG_CI_START="-1.2127846577538897" LOG_EFFECT_SIZE="0.17468349613129086" ORDER="788" O_E="0.0" SE="1.6300113233405673" STUDY_ID="STD-Soininen-2007" TOTAL_1="308" TOTAL_2="153" VAR="2.6569369142184676" WEIGHT="12.63548456106513"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.771445601068861" CI_END="1.8550971414249853" CI_START="0.667107456363635" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1124518575306854" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" I2="55.69631395212781" I2_Q="0.0" ID="CMP-003.17" LOG_CI_END="0.268366656204562" LOG_CI_START="-0.1758042051434227" LOG_EFFECT_SIZE="0.04628122553056964" METHOD="MH" MODIFIED="2011-10-01 10:13:07 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.07955064165664472" P_Q="1.0" P_Z="0.6829474937099449" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="377" TOTAL_2="209" WEIGHT="99.99999999999997" Z="0.40844433119725054">
<NAME>Psychiatric side effects</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.370592892431301" CI_START="1.0197220910633795" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.6405403551501929" LOG_CI_START="0.008481827876815258" LOG_EFFECT_SIZE="0.3245110915135041" ORDER="795" O_E="0.0" SE="0.37127430766055175" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="0.13784461152882205" WEIGHT="28.26497526153995"/>
<DICH_DATA CI_END="1.63555882661377" CI_START="0.005326076304541385" EFFECT_SIZE="0.09333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2136661691362046" LOG_CI_START="-2.273592615891091" LOG_EFFECT_SIZE="-1.0299632233774432" ORDER="799" O_E="0.0" SE="1.4610281224545867" STUDY_ID="STD-Rogers-1993" TOTAL_1="24" TOTAL_2="20" VAR="2.134603174603175" WEIGHT="21.944856569518592"/>
<DICH_DATA CI_END="5.5601444144264285" CI_START="0.010359443155927786" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7450860717212663" LOG_CI_START="-1.9846635882980546" LOG_EFFECT_SIZE="-0.619788758288394" ORDER="796" O_E="0.0" SE="1.6034684627740925" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.571111111111111" WEIGHT="7.825297691456242"/>
<DICH_DATA CI_END="2.701446173006753" CI_START="0.47723138299979556" EFFECT_SIZE="1.1354359925788498" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="0.43159631853483443" LOG_CI_START="-0.3212710046171894" LOG_EFFECT_SIZE="0.055162656958822505" ORDER="792" O_E="0.0" SE="0.44223799237285266" STUDY_ID="STD-Soininen-2007" TOTAL_1="308" TOTAL_2="153" VAR="0.1955744418979713" WEIGHT="41.9648704774852"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="66.3533143927606" CI_START="0.17948973569036156" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4510489510489513" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="1.8218626210442543" LOG_CI_START="-0.7459603819630669" LOG_EFFECT_SIZE="0.5379511195405937" METHOD="MH" MODIFIED="2011-10-01 10:13:06 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.4115249589794142" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="285" TOTAL_2="140" WEIGHT="100.0" Z="0.8212130030050665">
<NAME>Bleeding</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="66.35331439276065" CI_START="0.17948973569036147" EFFECT_SIZE="3.4510489510489513" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8218626210442546" LOG_CI_START="-0.7459603819630671" LOG_EFFECT_SIZE="0.5379511195405937" ORDER="848" O_E="0.0" SE="1.508351942895365" STUDY_ID="STD-Soininen-2007" TOTAL_1="285" TOTAL_2="140" VAR="2.275125583636222" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.655304669101112" CI_END="38.89856583747885" CI_START="1.4757942999796092" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="7.576693324949402" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" I2="62.33953822185966" I2_Q="0.0" ID="CMP-003.19" LOG_CI_END="1.5899335894914932" LOG_CI_START="0.16902582861891813" LOG_EFFECT_SIZE="0.8794797090552057" METHOD="MH" MODIFIED="2011-10-01 10:13:06 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.1032050373331177" P_Q="1.0" P_Z="0.015255175599014433" Q="0.0" RANDOM="NO" SCALE="138.43491274800346" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="525" TOTAL_2="251" WEIGHT="100.0" Z="2.426263832669082">
<NAME>Heart disease</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.190082453092693" CI_START="0.14595483059687825" EFFECT_SIZE="1.3875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1202475103917973" LOG_CI_START="-0.8357815268023696" LOG_EFFECT_SIZE="0.14223299179471383" MODIFIED="2009-02-14 15:35:36 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="806" O_E="0.0" SE="1.1489811389477451" STUDY_ID="STD-Aisen-2003a" TOTAL_1="240" TOTAL_2="111" VAR="1.3201576576576577" WEIGHT="67.12385294059854"/>
<DICH_DATA CI_END="331.78518105737055" CI_START="1.2314502970007104" EFFECT_SIZE="20.213286713286713" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="0" LOG_CI_END="2.520856984675882" LOG_CI_START="0.09041688781626335" LOG_EFFECT_SIZE="1.3056369362460725" ORDER="803" O_E="0.0" SE="1.4276525437678507" STUDY_ID="STD-Soininen-2007" TOTAL_1="285" TOTAL_2="140" VAR="2.0381917857268146" WEIGHT="32.87614705940146"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.857127631408943" CI_END="2.0223802085758806" CI_START="0.5449416294633164" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0497995838519378" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="16" I2="48.78035465861371" I2_Q="0.0" ID="CMP-003.20" LOG_CI_END="0.3058628065289417" LOG_CI_START="-0.2636500139795063" LOG_EFFECT_SIZE="0.021106396274717644" METHOD="MH" MODIFIED="2011-10-01 10:13:06 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.11877220843987912" P_Q="1.0" P_Z="0.8844943373563247" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="920" TOTAL_2="635" WEIGHT="100.0" Z="0.1452742591639807">
<NAME>Cerebrovascular side effects</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="32.4536669046249" CI_START="0.5338813114992205" EFFECT_SIZE="4.1625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.5112637743712884" LOG_CI_START="-0.27255528134253615" LOG_EFFECT_SIZE="0.6193542465143762" MODIFIED="2009-02-14 15:40:58 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="818" O_E="0.0" SE="1.0478241433730355" STUDY_ID="STD-Aisen-2003a" TOTAL_1="240" TOTAL_2="111" VAR="1.0979354354354356" WEIGHT="7.504840553814108"/>
<DICH_DATA CI_END="67.75150586967578" CI_START="0.12318071613639271" EFFECT_SIZE="2.888888888888889" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.830918952441243" LOG_CI_START="-0.909457275378257" LOG_EFFECT_SIZE="0.4607308385314931" ORDER="815" O_E="0.0" SE="1.6097105613022769" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="2.591168091168091" WEIGHT="2.795730107252213"/>
<DICH_DATA CI_END="1.1309163367465815" CI_START="0.11692412662379678" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.05343047775193963" LOG_CI_START="-0.9320958654124649" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="812" O_E="0.0" SE="0.5789030524088482" STUDY_ID="STD-Reines-2004" TOTAL_1="346" TOTAL_2="346" VAR="0.33512874408828164" WEIGHT="60.36706120474223"/>
<DICH_DATA CI_END="4.543999456155134" CI_START="0.48874875863612044" EFFECT_SIZE="1.4902597402597402" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.6574382707247849" LOG_CI_START="-0.3109143326511511" LOG_EFFECT_SIZE="0.17326196903681695" ORDER="810" O_E="0.0" SE="0.5688151126457188" STUDY_ID="STD-Soininen-2007" TOTAL_1="308" TOTAL_2="153" VAR="0.3235506323741618" WEIGHT="29.33236813419145"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5276545089730258" CI_END="21.597545762316614" CI_START="1.3573654308999739" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="5.414403199804093" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" I2="34.54017291696042" I2_Q="0.0" ID="CMP-003.21" LOG_CI_END="1.3344044028897966" LOG_CI_START="0.1326967844748967" LOG_EFFECT_SIZE="0.7335505936823467" METHOD="MH" MODIFIED="2011-10-01 10:13:05 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.21646523246323557" P_Q="1.0" P_Z="0.016719613212464797" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="266" TOTAL_2="136" WEIGHT="100.0" Z="2.392816226549019">
<NAME>Hypertension</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="238.63010920740263" CI_START="0.8697613561224465" EFFECT_SIZE="14.406639004149378" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" LOG_CI_END="2.3777252399950295" LOG_CI_START="-0.06059989213585802" LOG_EFFECT_SIZE="1.158562673929586" MODIFIED="2009-02-14 15:43:04 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="829" O_E="0.0" SE="1.4322842525177484" STUDY_ID="STD-Aisen-2003a" TOTAL_1="240" TOTAL_2="111" VAR="2.0514381800103254" WEIGHT="25.082137828296226"/>
<DICH_DATA CI_END="11.271312186191732" CI_START="0.5126711278958315" EFFECT_SIZE="2.4038461538461537" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0519744787833807" LOG_CI_START="-0.29016114003686627" LOG_EFFECT_SIZE="0.38090666937325723" ORDER="824" O_E="0.0" SE="0.7883771061734742" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="0.6215384615384615" WEIGHT="74.91786217170377"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.900760915747465" CI_START="0.1858333391234605" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.22" LOG_CI_END="1.2988696821982773" LOG_CI_START="-0.7308763694678754" LOG_EFFECT_SIZE="0.28399665636520083" METHOD="MH" MODIFIED="2011-10-05 12:57:28 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="1.0" P_Q="1.0" P_Z="0.5833720597865653" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="0.5484658711356307">
<NAME>Hyperglycemia</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.900760915747448" CI_START="0.1858333391234606" EFFECT_SIZE="1.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2988696821982768" LOG_CI_START="-0.7308763694678753" LOG_EFFECT_SIZE="0.28399665636520083" ORDER="855" O_E="0.0" SE="1.192282878153696" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="1.4215384615384614" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2602674330118188" CI_END="12.04086338577082" CI_START="1.0005238722908478" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.470903522205207" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.23" LOG_CI_END="1.0806576289676846" LOG_CI_START="2.274552715807135E-4" LOG_EFFECT_SIZE="0.5404425421196327" METHOD="MH" MODIFIED="2011-10-05 12:57:28 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="0.6099365261725356" P_Q="1.0" P_Z="0.049903616202090224" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="24" WEIGHT="99.99999999999999" Z="1.960789219064682">
<NAME>Rash</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.524902600773654" CI_START="1.0031242551147515" EFFECT_SIZE="4.071428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2181389083954266" LOG_CI_START="0.0013547315930800402" LOG_EFFECT_SIZE="0.6097468199942534" ORDER="834" O_E="0.0" SE="0.7147450486325142" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="0.5108604845446951" WEIGHT="73.96630934150076"/>
<DICH_DATA CI_END="31.7594363676301" CI_START="0.09805548231911063" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.5018727864313772" LOG_CI_START="-1.0085281197486002" LOG_EFFECT_SIZE="0.2466723333413885" ORDER="836" O_E="0.0" SE="1.4746219189750194" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="2.174509803921569" WEIGHT="26.03369065849923"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.172740216038529" CI_START="0.6132230261516252" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.732142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.24" LOG_CI_END="1.0853883536406572" LOG_CI_START="-0.21238154601786055" LOG_EFFECT_SIZE="0.4365034038113984" METHOD="MH" MODIFIED="2011-10-05 12:57:28 +0100" MODIFIED_BY="[Empty name]" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.18734862429249438" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="308" TOTAL_2="153" WEIGHT="100.0" Z="1.3184632357779305">
<NAME>Respiratory side effects</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="12.172740216038529" CI_START="0.6132230261516252" EFFECT_SIZE="2.732142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.0853883536406572" LOG_CI_START="-0.21238154601786055" LOG_EFFECT_SIZE="0.4365034038113984" ORDER="866" O_E="0.0" SE="0.7623164631240227" STUDY_ID="STD-Soininen-2007" TOTAL_1="308" TOTAL_2="153" VAR="0.5811263899499194" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="25.996919457582308" CI_START="0.40317877920504824" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.2375000000000003" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.25" LOG_CI_END="1.4149218886694288" LOG_CI_START="-0.39450233449081235" LOG_EFFECT_SIZE="0.5102097770893083" METHOD="MH" MODIFIED="2011-10-05 12:57:28 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="1.0" P_Q="1.0" P_Z="0.2690226975622614" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="240" TOTAL_2="111" WEIGHT="100.0" Z="1.1053160169467842">
<NAME>Dry mouth</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="25.996919457582308" CI_START="0.40317877920504824" EFFECT_SIZE="3.2375" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.4149218886694288" LOG_CI_START="-0.39450233449081235" LOG_EFFECT_SIZE="0.5102097770893083" MODIFIED="2009-02-14 15:48:32 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="884" O_E="0.0" SE="1.0628647454786837" STUDY_ID="STD-Aisen-2003a" TOTAL_1="240" TOTAL_2="111" VAR="1.1296814671814672" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.043108755932988" CI_START="1.0603888412497007" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.3125" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.26" LOG_CI_END="0.7026983339319435" LOG_CI_START="0.025465148890197013" LOG_EFFECT_SIZE="0.3640817414110702" METHOD="MH" MODIFIED="2011-10-05 12:57:28 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="1.0" P_Q="1.0" P_Z="0.035086376332215057" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="240" TOTAL_2="111" WEIGHT="100.0" Z="2.1073601127515196">
<NAME>Fatigue</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.043108755932988" CI_START="1.0603888412497007" EFFECT_SIZE="2.3125" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="7" LOG_CI_END="0.7026983339319435" LOG_CI_START="0.025465148890197013" LOG_EFFECT_SIZE="0.3640817414110702" MODIFIED="2009-02-14 15:49:08 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="898" O_E="0.0" SE="0.397810125251854" STUDY_ID="STD-Aisen-2003a" TOTAL_1="240" TOTAL_2="111" VAR="0.15825289575289575" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.48459955349409717" CI_END="5.2490170672229715" CI_START="1.1013370802336575" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.404357945671148" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-003.27" LOG_CI_END="0.7200779848825829" LOG_CI_START="0.041920261460795014" LOG_EFFECT_SIZE="0.38099912317168894" METHOD="MH" MODIFIED="2011-10-05 12:57:28 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.7848208791087778" P_Q="1.0" P_Z="0.027645959937417936" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="282" TOTAL_2="141" WEIGHT="100.0" Z="2.2022739954652235">
<NAME>Dizziness</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.528983397376347" CI_START="1.0274340723083517" EFFECT_SIZE="2.59" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="5" LOG_CI_END="0.8148455642336553" LOG_CI_START="0.011753963928848192" LOG_EFFECT_SIZE="0.4132997640812518" MODIFIED="2009-02-14 15:49:48 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="904" O_E="0.0" SE="0.47173998138657913" STUDY_ID="STD-Aisen-2003a" TOTAL_1="240" TOTAL_2="111" VAR="0.22253861003861003" WEIGHT="72.88763666431875"/>
<DICH_DATA CI_END="25.918681763942033" CI_START="0.3210427904067218" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4136129093434457" LOG_CI_START="-0.4934370785016816" LOG_EFFECT_SIZE="0.46008791542088207" ORDER="901" O_E="0.0" SE="1.1202106029099148" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="1.2548717948717947" WEIGHT="10.868832879061648"/>
<DICH_DATA CI_END="8.765462110799932" CI_START="0.17825643191986906" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.9427748168223009" LOG_CI_START="-0.7489547908061881" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="908" O_E="0.0" SE="0.9937303457175896" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="0.9875" WEIGHT="16.243530456619606"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.15328802209116532" CI_END="8.694510550823038" CI_START="0.20607480753917679" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.338551302120393" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.28" LOG_CI_END="0.9392451388333042" LOG_CI_START="-0.6859750970876203" LOG_EFFECT_SIZE="0.12663502087284195" METHOD="MH" MODIFIED="2011-10-05 12:57:28 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.6954129743002346" P_Q="1.0" P_Z="0.7600343920914248" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="309" TOTAL_2="157" WEIGHT="100.0" Z="0.3054356260234561">
<NAME>Abnormal labs other than Cr. and LFT</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="50.04129972983788" CI_START="0.09323498840335014" EFFECT_SIZE="2.16" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6993285811605914" LOG_CI_START="-1.0304210788587294" LOG_EFFECT_SIZE="0.3344537511509309" ORDER="914" O_E="0.0" SE="1.6034684627740925" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.571111111111111" WEIGHT="30.240500925003563"/>
<DICH_DATA CI_END="10.742610844037051" CI_START="0.08984967264721418" EFFECT_SIZE="0.9824561403508771" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.031109843501418" LOG_CI_START="-1.046483500834" LOG_EFFECT_SIZE="-0.0076868286662910065" ORDER="918" O_E="0.0" SE="1.2203886147155414" STUDY_ID="STD-Soininen-2007" TOTAL_1="285" TOTAL_2="140" VAR="1.4893483709273183" WEIGHT="69.75949907499644"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5747745495780608" CI_END="1.654284822483472" CI_START="0.8926540548571726" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2151971258518304" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-003.29" LOG_CI_END="0.21861028525502932" LOG_CI_START="-0.04931681790397359" LOG_EFFECT_SIZE="0.08464673367552784" METHOD="MH" MODIFIED="2011-10-05 12:57:28 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.7502211558349356" P_Q="1.0" P_Z="0.21555649753801198" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="607" TOTAL_2="476" WEIGHT="100.0" Z="1.2384305093205248">
<NAME>Withdrawal due to side effects</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.482091688489398" CI_START="0.060717144136267914" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1297572763459856" LOG_CI_START="-1.2166886639081658" LOG_EFFECT_SIZE="-0.0434656937810903" ORDER="944" O_E="0.0" SE="1.3783139604000185" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="1.899749373433584" WEIGHT="1.6561402562737184"/>
<DICH_DATA CI_END="1.7093436684195407" CI_START="0.6619874536676666" EFFECT_SIZE="1.06375" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="20" LOG_CI_END="0.23282938764367694" LOG_CI_START="-0.17915024145838837" LOG_EFFECT_SIZE="0.02683957309264428" MODIFIED="2009-02-14 15:57:48 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="949" O_E="0.0" SE="0.24199887346660715" STUDY_ID="STD-Aisen-2003a" TOTAL_1="240" TOTAL_2="111" VAR="0.05856345475910694" WEIGHT="43.13918453460234"/>
<DICH_DATA CI_END="2.0263600682295966" CI_START="0.889903692041236" EFFECT_SIZE="1.3428571428571427" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="35" LOG_CI_END="0.30671661859140825" LOG_CI_START="-0.0506569914205246" LOG_EFFECT_SIZE="0.1280298135854418" ORDER="941" O_E="0.0" SE="0.2099230275489094" STUDY_ID="STD-Reines-2004" TOTAL_1="346" TOTAL_2="346" VAR="0.044067677495300175" WEIGHT="55.20467520912394"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.320341283423515" CI_END="3.2165299200746746" CI_START="0.967200222112954" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7638107758853236" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="11" I2="47.44879390807244" I2_Q="0.0" ID="CMP-003.30" LOG_CI_END="0.5073875955507484" LOG_CI_START="-0.014483612413600496" LOG_EFFECT_SIZE="0.24645199156857392" METHOD="MH" MODIFIED="2011-10-05 12:57:28 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="0.0646775574606101" P_Q="1.0" P_Z="0.0641446232378868" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="648" TOTAL_2="346" WEIGHT="99.99999999999999" Z="1.8511733164078759">
<NAME>Abdominal pain or dyspepsia</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="18.088821826911197" CI_START="1.0350183938323658" EFFECT_SIZE="4.326923076923077" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.257410281025973" LOG_CI_START="0.014948067927153667" LOG_EFFECT_SIZE="0.6361791744765632" ORDER="954" O_E="0.0" SE="0.729828454261392" STUDY_ID="STD-Aisen-2002a" TOTAL_1="26" TOTAL_2="25" VAR="0.5326495726495727" WEIGHT="13.797985374986942"/>
<DICH_DATA CI_END="22.775052429998958" CI_START="0.3381166749744493" EFFECT_SIZE="2.775" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.357459385426947" LOG_CI_START="-0.47093341050955684" LOG_EFFECT_SIZE="0.443262987458695" MODIFIED="2009-02-14 15:58:23 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="959" O_E="0.0" SE="1.07400697902341" STUDY_ID="STD-Aisen-2003a" TOTAL_1="240" TOTAL_2="111" VAR="1.1534909909909912" WEIGHT="9.253086839241737"/>
<DICH_DATA CI_END="2.8798535293268928" CI_START="0.035671421156302424" EFFECT_SIZE="0.32051282051282054" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.459370399904121" LOG_CI_START="-1.4476795879410065" LOG_EFFECT_SIZE="-0.49415459401844275" ORDER="952" O_E="0.0" SE="1.1202106029099148" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="1.2548717948717947" WEIGHT="20.69697806248041"/>
<DICH_DATA CI_END="4.816917538103997" CI_START="0.03813091420702448" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.6827692115930425" LOG_CI_START="-1.4187227821822312" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="955" O_E="0.0" SE="1.2344267996967353" STUDY_ID="STD-H_x00fc_ll-1999" TOTAL_1="7" TOTAL_2="3" VAR="1.523809523809524" WEIGHT="9.472847651673728"/>
<DICH_DATA CI_END="1.264525601529265" CI_START="0.13729347266765737" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.10192762647625903" LOG_CI_START="-0.862350109899471" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="956" O_E="0.0" SE="0.5664215155988809" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="0.32083333333333325" WEIGHT="30.931747434036662"/>
<DICH_DATA CI_END="32.80285982197966" CI_START="0.5292560223507785" EFFECT_SIZE="4.166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5159117080642133" LOG_CI_START="-0.27633419148742516" LOG_EFFECT_SIZE="0.619788758288394" ORDER="950" O_E="0.0" SE="1.052774113156917" STUDY_ID="STD-Rogers-1993" TOTAL_1="24" TOTAL_2="20" VAR="1.1083333333333332" WEIGHT="7.381439728576931"/>
<DICH_DATA CI_END="112.95106309578426" CI_START="0.37175745715993386" EFFECT_SIZE="6.48" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.0528903228567366" LOG_CI_START="-0.42974031111555" LOG_EFFECT_SIZE="0.8115750058705934" ORDER="953" O_E="0.0" SE="1.4583095236151573" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.126666666666667" WEIGHT="3.933906832090419"/>
<DICH_DATA CI_END="51.0019353990946" CI_START="0.11914052537999964" EFFECT_SIZE="2.465034965034965" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7075866568273241" LOG_CI_START="-0.9239404891026126" LOG_EFFECT_SIZE="0.3918230838623557" ORDER="957" O_E="0.0" SE="1.545772071788702" STUDY_ID="STD-Soininen-2007" TOTAL_1="285" TOTAL_2="140" VAR="2.3894112979219364" WEIGHT="4.532008076913159"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.373362241464217" CI_END="4.884524592201563" CI_START="0.8409376654635947" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0267167309383667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="6" I2="15.731363503696578" I2_Q="0.0" ID="CMP-003.31" LOG_CI_END="0.6888223004947424" LOG_CI_START="-0.07523619510399945" LOG_EFFECT_SIZE="0.3067930526953715" METHOD="MH" MODIFIED="2011-10-05 12:57:28 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.30523267077675864" P_Q="1.0" P_Z="0.11549392596971683" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="337" TOTAL_2="190" WEIGHT="100.0" Z="1.573971986317162">
<NAME>Constipation or diarrhea</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.441374752389267" CI_START="0.8813341420489659" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9750352362373373" LOG_CI_START="-0.054859405395573234" LOG_EFFECT_SIZE="0.46008791542088207" ORDER="968" O_E="0.0" SE="0.6049652105558683" STUDY_ID="STD-Aisen-2002a" TOTAL_1="26" TOTAL_2="25" VAR="0.365982905982906" WEIGHT="45.065963060686016"/>
<DICH_DATA CI_END="3.5190698583025863" CI_START="0.11676775085406724" EFFECT_SIZE="0.6410256410256411" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.546427888254399" LOG_CI_START="-0.932677084963322" LOG_EFFECT_SIZE="-0.19312459835446155" ORDER="967" O_E="0.0" SE="0.8688335829557895" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="0.7548717948717948" WEIGHT="45.065963060686016"/>
<DICH_DATA CI_END="81.83992620207357" CI_START="0.24056140347495508" EFFECT_SIZE="4.437062937062937" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9129652290857426" LOG_CI_START="-0.6187740511544193" LOG_EFFECT_SIZE="0.6470955889656618" ORDER="961" O_E="0.0" SE="1.487156185524627" STUDY_ID="STD-Soininen-2007" TOTAL_1="285" TOTAL_2="140" VAR="2.211633520144159" WEIGHT="9.868073878627968"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.690187034951295" CI_END="7.381161709263068" CI_START="0.3852121088603428" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6862125808641206" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.32" LOG_CI_END="0.8681247201180735" LOG_CI_START="-0.4143000696041627" LOG_EFFECT_SIZE="0.22691232525695537" METHOD="MH" MODIFIED="2011-10-05 12:57:28 +0100" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.42951747300991205" P_Q="1.0" P_Z="0.48793792347174714" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="49" WEIGHT="100.0" Z="0.6935923084396995">
<NAME>Nausea or vomiting</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.02081776524327" CI_START="0.013079297544116708" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8463877004842707" LOG_CI_START="-1.8834155802400456" LOG_EFFECT_SIZE="-0.5185139398778875" ORDER="971" O_E="0.0" SE="1.6034999598416337" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="2.5712121212121213" WEIGHT="55.724556372854586"/>
<DICH_DATA CI_END="95.57588616873608" CI_START="0.2425553414177336" EFFECT_SIZE="4.814814814814815" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.980348333438729" LOG_CI_START="-0.6151891571430301" LOG_EFFECT_SIZE="0.6825795881478495" ORDER="970" O_E="0.0" SE="1.5246315700855155" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="2.3245014245014244" WEIGHT="18.065079167186134"/>
<DICH_DATA CI_END="41.169051705332095" CI_START="0.14826200690901886" EFFECT_SIZE="2.4705882352941178" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.6145708635025957" LOG_CI_START="-0.8289701254633426" LOG_EFFECT_SIZE="0.39280036901962656" ORDER="978" O_E="0.0" SE="1.4353480726415648" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="2.0602240896358546" WEIGHT="26.210364459959273"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.226913727275915" CI_END="3.306541696037148" CI_START="0.8477024142136693" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6742052975751962" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.33" LOG_CI_END="0.5193740035997088" LOG_CI_START="-0.07175657999217576" LOG_EFFECT_SIZE="0.22380871180376652" METHOD="MH" MODIFIED="2011-10-05 12:57:28 +0100" MODIFIED_BY="[Empty name]" NO="33" P_CHI2="0.6650484238646546" P_Q="1.0" P_Z="0.1377747067616303" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1012" TOTAL_2="699" WEIGHT="100.0" Z="1.4841289783934946">
<NAME>Death</NAME>
<GROUP_LABEL_1>NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="426" O_E="0.0" SE="0.0" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="13.190082453092693" CI_START="0.14595483059687825" EFFECT_SIZE="1.3875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1202475103917973" LOG_CI_START="-0.8357815268023696" LOG_EFFECT_SIZE="0.14223299179471383" ORDER="430" O_E="0.0" SE="1.1489811389477451" STUDY_ID="STD-Aisen-2003a" TOTAL_1="240" TOTAL_2="111" VAR="1.3201576576576577" WEIGHT="10.321495794858883"/>
<DICH_DATA CI_END="7.527945096630645" CI_START="0.013686746237376972" EFFECT_SIZE="0.32098765432098764" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8766764430019184" LOG_CI_START="-1.8636997848175818" LOG_EFFECT_SIZE="-0.4935116709078318" MODIFIED="2011-10-01 17:09:06 +0100" MODIFIED_BY="[Empty name]" ORDER="427" O_E="0.0" SE="1.6097105613022769" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="2.591168091168091" WEIGHT="11.53500184526859"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-10-01 17:09:10 +0100" MODIFIED_BY="[Empty name]" ORDER="432" O_E="0.0" SE="0.0" STUDY_ID="STD-H_x00fc_ll-1999" TOTAL_1="7" TOTAL_2="3" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-10-01 17:09:09 +0100" MODIFIED_BY="[Empty name]" ORDER="425" O_E="0.0" SE="0.0" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="20.676303388823243" CI_START="0.9793820306847656" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3154728960592597" LOG_CI_START="-0.009047868508572171" LOG_EFFECT_SIZE="0.6532125137753437" ORDER="429" O_E="0.0" SE="0.7780300535906707" STUDY_ID="STD-Reines-2004" TOTAL_1="346" TOTAL_2="346" VAR="0.6053307642903019" WEIGHT="15.095187599981116"/>
<DICH_DATA CI_END="12.493649640918552" CI_START="0.05558379371949381" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.09668932287227" LOG_CI_START="-1.2550518149675196" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="424" O_E="0.0" SE="1.3814243856734734" STUDY_ID="STD-Rogers-1993" TOTAL_1="24" TOTAL_2="20" VAR="1.9083333333333332" WEIGHT="8.23373869089879"/>
<DICH_DATA CI_END="50.04129972983788" CI_START="0.09323498840335014" EFFECT_SIZE="2.16" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6993285811605914" LOG_CI_START="-1.0304210788587294" LOG_EFFECT_SIZE="0.3344537511509309" ORDER="428" O_E="0.0" SE="1.6034684627740925" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.571111111111111" WEIGHT="4.388135930227069"/>
<DICH_DATA CI_END="3.556828243775724" CI_START="0.4689917796508742" EFFECT_SIZE="1.2915584415584416" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.5510628939793092" LOG_CI_START="-0.32883476940336426" LOG_EFFECT_SIZE="0.1111140622879725" ORDER="431" O_E="0.0" SE="0.5168562430346618" STUDY_ID="STD-Soininen-2007" TOTAL_1="308" TOTAL_2="153" VAR="0.26714037596390544" WEIGHT="50.42644013876556"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2012-01-02 08:42:40 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Traditional NSAIDs vs. placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="95.57588616873608" CI_START="0.2425553414177335" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.814814814814815" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="1.980348333438729" LOG_CI_START="-0.6151891571430304" LOG_EFFECT_SIZE="0.6825795881478495" METHOD="MH" MODIFIED="2011-10-01 16:58:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3026016049616902" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="1.030870418328736">
<NAME>Nausea or vomiting</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="95.57588616873608" CI_START="0.2425553414177335" DF="0" EFFECT_SIZE="4.814814814814815" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="1.980348333438729" LOG_CI_START="-0.6151891571430304" LOG_EFFECT_SIZE="0.6825795881478495" MODIFIED="2011-03-21 04:24:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3026016049616902" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="1.030870418328736">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="95.57588616873608" CI_START="0.2425553414177336" EFFECT_SIZE="4.814814814814815" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.980348333438729" LOG_CI_START="-0.6151891571430301" LOG_EFFECT_SIZE="0.6825795881478495" ORDER="571" O_E="0.0" SE="1.5246315700855155" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="2.3245014245014244" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.34038610845813" CI_END="2.9987174512703088" CI_START="0.6838291637089611" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4319952677651007" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" I2="7.84230019985591" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.47693554707495706" LOG_CI_START="-0.16505238150404844" LOG_EFFECT_SIZE="0.1559415827854543" METHOD="MH" MODIFIED="2011-10-01 16:58:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36189529449125946" P_Q="1.0" P_Z="0.34101226484618274" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="121" WEIGHT="100.0" Z="0.9521670808613919">
<NAME>Gastrointestinal side effects</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.34038610845813" CI_END="2.9987174512703088" CI_START="0.6838291637089611" DF="4" EFFECT_SIZE="1.4319952677651007" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" I2="7.84230019985591" ID="CMP-004.02.01" LOG_CI_END="0.47693554707495706" LOG_CI_START="-0.16505238150404844" LOG_EFFECT_SIZE="0.1559415827854543" MODIFIED="2011-06-13 16:19:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.36189529449125946" P_Z="0.34101226484618274" STUDIES="5" TAU2="0.0" TOTAL_1="199" TOTAL_2="121" WEIGHT="100.0" Z="0.9521670808613919">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="10.248254748143463" CI_START="0.08790672859260322" EFFECT_SIZE="0.9491525423728814" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.010649912437049" LOG_CI_START="-1.0559778817089363" LOG_EFFECT_SIZE="-0.02266398463594376" MODIFIED="2011-06-13 12:27:18 +0100" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="1.2139473962539196" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="56" VAR="1.4736682808716708" WEIGHT="12.86067405666776"/>
<DICH_DATA CI_END="2.2948312108828905" CI_START="0.27978220039100604" EFFECT_SIZE="0.8012820512820513" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3607507478785395" LOG_CI_START="-0.5531799185713498" LOG_EFFECT_SIZE="-0.09621458534640516" ORDER="352" O_E="0.0" SE="0.5368473975024265" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="0.2882051282051283" WEIGHT="58.007666433065744"/>
<DICH_DATA CI_END="4.816917538103997" CI_START="0.03813091420702448" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.6827692115930425" LOG_CI_START="-1.4187227821822312" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2011-06-13 16:19:21 +0100" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="1.2344267996967353" STUDY_ID="STD-H_x00fc_ll-1999" TOTAL_1="7" TOTAL_2="3" VAR="1.523809523809524" WEIGHT="13.274831356797739"/>
<DICH_DATA CI_END="32.80285982197966" CI_START="0.5292560223507785" EFFECT_SIZE="4.166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5159117080642133" LOG_CI_START="-0.27633419148742516" LOG_EFFECT_SIZE="0.619788758288394" MODIFIED="2011-06-13 16:19:20 +0100" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="1.052774113156917" STUDY_ID="STD-Rogers-1993" TOTAL_1="24" TOTAL_2="20" VAR="1.1083333333333332" WEIGHT="10.344024433868366"/>
<DICH_DATA CI_END="112.95106309578426" CI_START="0.37175745715993386" EFFECT_SIZE="6.48" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.0528903228567366" LOG_CI_START="-0.42974031111555" LOG_EFFECT_SIZE="0.8115750058705934" ORDER="347" O_E="0.0" SE="1.4583095236151573" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.126666666666667" WEIGHT="5.51280371960039"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2757894374947357" CI_END="34.30282088073016" CI_START="0.5388412141977496" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.299275945293644" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="1.5353298355693386" LOG_CI_START="-0.2685391939176497" LOG_EFFECT_SIZE="0.6333953208258445" METHOD="MH" MODIFIED="2011-10-01 16:58:29 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5994744008431871" P_Q="1.0" P_Z="0.1686946200605738" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="42" WEIGHT="100.0" Z="1.3764103673844943">
<NAME>Elevated creatinine</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2757894374947357" CI_END="34.30282088073016" CI_START="0.5388412141977496" DF="1" EFFECT_SIZE="4.299275945293644" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="1.5353298355693386" LOG_CI_START="-0.2685391939176497" LOG_EFFECT_SIZE="0.6333953208258445" MODIFIED="2009-03-06 02:05:44 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="1" P_CHI2="0.5994744008431871" P_Z="0.1686946200605738" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="42" WEIGHT="100.0" Z="1.3764103673844943">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="124.2142564295905" CI_START="0.3658000863985998" EFFECT_SIZE="6.7407407407407405" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.094171443935422" LOG_CI_START="-0.4367561962832468" LOG_EFFECT_SIZE="0.8287076238260874" ORDER="361" O_E="0.0" SE="1.4866794241583188" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="2.21021571021571" WEIGHT="46.70152855993564"/>
<DICH_DATA CI_END="50.04129972983788" CI_START="0.09323498840335014" EFFECT_SIZE="2.16" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6993285811605914" LOG_CI_START="-1.0304210788587294" LOG_EFFECT_SIZE="0.3344537511509309" ORDER="358" O_E="0.0" SE="1.6034684627740925" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.571111111111111" WEIGHT="53.29847144006436"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06567605261244136" CI_END="33.975491689989774" CI_START="0.4792995793552933" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="4.035398230088496" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="1.5311657505172385" LOG_CI_START="-0.31939295215520797" LOG_EFFECT_SIZE="0.6058863991810153" METHOD="MH" MODIFIED="2011-10-01 16:58:29 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7977397436268545" P_Q="1.0" P_Z="0.19934743199220198" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="42" WEIGHT="100.0" Z="1.283412970799059">
<NAME>Elevated liver function test</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.06567605261244136" CI_END="33.975491689989774" CI_START="0.4792995793552933" DF="1" EFFECT_SIZE="4.035398230088496" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="1.5311657505172385" LOG_CI_START="-0.31939295215520797" LOG_EFFECT_SIZE="0.6058863991810153" MODIFIED="2011-03-21 04:24:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7977397436268545" P_Z="0.19934743199220198" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="42" WEIGHT="100.0" Z="1.283412970799059">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="67.75150586967578" CI_START="0.12318071613639271" EFFECT_SIZE="2.888888888888889" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.830918952441243" LOG_CI_START="-0.909457275378257" LOG_EFFECT_SIZE="0.4607308385314931" ORDER="371" O_E="0.0" SE="1.6097105613022769" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="2.591168091168091" WEIGHT="46.70152855993564"/>
<DICH_DATA CI_END="91.65147041627819" CI_START="0.2771543095230956" EFFECT_SIZE="5.04" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9621394369856662" LOG_CI_START="-0.5572783640946156" LOG_EFFECT_SIZE="0.7024305364455253" ORDER="368" O_E="0.0" SE="1.4799184876738076" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.19015873015873" WEIGHT="53.29847144006436"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3586688870879929" CI_END="13.342168439894195" CI_START="0.8440470181298928" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.35580355311205" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="1.1252264191568295" LOG_CI_START="-0.07363336007386477" LOG_EFFECT_SIZE="0.5257965295414824" METHOD="MH" MODIFIED="2011-10-01 16:59:35 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5492466669593794" P_Q="1.0" P_Z="0.08557723359794549" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="144" TOTAL_2="81" WEIGHT="100.0" Z="1.7192039952474725">
<NAME>Hypertension</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.3586688870879929" CI_END="13.342168439894195" CI_START="0.8440470181298928" DF="1" EFFECT_SIZE="3.35580355311205" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="1.1252264191568295" LOG_CI_START="-0.07363336007386477" LOG_EFFECT_SIZE="0.5257965295414824" MODIFIED="2011-06-13 12:29:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5492466669593794" P_Z="0.08557723359794549" STUDIES="2" TAU2="0.0" TOTAL_1="144" TOTAL_2="81" WEIGHT="100.0" Z="1.7192039952474725">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="108.62909029237449" CI_START="0.3569409297874573" EFFECT_SIZE="6.226890756302521" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.035946142579515" LOG_CI_START="-0.44740364940592" LOG_EFFECT_SIZE="0.7942712465867974" MODIFIED="2011-06-13 12:29:15 +0100" MODIFIED_BY="[Empty name]" ORDER="428" O_E="0.0" SE="1.4587319605919702" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="56" VAR="2.127898932852493" WEIGHT="24.900504656792354"/>
<DICH_DATA CI_END="11.271312186191732" CI_START="0.5126711278958315" EFFECT_SIZE="2.4038461538461537" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0519744787833807" LOG_CI_START="-0.29016114003686627" LOG_EFFECT_SIZE="0.38090666937325723" ORDER="431" O_E="0.0" SE="0.7883771061734742" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="0.6215384615384615" WEIGHT="75.09949534320765"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.353643741191874" CI_END="3.624397774956645" CI_START="0.09994296152436907" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6018579960185798" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="26.12531868100636" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.5592358551164451" LOG_CI_START="-1.0002477856255185" LOG_EFFECT_SIZE="-0.22050596525453667" METHOD="MH" MODIFIED="2011-10-01 16:59:35 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.24464228788032316" P_Q="1.0" P_Z="0.5793973703878982" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="45" WEIGHT="99.99999999999999" Z="0.5542651926371093">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.353643741191874" CI_END="3.624397774956645" CI_START="0.09994296152436907" DF="1" EFFECT_SIZE="0.6018579960185798" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="26.12531868100636" ID="CMP-004.06.01" LOG_CI_END="0.5592358551164451" LOG_CI_START="-1.0002477856255185" LOG_EFFECT_SIZE="-0.22050596525453667" MODIFIED="2009-03-06 02:05:44 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="1" P_CHI2="0.24464228788032316" P_Z="0.5793973703878982" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="45" WEIGHT="99.99999999999999" Z="0.5542651926371093">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="3.8230354467494423" CI_START="0.009702213656709344" EFFECT_SIZE="0.1925925925925926" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5824083247666914" LOG_CI_START="-2.0131291658150676" LOG_EFFECT_SIZE="-0.7153604205241881" MODIFIED="2009-02-12 03:33:36 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="382" O_E="0.0" SE="1.5246315700855155" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="2.3245014245014244" WEIGHT="82.41539482415394"/>
<DICH_DATA CI_END="58.665164940986045" CI_START="0.10824822543988676" EFFECT_SIZE="2.52" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7683802960571493" LOG_CI_START="-0.9655792144940613" LOG_EFFECT_SIZE="0.4014005407815441" ORDER="381" O_E="0.0" SE="1.605941349815621" STUDY_ID="STD-Rogers-1993" TOTAL_1="24" TOTAL_2="20" VAR="2.579047619047619" WEIGHT="17.58460517584605"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19541788858826392" CI_END="1.0731795278514997" CI_START="0.016207765039532054" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.13188571428571427" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="0.030672379406229796" LOG_CI_START="-1.7902768678114311" LOG_EFFECT_SIZE="-0.8798022442026007" METHOD="MH" MODIFIED="2011-10-01 16:59:34 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.6584451059480368" P_Q="1.0" P_Z="0.058233498730700904" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="37" WEIGHT="99.99999999999999" Z="1.8939360498810136">
<NAME>Psychiatric side effects</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.19541788858826392" CI_END="1.0731795278514997" CI_START="0.016207765039532054" DF="1" EFFECT_SIZE="0.13188571428571427" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" ID="CMP-004.07.01" LOG_CI_END="0.030672379406229796" LOG_CI_START="-1.7902768678114311" LOG_EFFECT_SIZE="-0.8798022442026007" MODIFIED="2011-03-21 04:24:45 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6584451059480368" P_Z="0.058233498730700904" STUDIES="2" TAU2="0.0" TOTAL_1="48" TOTAL_2="37" WEIGHT="99.99999999999999" Z="1.8939360498810136">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="1.63555882661377" CI_START="0.005326076304541385" EFFECT_SIZE="0.09333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.2136661691362046" LOG_CI_START="-2.273592615891091" LOG_EFFECT_SIZE="-1.0299632233774432" ORDER="392" O_E="0.0" SE="1.4610281224545867" STUDY_ID="STD-Rogers-1993" TOTAL_1="24" TOTAL_2="20" VAR="2.134603174603175" WEIGHT="73.71428571428571"/>
<DICH_DATA CI_END="5.5601444144264285" CI_START="0.010359443155927786" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7450860717212663" LOG_CI_START="-1.9846635882980546" LOG_EFFECT_SIZE="-0.619788758288394" ORDER="389" O_E="0.0" SE="1.6034684627740925" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.571111111111111" WEIGHT="26.28571428571428"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.8586366337058804" CI_START="0.00660662103772067" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.15966386554621848" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.08" LOG_CI_END="0.5864338831563746" LOG_CI_START="-2.180020604035778" LOG_EFFECT_SIZE="-0.7967933604397018" METHOD="MH" MODIFIED="2011-10-01 16:59:33 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.25889091980349865" Q="0.0" RANDOM="NO" SCALE="138.43491274800346" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="56" WEIGHT="100.0" Z="1.1290164337151345">
<NAME>Heart disease</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8586366337058804" CI_START="0.00660662103772067" DF="0" EFFECT_SIZE="0.15966386554621848" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.08.01" LOG_CI_END="0.5864338831563746" LOG_CI_START="-2.180020604035778" LOG_EFFECT_SIZE="-0.7967933604397018" MODIFIED="2011-06-13 12:28:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.25889091980349865" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="56" WEIGHT="100.0" Z="1.1290164337151345">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="3.8586366337058786" CI_START="0.00660662103772067" EFFECT_SIZE="0.15966386554621848" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5864338831563743" LOG_CI_START="-2.180020604035778" LOG_EFFECT_SIZE="-0.7967933604397018" MODIFIED="2011-06-13 12:28:38 +0100" MODIFIED_BY="[Empty name]" ORDER="408" O_E="0.0" SE="1.6250290599472386" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="56" VAR="2.640719445673006" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.010300501791616247" CI_END="14.629100562098362" CI_START="0.4319514400426618" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5137742647913517" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.09" LOG_CI_END="1.165217625310172" LOG_CI_START="-0.36456507380291014" LOG_EFFECT_SIZE="0.4003262757536309" METHOD="MH" MODIFIED="2011-10-01 16:59:32 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.9191603946619051" P_Q="1.0" P_Z="0.3049861663484942" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="144" TOTAL_2="81" WEIGHT="100.0" Z="1.0257993935963152">
<NAME>Cerebrovascular side effects</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.010300501791616247" CI_END="14.629100562098362" CI_START="0.4319514400426618" DF="1" EFFECT_SIZE="2.5137742647913517" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-004.09.01" LOG_CI_END="1.165217625310172" LOG_CI_START="-0.36456507380291014" LOG_EFFECT_SIZE="0.4003262757536309" MODIFIED="2011-06-13 12:29:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9191603946619051" P_Z="0.3049861663484942" STUDIES="2" TAU2="0.0" TOTAL_1="144" TOTAL_2="81" WEIGHT="100.0" Z="1.0257993935963152">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="19.835058640026684" CI_START="0.2838693866005671" EFFECT_SIZE="2.3728813559322033" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.2974334887528143" LOG_CI_START="-0.5468814406806265" LOG_EFFECT_SIZE="0.37527602403609384" MODIFIED="2011-06-13 12:29:02 +0100" MODIFIED_BY="[Empty name]" ORDER="417" O_E="0.0" SE="1.0833597190553426" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="56" VAR="1.1736682808716707" WEIGHT="72.6955713123329"/>
<DICH_DATA CI_END="67.75150586967578" CI_START="0.12318071613639271" EFFECT_SIZE="2.888888888888889" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.830918952441243" LOG_CI_START="-0.909457275378257" LOG_EFFECT_SIZE="0.4607308385314931" ORDER="422" O_E="0.0" SE="1.6097105613022769" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="2.591168091168091" WEIGHT="27.30442868766709"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.900760915747465" CI_START="0.1858333391234605" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="1.2988696821982773" LOG_CI_START="-0.7308763694678754" LOG_EFFECT_SIZE="0.28399665636520083" METHOD="MH" MODIFIED="2011-10-01 16:58:26 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.5833720597865653" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="0.5484658711356307">
<NAME>Hyperglycemia</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.900760915747465" CI_START="0.1858333391234605" DF="0" EFFECT_SIZE="1.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-004.10.01" LOG_CI_END="1.2988696821982773" LOG_CI_START="-0.7308763694678754" LOG_EFFECT_SIZE="0.28399665636520083" MODIFIED="2009-03-06 02:05:44 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="1" P_CHI2="1.0" P_Z="0.5833720597865653" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="0.5484658711356307">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="19.900760915747448" CI_START="0.1858333391234606" EFFECT_SIZE="1.9230769230769231" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2988696821982768" LOG_CI_START="-0.7308763694678753" LOG_EFFECT_SIZE="0.28399665636520083" ORDER="440" O_E="0.0" SE="1.192282878153696" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="1.4215384615384614" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="23.09007389465803" CI_START="0.3511472061642885" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.847457627118644" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.11" LOG_CI_END="1.3634253227825237" LOG_CI_START="-0.45451078261508643" LOG_EFFECT_SIZE="0.45445727008371867" METHOD="MH" MODIFIED="2011-10-01 16:58:26 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.32712350015724867" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="56" WEIGHT="100.0" Z="0.9799242990244335">
<NAME>Dry mouth</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.09007389465803" CI_START="0.3511472061642885" DF="0" EFFECT_SIZE="2.847457627118644" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-004.11.01" LOG_CI_END="1.3634253227825237" LOG_CI_START="-0.45451078261508643" LOG_EFFECT_SIZE="0.45445727008371867" MODIFIED="2011-06-13 12:29:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.32712350015724867" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="56" WEIGHT="100.0" Z="0.9799242990244335">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="23.09007389465803" CI_START="0.3511472061642885" EFFECT_SIZE="2.847457627118644" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.3634253227825237" LOG_CI_START="-0.45451078261508643" LOG_EFFECT_SIZE="0.45445727008371867" MODIFIED="2011-06-13 12:29:29 +0100" MODIFIED_BY="[Empty name]" ORDER="478" O_E="0.0" SE="1.0678646672394108" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="56" VAR="1.1403349475383375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.6187551550609527" CI_START="0.507246322253471" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.152542372881356" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.12" LOG_CI_END="0.41809489522677035" LOG_CI_START="-0.29478109309858613" LOG_EFFECT_SIZE="0.06165690106409214" METHOD="MH" MODIFIED="2011-10-01 16:58:25 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="1.0" P_Q="1.0" P_Z="0.73458262436752" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="56" WEIGHT="100.0" Z="0.3390359823111791">
<NAME>Fatigue</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6187551550609527" CI_START="0.507246322253471" DF="0" EFFECT_SIZE="1.152542372881356" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" I2="0.0" ID="CMP-004.12.01" LOG_CI_END="0.41809489522677035" LOG_CI_START="-0.29478109309858613" LOG_EFFECT_SIZE="0.06165690106409214" MODIFIED="2011-06-13 12:29:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.73458262436752" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="56" WEIGHT="100.0" Z="0.3390359823111791">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="2.6187551550609527" CI_START="0.507246322253471" EFFECT_SIZE="1.152542372881356" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.41809489522677035" LOG_CI_START="-0.29478109309858613" LOG_EFFECT_SIZE="0.06165690106409214" MODIFIED="2011-06-13 12:29:41 +0100" MODIFIED_BY="[Empty name]" ORDER="492" O_E="0.0" SE="0.4187468843353683" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="56" VAR="0.17534895314057827" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.40174116586780084" CI_END="3.6890536906824973" CI_START="0.6363414509362685" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.532154619518114" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-004.13" LOG_CI_END="0.566914976017656" LOG_CI_START="-0.1963097861358314" LOG_EFFECT_SIZE="0.18530259494091228" METHOD="MH" MODIFIED="2011-10-01 16:58:24 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.5261914268548538" P_Q="1.0" P_Z="0.3412413056607214" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="144" TOTAL_2="81" WEIGHT="100.0" Z="0.9517154849673601">
<NAME>Dizziness</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.40174116586780084" CI_END="3.6890536906824973" CI_START="0.6363414509362685" DF="1" EFFECT_SIZE="1.532154619518114" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" I2="0.0" ID="CMP-004.13.01" LOG_CI_END="0.566914976017656" LOG_CI_START="-0.1963097861358314" LOG_EFFECT_SIZE="0.18530259494091228" MODIFIED="2011-06-13 12:29:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5261914268548538" P_Z="0.3412413056607214" STUDIES="2" TAU2="0.0" TOTAL_1="144" TOTAL_2="81" WEIGHT="100.0" Z="0.9517154849673601">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="3.506473725196331" CI_START="0.5035672911934415" EFFECT_SIZE="1.3288135593220338" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.5448705889798465" LOG_CI_START="-0.2979424868952581" LOG_EFFECT_SIZE="0.12346405104229423" MODIFIED="2011-06-13 12:29:49 +0100" MODIFIED_BY="[Empty name]" ORDER="501" O_E="0.0" SE="0.49507257276104705" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="56" VAR="0.2450968523002422" WEIGHT="86.93014387242157"/>
<DICH_DATA CI_END="25.918681763942033" CI_START="0.3210427904067218" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4136129093434457" LOG_CI_START="-0.4934370785016816" LOG_EFFECT_SIZE="0.46008791542088207" ORDER="498" O_E="0.0" SE="1.1202106029099148" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="1.2548717948717947" WEIGHT="13.069856127578435"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="50.04129972983783" CI_START="0.09323498840335014" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.16" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.14" LOG_CI_END="1.699328581160591" LOG_CI_START="-1.0304210788587294" LOG_EFFECT_SIZE="0.3344537511509309" METHOD="MH" MODIFIED="2011-10-01 16:58:24 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.6310307980146352" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="17" WEIGHT="100.0" Z="0.48027650033337255">
<NAME>Abnormal labs other than Cr. and LFT</NAME>
<GROUP_LABEL_1>Favours experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="50.04129972983783" CI_START="0.09323498840335014" DF="0" EFFECT_SIZE="2.16" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-004.14.01" LOG_CI_END="1.699328581160591" LOG_CI_START="-1.0304210788587294" LOG_EFFECT_SIZE="0.3344537511509309" MODIFIED="2009-02-18 01:49:38 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="1" P_CHI2="1.0" P_Z="0.6310307980146352" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="17" WEIGHT="100.0" Z="0.48027650033337255">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="50.04129972983788" CI_START="0.09323498840335014" EFFECT_SIZE="2.16" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6993285811605914" LOG_CI_START="-1.0304210788587294" LOG_EFFECT_SIZE="0.3344537511509309" ORDER="510" O_E="0.0" SE="1.6034684627740925" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.571111111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8207855954163412" CI_END="2.873101737004876" CI_START="0.1824351451650061" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7239853123263729" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.15" LOG_CI_END="0.45835100470323725" LOG_CI_START="-0.7388914934147769" LOG_EFFECT_SIZE="-0.14027024435576987" METHOD="MH" MODIFIED="2011-10-01 16:58:23 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.844489267414131" P_Q="1.0" P_Z="0.6460452722985741" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="121" WEIGHT="100.0" Z="0.459263060695064">
<NAME>Death</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.8207855954163412" CI_END="2.873101737004876" CI_START="0.1824351451650061" DF="3" EFFECT_SIZE="0.7239853123263729" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-004.15.01" LOG_CI_END="0.45835100470323725" LOG_CI_START="-0.7388914934147769" LOG_EFFECT_SIZE="-0.14027024435576987" MODIFIED="2011-06-13 16:19:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.844489267414131" P_Z="0.6460452722985741" STUDIES="5" TAU2="0.0" TOTAL_1="199" TOTAL_2="121" WEIGHT="100.0" Z="0.459263060695064">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="7.449654407892874" CI_START="0.030232628903510448" EFFECT_SIZE="0.4745762711864407" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.872136126140723" LOG_CI_START="-1.5195240867405728" LOG_EFFECT_SIZE="-0.32369398029992497" MODIFIED="2011-06-13 12:32:39 +0100" MODIFIED_BY="[Empty name]" ORDER="532" O_E="0.0" SE="1.4048730479554623" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="56" VAR="1.9736682808716708" WEIGHT="29.763950402236755"/>
<DICH_DATA CI_END="7.527945096630645" CI_START="0.013686746237376972" EFFECT_SIZE="0.32098765432098764" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8766764430019184" LOG_CI_START="-1.8636997848175818" LOG_EFFECT_SIZE="-0.4935116709078318" ORDER="531" O_E="0.0" SE="1.6097105613022769" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="2.591168091168091" WEIGHT="33.537985047099845"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-06-13 16:19:49 +0100" MODIFIED_BY="[Empty name]" ORDER="528" O_E="0.0" SE="0.0" STUDY_ID="STD-H_x00fc_ll-1999" TOTAL_1="7" TOTAL_2="3" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.493649640918552" CI_START="0.05558379371949381" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.09668932287227" LOG_CI_START="-1.2550518149675196" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2011-06-13 16:19:48 +0100" MODIFIED_BY="[Empty name]" ORDER="530" O_E="0.0" SE="1.3814243856734734" STUDY_ID="STD-Rogers-1993" TOTAL_1="24" TOTAL_2="20" VAR="1.9083333333333332" WEIGHT="23.939571818131874"/>
<DICH_DATA CI_END="50.04129972983788" CI_START="0.09323498840335014" EFFECT_SIZE="2.16" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6993285811605914" LOG_CI_START="-1.0304210788587294" LOG_EFFECT_SIZE="0.3344537511509309" ORDER="527" O_E="0.0" SE="1.6034684627740925" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.571111111111111" WEIGHT="12.758492732531524"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8409370100036009" CI_START="0.29527533516739685" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.49830508474576274" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-004.16" LOG_CI_END="-0.07523653361038472" LOG_CI_START="-0.529772828849589" LOG_EFFECT_SIZE="-0.30250468122998686" METHOD="MH" MODIFIED="2011-10-01 16:58:22 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.009085900120536991" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="118" TOTAL_2="56" WEIGHT="100.0" Z="2.6088050022651124">
<NAME>Withdrawal due to side effects</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8409370100036009" CI_START="0.29527533516739685" DF="0" EFFECT_SIZE="0.49830508474576274" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" I2="0.0" ID="CMP-004.16.01" LOG_CI_END="-0.07523653361038472" LOG_CI_START="-0.529772828849589" LOG_EFFECT_SIZE="-0.30250468122998686" MODIFIED="2011-06-13 12:33:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.009085900120536991" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="56" WEIGHT="100.0" Z="2.6088050022651124">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="0.8409370100036009" CI_START="0.29527533516739685" EFFECT_SIZE="0.49830508474576274" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="-0.07523653361038472" LOG_CI_START="-0.529772828849589" LOG_EFFECT_SIZE="-0.30250468122998686" MODIFIED="2011-06-13 12:33:11 +0100" MODIFIED_BY="[Empty name]" ORDER="540" O_E="0.0" SE="0.2669968698144574" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="56" VAR="0.07128732849071831" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.011897220825395" CI_END="3.683902200883407" CI_START="0.6052820114253328" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4932513967999224" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" I2="20.18990366803149" I2_Q="0.0" ID="CMP-004.17" LOG_CI_END="0.566308092159867" LOG_CI_START="-0.21804223283584193" LOG_EFFECT_SIZE="0.17413292966201258" METHOD="MH" MODIFIED="2011-10-01 16:58:21 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.28607901430897165" P_Q="1.0" P_Z="0.3841584624785801" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="121" WEIGHT="100.0" Z="0.8702597800590147">
<NAME>Abdominal pain or dyspepsia</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.011897220825395" CI_END="3.683902200883407" CI_START="0.6052820114253328" DF="4" EFFECT_SIZE="1.4932513967999224" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" I2="20.18990366803149" ID="CMP-004.17.01" LOG_CI_END="0.566308092159867" LOG_CI_START="-0.21804223283584193" LOG_EFFECT_SIZE="0.17413292966201258" MODIFIED="2011-06-13 12:33:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.28607901430897165" P_Z="0.3841584624785801" STUDIES="5" TAU2="0.0" TOTAL_1="199" TOTAL_2="121" WEIGHT="100.0" Z="0.8702597800590147">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="10.248254748143463" CI_START="0.08790672859260322" EFFECT_SIZE="0.9491525423728814" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.010649912437049" LOG_CI_START="-1.0559778817089363" LOG_EFFECT_SIZE="-0.02266398463594376" MODIFIED="2011-06-13 12:33:30 +0100" MODIFIED_BY="[Empty name]" ORDER="549" O_E="0.0" SE="1.2139473962539196" STUDY_ID="STD-Aisen-2003a" TOTAL_1="118" TOTAL_2="56" VAR="1.4736682808716708" WEIGHT="18.114603420621044"/>
<DICH_DATA CI_END="2.8798535293268928" CI_START="0.035671421156302424" EFFECT_SIZE="0.32051282051282054" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.459370399904121" LOG_CI_START="-1.4476795879410065" LOG_EFFECT_SIZE="-0.49415459401844275" ORDER="551" O_E="0.0" SE="1.1202106029099148" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="1.2548717948717947" WEIGHT="40.85267491270669"/>
<DICH_DATA CI_END="4.816917538103997" CI_START="0.03813091420702448" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.6827692115930425" LOG_CI_START="-1.4187227821822312" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="548" O_E="0.0" SE="1.2344267996967353" STUDY_ID="STD-H_x00fc_ll-1999" TOTAL_1="7" TOTAL_2="3" VAR="1.523809523809524" WEIGHT="18.697955056200367"/>
<DICH_DATA CI_END="32.80285982197966" CI_START="0.5292560223507785" EFFECT_SIZE="4.166666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5159117080642133" LOG_CI_START="-0.27633419148742516" LOG_EFFECT_SIZE="0.619788758288394" ORDER="547" O_E="0.0" SE="1.052774113156917" STUDY_ID="STD-Rogers-1993" TOTAL_1="24" TOTAL_2="20" VAR="1.1083333333333332" WEIGHT="14.56983510872756"/>
<DICH_DATA CI_END="112.95106309578426" CI_START="0.37175745715993386" EFFECT_SIZE="6.48" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.0528903228567366" LOG_CI_START="-0.42974031111555" LOG_EFFECT_SIZE="0.8115750058705934" ORDER="550" O_E="0.0" SE="1.4583095236151573" STUDY_ID="STD-Scharf-1999" TOTAL_1="24" TOTAL_2="17" VAR="2.126666666666667" WEIGHT="7.76493150174434"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.5190698583025872" CI_START="0.11676775085406718" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6410256410256411" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="100.00000000000001" ID="CMP-004.18" LOG_CI_END="0.5464278882543991" LOG_CI_START="-0.9326770849633222" LOG_EFFECT_SIZE="-0.19312459835446155" METHOD="MH" MODIFIED="2011-10-01 16:58:21 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.6087774634292231" Q="4.082134121255554E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="0.5118193287932257">
<NAME>Constipation or diarrhea</NAME>
<GROUP_LABEL_1>Traditional NSAIDs</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5190698583025872" CI_START="0.11676775085406718" DF="0" EFFECT_SIZE="0.6410256410256411" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-004.18.01" LOG_CI_END="0.5464278882543991" LOG_CI_START="-0.9326770849633222" LOG_EFFECT_SIZE="-0.19312459835446155" MODIFIED="2011-03-21 04:25:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6087774634292231" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="0.5118193287932257">
<NAME>traditional NSAIDs</NAME>
<DICH_DATA CI_END="3.5190698583025863" CI_START="0.11676775085406724" EFFECT_SIZE="0.6410256410256411" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.546427888254399" LOG_CI_START="-0.932677084963322" LOG_EFFECT_SIZE="-0.19312459835446155" ORDER="560" O_E="0.0" SE="0.8688335829557895" STUDY_ID="STD-De-Jong-2008" TOTAL_1="26" TOTAL_2="25" VAR="0.7548717948717948" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-01-02 08:42:48 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective COX-2 inhibitor vs. placebo</NAME>
<DICH_OUTCOME CHI2="6.011718729162943" CI_END="3.0288996938774444" CI_START="1.3659587688650054" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0340482041644012" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="27" I2="33.46328761863165" I2_Q="100.0" ID="CMP-005.01" LOG_CI_END="0.4812848913200354" LOG_CI_START="0.13543759046948226" LOG_EFFECT_SIZE="0.3083612408947588" METHOD="MH" MODIFIED="2011-06-13 12:33:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.19827494666341017" P_Q="0.0" P_Z="4.739717027824915E-4" Q="2.986595967617143E-31" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="790" TOTAL_2="565" WEIGHT="100.0" Z="3.495050705299385">
<NAME>Gastrointestinal side effects</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.011718729162943" CI_END="3.0288996938774444" CI_START="1.3659587688650054" DF="4" EFFECT_SIZE="2.0340482041644012" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="27" I2="33.46328761863165" ID="CMP-005.01.01" LOG_CI_END="0.4812848913200354" LOG_CI_START="0.13543759046948226" LOG_EFFECT_SIZE="0.3083612408947588" MODIFIED="2011-06-13 12:33:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.19827494666341017" P_Z="4.739717027824915E-4" STUDIES="5" TAU2="0.0" TOTAL_1="790" TOTAL_2="565" WEIGHT="100.0" Z="3.495050705299385">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="5.381865820367336" CI_START="1.368920590865392" EFFECT_SIZE="2.7142857142857144" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.7309328658170937" LOG_CI_START="0.13637825606005063" LOG_EFFECT_SIZE="0.43365556093857216" MODIFIED="2011-03-21 04:25:53 +0000" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="0.349244320864071" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="0.12197159565580618" WEIGHT="21.290159240313432"/>
<DICH_DATA CI_END="15.763043521426319" CI_START="0.20629353868539763" EFFECT_SIZE="1.8032786885245902" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.1976400746350089" LOG_CI_START="-0.6855143743400927" LOG_EFFECT_SIZE="0.256062850147458" MODIFIED="2011-06-13 12:33:49 +0100" MODIFIED_BY="[Empty name]" ORDER="683" O_E="0.0" SE="1.1061742450928365" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="55" VAR="1.2236214605067066" WEIGHT="4.65859461450675"/>
<DICH_DATA CI_END="1.8043006754171937" CI_START="0.2946759567414343" EFFECT_SIZE="0.7291666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.25630891169462433" LOG_CI_START="-0.5306552977452476" LOG_EFFECT_SIZE="-0.1371731930253116" ORDER="686" O_E="0.0" SE="0.4622666721606438" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="0.21369047619047615" WEIGHT="15.448641625624258"/>
<DICH_DATA CI_END="3.576791602279195" CI_START="1.1183206752809218" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="16" LOG_CI_END="0.5534936372088661" LOG_CI_START="0.048566354119096225" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="685" O_E="0.0" SE="0.2965967855172924" STUDY_ID="STD-Reines-2004" TOTAL_1="346" TOTAL_2="346" VAR="0.08796965317919075" WEIGHT="54.07024568968491"/>
<DICH_DATA CI_END="31.11175407662241" CI_START="0.4963886332276794" EFFECT_SIZE="3.9298245614035086" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.492924497265015" LOG_CI_START="-0.3041781719416721" LOG_EFFECT_SIZE="0.5943731626616714" MODIFIED="2009-02-12 02:05:47 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="684" O_E="0.0" SE="1.0556270036936903" STUDY_ID="STD-Soininen-2007" TOTAL_1="285" TOTAL_2="140" VAR="1.1143483709273183" WEIGHT="4.532358829870646"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="146.03035774343485" CI_START="0.5124244974941519" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="8.65040650406504" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="2.1644431491402796" LOG_CI_START="-0.2903701161010164" LOG_EFFECT_SIZE="0.9370365165196315" METHOD="MH" MODIFIED="2011-10-01 17:01:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.13457777004538854" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="55" WEIGHT="100.0" Z="1.4962912662905339">
<NAME>Hypertension</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="146.03035774343485" CI_START="0.5124244974941519" DF="0" EFFECT_SIZE="8.65040650406504" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="2.1644431491402796" LOG_CI_START="-0.2903701161010164" LOG_EFFECT_SIZE="0.9370365165196315" MODIFIED="2011-06-13 12:34:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.13457777004538854" STUDIES="1" TAU2="0.0" TOTAL_1="122" TOTAL_2="55" WEIGHT="100.0" Z="1.4962912662905339">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="146.03035774343485" CI_START="0.5124244974941519" EFFECT_SIZE="8.65040650406504" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.1644431491402796" LOG_CI_START="-0.2903701161010164" LOG_EFFECT_SIZE="0.9370365165196315" MODIFIED="2011-06-13 12:34:41 +0100" MODIFIED_BY="[Empty name]" ORDER="765" O_E="0.0" SE="1.4419694635243774" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="55" VAR="2.0792759337367808" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7317684447197776" CI_END="38.40902593201717" CI_START="1.4722593866850897" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="7.519843679348879" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" I2="63.39367628567146" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="1.584433293426201" LOG_CI_START="0.1679843319321323" LOG_EFFECT_SIZE="0.8762088126791667" METHOD="MH" MODIFIED="2011-10-01 17:03:45 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.09837038054312441" P_Q="1.0" P_Z="0.015314737838710154" Q="0.0" RANDOM="NO" SCALE="138.43491274800346" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="407" TOTAL_2="195" WEIGHT="100.0" Z="2.4248494121190554">
<NAME>Heart disease</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.7317684447197776" CI_END="38.40902593201717" CI_START="1.4722593866850897" DF="1" EFFECT_SIZE="7.519843679348879" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" I2="63.39367628567146" ID="CMP-005.03.01" LOG_CI_END="1.584433293426201" LOG_CI_START="0.1679843319321323" LOG_EFFECT_SIZE="0.8762088126791667" MODIFIED="2011-10-01 17:03:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.09837038054312441" P_Z="0.015314737838710154" STUDIES="2" TAU2="0.0" TOTAL_1="407" TOTAL_2="195" WEIGHT="100.0" Z="2.4248494121190554">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="12.712641315459466" CI_START="0.1438839770299779" EFFECT_SIZE="1.3524590163934427" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.1042357936344895" LOG_CI_START="-0.8419875665561735" LOG_EFFECT_SIZE="0.13112411353915807" MODIFIED="2011-10-01 17:03:45 +0100" MODIFIED_BY="[Empty name]" ORDER="745" O_E="0.0" SE="1.1432212357370028" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="55" VAR="1.3069547938400399" WEIGHT="67.30056197920031"/>
<DICH_DATA CI_END="331.78518105737055" CI_START="1.2314502970007104" EFFECT_SIZE="20.213286713286713" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="0" LOG_CI_END="2.520856984675882" LOG_CI_START="0.09041688781626335" LOG_EFFECT_SIZE="1.3056369362460725" MODIFIED="2011-10-01 17:03:43 +0100" MODIFIED_BY="[Empty name]" ORDER="746" O_E="0.0" SE="1.4276525437678507" STUDY_ID="STD-Soininen-2007" TOTAL_1="285" TOTAL_2="140" VAR="2.0381917857268146" WEIGHT="32.69943802079969"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2602674330118188" CI_END="12.04086338577082" CI_START="1.0005238722908478" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.470903522205207" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="1.0806576289676846" LOG_CI_START="2.274552715807135E-4" LOG_EFFECT_SIZE="0.5404425421196327" METHOD="MH" MODIFIED="2011-10-01 17:01:34 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6099365261725356" P_Q="1.0" P_Z="0.049903616202090224" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="24" WEIGHT="99.99999999999999" Z="1.960789219064682">
<NAME>Rash</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2602674330118188" CI_END="12.04086338577082" CI_START="1.0005238722908478" DF="1" EFFECT_SIZE="3.470903522205207" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="1.0806576289676846" LOG_CI_START="2.274552715807135E-4" LOG_EFFECT_SIZE="0.5404425421196327" MODIFIED="2011-03-21 04:28:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6099365261725356" P_Z="0.049903616202090224" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="24" WEIGHT="99.99999999999999" Z="1.960789219064682">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="16.524902600773654" CI_START="1.0031242551147515" EFFECT_SIZE="4.071428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2181389083954266" LOG_CI_START="0.0013547315930800402" LOG_EFFECT_SIZE="0.6097468199942534" MODIFIED="2011-03-21 04:28:41 +0000" MODIFIED_BY="[Empty name]" ORDER="235" O_E="0.0" SE="0.7147450486325142" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="0.5108604845446951" WEIGHT="73.96630934150076"/>
<DICH_DATA CI_END="31.7594363676301" CI_START="0.09805548231911063" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.5018727864313772" LOG_CI_START="-1.0085281197486002" LOG_EFFECT_SIZE="0.2466723333413885" ORDER="785" O_E="0.0" SE="1.4746219189750194" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="2.174509803921569" WEIGHT="26.03369065849923"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.01444883080673424" CI_END="8.80903954284652" CI_START="0.3513612602056068" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.759305327387937" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.9449285594925725" LOG_CI_START="-0.45424612390618596" LOG_EFFECT_SIZE="0.24534121779319334" METHOD="MH" MODIFIED="2011-10-01 17:01:34 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9043221147672003" P_Q="1.0" P_Z="0.491863470814467" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="324" TOTAL_2="158" WEIGHT="100.0" Z="0.6873479866427994">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.01444883080673424" CI_END="8.80903954284652" CI_START="0.3513612602056068" DF="1" EFFECT_SIZE="1.759305327387937" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="0.9449285594925725" LOG_CI_START="-0.45424612390618596" LOG_EFFECT_SIZE="0.24534121779319334" MODIFIED="2009-02-18 02:22:03 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="1" P_CHI2="0.9043221147672003" P_Z="0.491863470814467" STUDIES="2" TAU2="0.0" TOTAL_1="324" TOTAL_2="158" WEIGHT="100.0" Z="0.6873479866427994">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="12.08896337218474" CI_START="0.2908127762293526" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.082389061734073" LOG_CI_START="-0.5363865176065977" LOG_EFFECT_SIZE="0.27300127206373764" ORDER="714" O_E="0.0" SE="0.9508767883730609" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="0.9041666666666668" WEIGHT="69.54236094813423"/>
<DICH_DATA CI_END="36.488133652671934" CI_START="0.06126540971869944" EFFECT_SIZE="1.4951456310679612" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5621516500164712" LOG_CI_START="-1.2127846577538897" LOG_EFFECT_SIZE="0.17468349613129086" MODIFIED="2009-02-12 02:07:33 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="716" O_E="0.0" SE="1.6300113233405673" STUDY_ID="STD-Soininen-2007" TOTAL_1="308" TOTAL_2="153" VAR="2.6569369142184676" WEIGHT="30.457639051865762"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.208786716103356" CI_END="2.6852640123712854" CI_START="0.8696054017792052" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.528109973254992" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" I2="17.272419800938977" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.428986991517599" LOG_CI_START="-0.06067777118071428" LOG_EFFECT_SIZE="0.1841546101684424" METHOD="MH" MODIFIED="2011-10-01 17:01:31 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.2715726105266886" P_Q="1.0" P_Z="0.1404227950576842" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="329" TOTAL_2="172" WEIGHT="100.0" Z="1.474218408235909">
<NAME>Psychiatric side effects</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.208786716103356" CI_END="2.6852640123712854" CI_START="0.8696054017792052" DF="1" EFFECT_SIZE="1.528109973254992" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="13" I2="17.272419800938977" ID="CMP-005.06.01" LOG_CI_END="0.428986991517599" LOG_CI_START="-0.06067777118071428" LOG_EFFECT_SIZE="0.1841546101684424" MODIFIED="2011-03-21 04:27:59 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2715726105266886" P_Z="0.1404227950576842" STUDIES="2" TAU2="0.0" TOTAL_1="329" TOTAL_2="172" WEIGHT="100.0" Z="1.474218408235909">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="4.370592892431301" CI_START="1.0197220910633795" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.6405403551501929" LOG_CI_START="0.008481827876815258" LOG_EFFECT_SIZE="0.3245110915135041" MODIFIED="2011-03-21 04:27:59 +0000" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.37127430766055175" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="0.13784461152882205" WEIGHT="40.24638665243961"/>
<DICH_DATA CI_END="2.701446173006753" CI_START="0.47723138299979556" EFFECT_SIZE="1.1354359925788498" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="7" LOG_CI_END="0.43159631853483443" LOG_CI_START="-0.3212710046171894" LOG_EFFECT_SIZE="0.055162656958822505" MODIFIED="2009-02-12 02:09:06 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="723" O_E="0.0" SE="0.44223799237285266" STUDY_ID="STD-Soininen-2007" TOTAL_1="308" TOTAL_2="153" VAR="0.1955744418979713" WEIGHT="59.75361334756038"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="66.3533143927606" CI_START="0.17948973569036156" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.4510489510489513" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="1.8218626210442543" LOG_CI_START="-0.7459603819630669" LOG_EFFECT_SIZE="0.5379511195405937" METHOD="MH" MODIFIED="2011-10-01 17:01:30 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.4115249589794142" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="285" TOTAL_2="140" WEIGHT="100.0" Z="0.8212130030050665">
<NAME>Bleeding</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="66.3533143927606" CI_START="0.17948973569036156" DF="0" EFFECT_SIZE="3.4510489510489513" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-005.07.01" LOG_CI_END="1.8218626210442543" LOG_CI_START="-0.7459603819630669" LOG_EFFECT_SIZE="0.5379511195405937" MODIFIED="2009-02-18 02:21:59 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="1" P_CHI2="1.0" P_Z="0.4115249589794142" STUDIES="1" TAU2="0.0" TOTAL_1="285" TOTAL_2="140" WEIGHT="100.0" Z="0.8212130030050665">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="66.35331439276065" CI_START="0.17948973569036147" EFFECT_SIZE="3.4510489510489513" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.8218626210442546" LOG_CI_START="-0.7459603819630671" LOG_EFFECT_SIZE="0.5379511195405937" MODIFIED="2009-02-12 02:10:36 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="734" O_E="0.0" SE="1.508351942895365" STUDY_ID="STD-Soininen-2007" TOTAL_1="285" TOTAL_2="140" VAR="2.275125583636222" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5845329927082767" CI_END="1.6427196056385323" CI_START="0.4047126452255693" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8153707113711373" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" I2="44.20472613675374" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="0.21556344041858225" LOG_CI_START="-0.3928532258879205" LOG_EFFECT_SIZE="-0.08864489273466913" METHOD="MH" MODIFIED="2011-10-01 17:01:29 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.16658224388687404" P_Q="1.0" P_Z="0.5679153327651749" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="776" TOTAL_2="554" WEIGHT="100.0" Z="0.5711243849649648">
<NAME>Cerebrovascular side effects</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5845329927082767" CI_END="1.6427196056385323" CI_START="0.4047126452255693" DF="2" EFFECT_SIZE="0.8153707113711373" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" I2="44.20472613675374" ID="CMP-005.08.01" LOG_CI_END="0.21556344041858225" LOG_CI_START="-0.3928532258879205" LOG_EFFECT_SIZE="-0.08864489273466913" MODIFIED="2011-06-13 12:34:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.16658224388687404" P_Z="0.5679153327651749" STUDIES="3" TAU2="0.0" TOTAL_1="776" TOTAL_2="554" WEIGHT="100.0" Z="0.5711243849649648">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="15.763043521426319" CI_START="0.20629353868539763" EFFECT_SIZE="1.8032786885245902" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.1976400746350089" LOG_CI_START="-0.6855143743400927" LOG_EFFECT_SIZE="0.256062850147458" MODIFIED="2011-06-13 12:34:37 +0100" MODIFIED_BY="[Empty name]" ORDER="756" O_E="0.0" SE="1.1061742450928365" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="55" VAR="1.2236214605067066" WEIGHT="7.778013648379626"/>
<DICH_DATA CI_END="1.1309163367465815" CI_START="0.11692412662379678" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="0.05343047775193963" LOG_CI_START="-0.9320958654124649" LOG_EFFECT_SIZE="-0.43933269383026263" ORDER="755" O_E="0.0" SE="0.5789030524088482" STUDY_ID="STD-Reines-2004" TOTAL_1="346" TOTAL_2="346" VAR="0.33512874408828164" WEIGHT="62.06472366145546"/>
<DICH_DATA CI_END="4.543999456155134" CI_START="0.48874875863612044" EFFECT_SIZE="1.4902597402597402" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.6574382707247849" LOG_CI_START="-0.3109143326511511" LOG_EFFECT_SIZE="0.17326196903681695" MODIFIED="2009-02-12 02:19:06 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="753" O_E="0.0" SE="0.5688151126457188" STUDY_ID="STD-Soininen-2007" TOTAL_1="308" TOTAL_2="153" VAR="0.3235506323741618" WEIGHT="30.15726269016491"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.172740216038529" CI_START="0.6132230261516252" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.732142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="1.0853883536406572" LOG_CI_START="-0.21238154601786055" LOG_EFFECT_SIZE="0.4365034038113984" METHOD="MH" MODIFIED="2009-02-20 06:12:16 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.18734862429249438" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="308" TOTAL_2="153" WEIGHT="100.0" Z="1.3184632357779305">
<NAME>Respiratory side effects</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.172740216038529" CI_START="0.6132230261516252" DF="0" EFFECT_SIZE="2.732142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" I2="0.0" ID="CMP-005.09.01" LOG_CI_END="1.0853883536406572" LOG_CI_START="-0.21238154601786055" LOG_EFFECT_SIZE="0.4365034038113984" MODIFIED="2009-02-18 02:21:35 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="1" P_CHI2="1.0" P_Z="0.18734862429249438" STUDIES="1" TAU2="0.0" TOTAL_1="308" TOTAL_2="153" WEIGHT="100.0" Z="1.3184632357779305">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="12.172740216038529" CI_START="0.6132230261516252" EFFECT_SIZE="2.732142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.0853883536406572" LOG_CI_START="-0.21238154601786055" LOG_EFFECT_SIZE="0.4365034038113984" MODIFIED="2009-02-12 02:14:34 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="795" O_E="0.0" SE="0.7623164631240227" STUDY_ID="STD-Soininen-2007" TOTAL_1="308" TOTAL_2="153" VAR="0.5811263899499194" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="33.00813120137118" CI_START="0.05651808050436614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3658536585365855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.10" LOG_CI_END="1.5186209368747827" LOG_CI_START="-1.2478125963018527" LOG_EFFECT_SIZE="0.13540417028646495" METHOD="MH" MODIFIED="2011-06-13 12:34:57 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.847849985924388" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="55" WEIGHT="100.0" Z="0.19186240618856398">
<NAME>Dry mouth</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="33.00813120137118" CI_START="0.05651808050436614" DF="0" EFFECT_SIZE="1.3658536585365855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-005.10.01" LOG_CI_END="1.5186209368747827" LOG_CI_START="-1.2478125963018527" LOG_EFFECT_SIZE="0.13540417028646495" MODIFIED="2011-06-13 12:34:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.847849985924388" STUDIES="1" TAU2="0.0" TOTAL_1="122" TOTAL_2="55" WEIGHT="100.0" Z="0.19186240618856398">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="33.008131201371164" CI_START="0.056518080504366165" EFFECT_SIZE="1.3658536585365855" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5186209368747825" LOG_CI_START="-1.2478125963018525" LOG_EFFECT_SIZE="0.13540417028646495" MODIFIED="2011-06-13 12:34:57 +0100" MODIFIED_BY="[Empty name]" ORDER="814" O_E="0.0" SE="1.6250167514547997" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="55" VAR="2.6406794425087106" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.613546275717642" CI_START="0.5141909796745171" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1592505854800936" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="0.41723019416435847" LOG_CI_START="-0.2888755463472688" LOG_EFFECT_SIZE="0.06417732390854484" METHOD="MH" MODIFIED="2011-06-13 12:35:02 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.7216318049835401" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="122" TOTAL_2="55" WEIGHT="100.0" Z="0.3562787731870535">
<NAME>Fatigue</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.613546275717642" CI_START="0.5141909796745171" DF="0" EFFECT_SIZE="1.1592505854800936" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" I2="0.0" ID="CMP-005.11.01" LOG_CI_END="0.41723019416435847" LOG_CI_START="-0.2888755463472688" LOG_EFFECT_SIZE="0.06417732390854484" MODIFIED="2011-06-13 12:35:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7216318049835401" STUDIES="1" TAU2="0.0" TOTAL_1="122" TOTAL_2="55" WEIGHT="100.0" Z="0.3562787731870535">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="2.613546275717642" CI_START="0.5141909796745171" EFFECT_SIZE="1.1592505854800936" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" LOG_CI_END="0.41723019416435847" LOG_CI_START="-0.2888755463472688" LOG_EFFECT_SIZE="0.06417732390854484" MODIFIED="2011-06-13 12:35:02 +0100" MODIFIED_BY="[Empty name]" ORDER="824" O_E="0.0" SE="0.41477000725631646" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="55" VAR="0.1720341589194048" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.7895956936055E-5" CI_END="3.0057893187857783" CI_START="0.5282386187013621" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2600690448791716" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" I2="0.0" I2_Q="100.0" ID="CMP-005.12" LOG_CI_END="0.47795853683128803" LOG_CI_START="-0.2771698513763466" LOG_EFFECT_SIZE="0.10039434272747072" METHOD="MH" MODIFIED="2011-06-13 12:35:06 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.9929580671166689" P_Q="0.0" P_Z="0.6022591179186322" Q="3.91546799276014E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="138" TOTAL_2="60" WEIGHT="100.0" Z="0.5211545455587043">
<NAME>Dizziness</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.7895956936055E-5" CI_END="3.0057893187857783" CI_START="0.5282386187013621" DF="1" EFFECT_SIZE="1.2600690448791716" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" I2="0.0" ID="CMP-005.12.01" LOG_CI_END="0.47795853683128803" LOG_CI_START="-0.2771698513763466" LOG_EFFECT_SIZE="0.10039434272747072" MODIFIED="2011-06-13 12:35:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9929580671166689" P_Z="0.6022591179186322" STUDIES="2" TAU2="0.0" TOTAL_1="138" TOTAL_2="60" WEIGHT="100.0" Z="0.5211545455587043">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="3.330636030906393" CI_START="0.47840378209233253" EFFECT_SIZE="1.2622950819672132" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.5225271759498116" LOG_CI_START="-0.32020539562638184" LOG_EFFECT_SIZE="0.10116089016171487" MODIFIED="2011-06-13 12:35:06 +0100" MODIFIED_BY="[Empty name]" ORDER="833" O_E="0.0" SE="0.4950252841373639" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="55" VAR="0.24505003193527786" WEIGHT="81.89489835059456"/>
<DICH_DATA CI_END="8.765462110799932" CI_START="0.17825643191986906" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.9427748168223009" LOG_CI_START="-0.7489547908061881" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="836" O_E="0.0" SE="0.9937303457175896" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="0.9875" WEIGHT="18.105101649405448"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.742610844037051" CI_START="0.08984967264721418" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9824561403508771" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.13" LOG_CI_END="1.031109843501418" LOG_CI_START="-1.046483500834" LOG_EFFECT_SIZE="-0.0076868286662910065" METHOD="MH" MODIFIED="2009-02-20 06:12:16 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.9884285021504472" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="285" TOTAL_2="140" WEIGHT="100.0" Z="0.014503230271061275">
<NAME>Abnormal labs other than Cr. and LFT</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.742610844037051" CI_START="0.08984967264721418" DF="0" EFFECT_SIZE="0.9824561403508771" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-005.13.01" LOG_CI_END="1.031109843501418" LOG_CI_START="-1.046483500834" LOG_EFFECT_SIZE="-0.0076868286662910065" MODIFIED="2009-02-18 02:21:18 +0000" MODIFIED_BY="Darin   Jaturapatporn" NO="1" P_CHI2="1.0" P_Z="0.9884285021504472" STUDIES="1" TAU2="0.0" TOTAL_1="285" TOTAL_2="140" WEIGHT="100.0" Z="0.014503230271061275">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="10.742610844037051" CI_START="0.08984967264721418" EFFECT_SIZE="0.9824561403508771" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.031109843501418" LOG_CI_START="-1.046483500834" LOG_EFFECT_SIZE="-0.0076868286662910065" MODIFIED="2009-02-12 02:16:06 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="845" O_E="0.0" SE="1.2203886147155414" STUDY_ID="STD-Soininen-2007" TOTAL_1="285" TOTAL_2="140" VAR="1.4893483709273183" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.150535878117544" CI_END="4.026202468312338" CI_START="0.8741258349764294" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8760084206627865" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" I2="6.999924049131168" I2_Q="0.0" ID="CMP-005.14" LOG_CI_END="0.6048956107562752" LOG_CI_START="-0.05842604390773751" LOG_EFFECT_SIZE="0.27323478342426877" METHOD="MH" MODIFIED="2011-06-13 12:35:20 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.34120653567348147" P_Q="1.0" P_Z="0.10637724738973929" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="813" TOTAL_2="578" WEIGHT="100.00000000000001" Z="1.614692754471967">
<NAME>Death</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.150535878117544" CI_END="4.026202468312338" CI_START="0.8741258349764294" DF="2" EFFECT_SIZE="1.8760084206627865" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="8" I2="6.999924049131168" ID="CMP-005.14.01" LOG_CI_END="0.6048956107562752" LOG_CI_START="-0.05842604390773751" LOG_EFFECT_SIZE="0.27323478342426877" MODIFIED="2011-06-13 12:35:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.34120653567348147" P_Z="0.10637724738973929" STUDIES="5" TAU2="0.0" TOTAL_1="813" TOTAL_2="578" WEIGHT="100.00000000000001" Z="1.614692754471967">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-21 04:29:33 +0000" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.0" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.734874040561195" CI_START="0.08350940173796811" EFFECT_SIZE="0.9016393442622951" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.9883303365604039" LOG_CI_START="-1.0782646275934502" LOG_EFFECT_SIZE="-0.044967145516523185" MODIFIED="2011-06-13 12:35:20 +0100" MODIFIED_BY="[Empty name]" ORDER="865" O_E="0.0" SE="1.2139281117540308" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="55" VAR="1.4736214605067066" WEIGHT="13.703556609221309"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-02-12 02:41:22 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="864" O_E="0.0" SE="0.0" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="20.676303388823243" CI_START="0.9793820306847656" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.3154728960592597" LOG_CI_START="-0.009047868508572171" LOG_EFFECT_SIZE="0.6532125137753437" ORDER="866" O_E="0.0" SE="0.7780300535906707" STUDY_ID="STD-Reines-2004" TOTAL_1="346" TOTAL_2="346" VAR="0.6053307642903019" WEIGHT="19.88138950682108"/>
<DICH_DATA CI_END="3.556828243775724" CI_START="0.4689917796508742" EFFECT_SIZE="1.2915584415584416" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.5510628939793092" LOG_CI_START="-0.32883476940336426" LOG_EFFECT_SIZE="0.1111140622879725" MODIFIED="2009-02-12 02:04:49 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="863" O_E="0.0" SE="0.5168562430346618" STUDY_ID="STD-Soininen-2007" TOTAL_1="308" TOTAL_2="153" VAR="0.26714037596390544" WEIGHT="66.41505388395763"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.7127686248242995" CI_END="1.3128141030748788" CI_START="0.7140332415220729" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9681905336938843" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="59" I2="61.10346172781318" I2_Q="0.0" ID="CMP-005.15" LOG_CI_END="0.11820323353460026" LOG_CI_START="-0.14628156935329908" LOG_EFFECT_SIZE="-0.014039167909349408" METHOD="MH" MODIFIED="2011-06-13 12:35:43 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.05233637458535256" P_Q="1.0" P_Z="0.8351708453168998" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="797" TOTAL_2="573" WEIGHT="100.0" Z="0.20807443886972943">
<NAME>Withdrawal due to side effects</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.7127686248242995" CI_END="1.3128141030748788" CI_START="0.7140332415220729" DF="3" EFFECT_SIZE="0.9681905336938843" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="59" I2="61.10346172781318" ID="CMP-005.15.01" LOG_CI_END="0.11820323353460026" LOG_CI_START="-0.14628156935329908" LOG_EFFECT_SIZE="-0.014039167909349408" MODIFIED="2011-06-13 12:35:43 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05233637458535256" P_Z="0.8351708453168998" STUDIES="4" TAU2="0.0" TOTAL_1="797" TOTAL_2="573" WEIGHT="100.0" Z="0.20807443886972943">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="13.482091688489398" CI_START="0.060717144136267914" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1297572763459856" LOG_CI_START="-1.2166886639081658" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2011-03-21 04:30:13 +0000" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="1.3783139604000185" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="1.899749373433584" WEIGHT="1.5525815394185416"/>
<DICH_DATA CI_END="0.9238765569459282" CI_START="0.3437255349017544" EFFECT_SIZE="0.5635245901639344" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="20" LOG_CI_END="-0.03438605282602442" LOG_CI_START="-0.46378820351887146" LOG_EFFECT_SIZE="-0.249087128172448" MODIFIED="2011-06-13 12:35:43 +0100" MODIFIED_BY="[Empty name]" ORDER="873" O_E="0.0" SE="0.2522329488919051" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="55" VAR="0.06362146050670642" WEIGHT="40.767274212335124"/>
<DICH_DATA CI_END="2.0263600682295966" CI_START="0.889903692041236" EFFECT_SIZE="1.3428571428571427" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="35" LOG_CI_END="0.30671661859140825" LOG_CI_START="-0.0506569914205246" LOG_EFFECT_SIZE="0.1280298135854418" ORDER="876" O_E="0.0" SE="0.2099230275489094" STUDY_ID="STD-Reines-2004" TOTAL_1="346" TOTAL_2="346" VAR="0.044067677495300175" WEIGHT="51.75271798061806"/>
<DICH_DATA CI_END="2.432348294438648" CI_START="0.10145084432360939" EFFECT_SIZE="0.4967532467532468" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.3860257628385409" LOG_CI_START="-0.9937443342042318" LOG_EFFECT_SIZE="-0.3038592856828454" MODIFIED="2009-02-12 02:16:34 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="874" O_E="0.0" SE="0.8104837849750574" STUDY_ID="STD-Soininen-2007" TOTAL_1="308" TOTAL_2="153" VAR="0.6568839657074951" WEIGHT="5.927426267628271"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.639850887554264" CI_END="3.5547670212460094" CI_START="0.7877568339674288" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6734073067094528" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" I2="60.73221789070301" I2_Q="0.0" ID="CMP-005.16" LOG_CI_END="0.5508111424208088" LOG_CI_START="-0.10360782053546708" LOG_EFFECT_SIZE="0.2236016609426709" METHOD="MH" MODIFIED="2011-06-13 12:35:52 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.05407195684039334" P_Q="1.0" P_Z="0.1804535929259562" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="444" TOTAL_2="219" WEIGHT="100.0" Z="1.3393597286704928">
<NAME>Abdominal pain or dyspepsia</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.639850887554264" CI_END="3.5547670212460094" CI_START="0.7877568339674288" DF="3" EFFECT_SIZE="1.6734073067094528" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" I2="60.73221789070301" ID="CMP-005.16.01" LOG_CI_END="0.5508111424208088" LOG_CI_START="-0.10360782053546708" LOG_EFFECT_SIZE="0.2236016609426709" MODIFIED="2011-06-13 12:35:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05407195684039334" P_Z="0.1804535929259562" STUDIES="4" TAU2="0.0" TOTAL_1="444" TOTAL_2="219" WEIGHT="100.0" Z="1.3393597286704928">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="16.524902600773654" CI_START="1.0031242551147515" EFFECT_SIZE="4.071428571428571" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.2181389083954266" LOG_CI_START="0.0013547315930800402" LOG_EFFECT_SIZE="0.6097468199942534" MODIFIED="2011-03-21 04:30:28 +0000" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.7147450486325142" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="0.5108604845446951" WEIGHT="24.083262383087625"/>
<DICH_DATA CI_END="15.763043521426319" CI_START="0.20629353868539763" EFFECT_SIZE="1.8032786885245902" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.1976400746350089" LOG_CI_START="-0.6855143743400927" LOG_EFFECT_SIZE="0.256062850147458" MODIFIED="2011-06-13 12:35:52 +0100" MODIFIED_BY="[Empty name]" ORDER="884" O_E="0.0" SE="1.1061742450928365" STUDY_ID="STD-Aisen-2003a" TOTAL_1="122" TOTAL_2="55" VAR="1.2236214605067066" WEIGHT="15.809297878593974"/>
<DICH_DATA CI_END="1.264525601529265" CI_START="0.13729347266765737" EFFECT_SIZE="0.4166666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.10192762647625903" LOG_CI_START="-0.862350109899471" LOG_EFFECT_SIZE="-0.38021124171160603" ORDER="886" O_E="0.0" SE="0.5664215155988809" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="0.32083333333333325" WEIGHT="52.42614940536081"/>
<DICH_DATA CI_END="51.0019353990946" CI_START="0.11914052537999964" EFFECT_SIZE="2.465034965034965" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7075866568273241" LOG_CI_START="-0.9239404891026126" LOG_EFFECT_SIZE="0.3918230838623557" MODIFIED="2009-02-12 02:06:14 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="885" O_E="0.0" SE="1.545772071788702" STUDY_ID="STD-Soininen-2007" TOTAL_1="285" TOTAL_2="140" VAR="2.3894112979219364" WEIGHT="7.681290332957578"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07502267285385805" CI_END="9.664849811491118" CI_START="1.0354702267074574" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1634892485036574" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.17" LOG_CI_END="0.9851951096271228" LOG_CI_START="0.015137615964813033" LOG_EFFECT_SIZE="0.5001663627959679" METHOD="MH" MODIFIED="2011-03-21 04:30:42 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.7841594264602552" P_Q="1.0" P_Z="0.04326590280996643" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="311" TOTAL_2="165" WEIGHT="100.0" Z="2.0211339302322844">
<NAME>Constipation or diarrhea</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.07502267285385805" CI_END="9.664849811491118" CI_START="1.0354702267074574" DF="1" EFFECT_SIZE="3.1634892485036574" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" I2="0.0" ID="CMP-005.17.01" LOG_CI_END="0.9851951096271228" LOG_CI_START="0.015137615964813033" LOG_EFFECT_SIZE="0.5001663627959679" MODIFIED="2011-03-21 04:30:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7841594264602552" P_Z="0.04326590280996643" STUDIES="2" TAU2="0.0" TOTAL_1="311" TOTAL_2="165" WEIGHT="100.0" Z="2.0211339302322844">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="9.441374752389267" CI_START="0.8813341420489659" EFFECT_SIZE="2.8846153846153846" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9750352362373373" LOG_CI_START="-0.054859405395573234" LOG_EFFECT_SIZE="0.46008791542088207" MODIFIED="2011-03-21 04:30:42 +0000" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.6049652105558683" STUDY_ID="STD-Aisen-2002a" TOTAL_1="26" TOTAL_2="25" VAR="0.365982905982906" WEIGHT="82.03650336215178"/>
<DICH_DATA CI_END="81.83992620207357" CI_START="0.24056140347495508" EFFECT_SIZE="4.437062937062937" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9129652290857426" LOG_CI_START="-0.6187740511544193" LOG_EFFECT_SIZE="0.6470955889656618" MODIFIED="2009-02-12 02:06:39 +0000" MODIFIED_BY="Darin   Jaturapatporn" ORDER="896" O_E="0.0" SE="1.487156185524627" STUDY_ID="STD-Soininen-2007" TOTAL_1="285" TOTAL_2="140" VAR="2.211633520144159" WEIGHT="17.963496637848223"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9512821726278939" CI_END="6.294259406006491" CI_START="0.1577380790775021" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.996415770609319" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.18" LOG_CI_END="0.7989446375723801" LOG_CI_START="-0.8020634522834226" LOG_EFFECT_SIZE="-0.0015594073555212932" METHOD="MH" MODIFIED="2011-03-21 04:31:07 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.32939332402970056" P_Q="1.0" P_Z="0.9969536265266987" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="24" WEIGHT="100.0" Z="0.00381807221764115">
<NAME>Nausea or vomiting</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9512821726278939" CI_END="6.294259406006491" CI_START="0.1577380790775021" DF="1" EFFECT_SIZE="0.996415770609319" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-005.18.01" LOG_CI_END="0.7989446375723801" LOG_CI_START="-0.8020634522834226" LOG_EFFECT_SIZE="-0.0015594073555212932" MODIFIED="2011-03-21 04:31:07 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.32939332402970056" P_Z="0.9969536265266987" STUDIES="2" TAU2="0.0" TOTAL_1="37" TOTAL_2="24" WEIGHT="100.0" Z="0.00381807221764115">
<NAME>Selective COX-2 inhibitor</NAME>
<DICH_DATA CI_END="7.02081776524327" CI_START="0.013079297544116708" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8463877004842707" LOG_CI_START="-1.8834155802400456" LOG_EFFECT_SIZE="-0.5185139398778875" MODIFIED="2011-03-21 04:31:07 +0000" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="1.6034999598416337" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="2.5712121212121213" WEIGHT="68.01075268817205"/>
<DICH_DATA CI_END="41.169051705332095" CI_START="0.14826200690901886" EFFECT_SIZE="2.4705882352941178" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.6145708635025957" LOG_CI_START="-0.8289701254633426" LOG_EFFECT_SIZE="0.39280036901962656" ORDER="906" O_E="0.0" SE="1.4353480726415648" STUDY_ID="STD-Jhee-2004" TOTAL_1="16" TOTAL_2="5" VAR="2.0602240896358546" WEIGHT="31.989247311827956"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="35.330542982297615" CI_START="0.5792396855594228" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.523809523809524" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.19" LOG_CI_END="1.548150312000471" LOG_CI_START="-0.23714169089061402" LOG_EFFECT_SIZE="0.6555043105549285" METHOD="MH" MODIFIED="2011-03-21 04:27:35 +0000" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.15007206258766545" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="19" WEIGHT="100.0" Z="1.4392769791360547">
<NAME>Abnormal liver function test</NAME>
<GROUP_LABEL_1>Selective COX-2 inhibitor</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="35.3305429822976" CI_START="0.5792396855594232" EFFECT_SIZE="4.523809523809524" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5481503120004707" LOG_CI_START="-0.23714169089061377" LOG_EFFECT_SIZE="0.6555043105549285" MODIFIED="2011-03-21 04:27:35 +0000" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="1.0486893598361642" STUDY_ID="STD-Aisen-2002a" TOTAL_1="21" TOTAL_2="19" VAR="1.099749373433584" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-01-11 14:31:50 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-01-11 14:31:50 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-01-11 14:31:50 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-06-05 17:34:31 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-06-05 17:34:16 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-04-26 13:43:54 +0100" MODIFIED_BY="[Empty name]">Pre-publication search: April 2011</TITLE>
<APPENDIX_BODY MODIFIED="2011-04-26 13:44:31 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="13">
<TR>
<TD VALIGN="TOP">
<P>Source</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Search strategy</P>
</TD>
<TD VALIGN="TOP">
<P>Hits retrieved</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1. ALOIS (www.medicine.ox.ac.uk/alois)</P>
</TD>
<TD VALIGN="TOP">
<P>Keyword search: aspirin OR "cyclooxygenase 2 inhibitor" OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflunisal OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indometacin OR indomethacin OR ketoprofen OR lumiracoxib OR mefenamic OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR "anti-inflammatory" OR prednisone OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR NSAIDS OR NSAID</P>
</TD>
<TD VALIGN="TOP">
<P>37</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2. MEDLINE In-process and other non-indexed citations and MEDLINE 1950-present (Ovid SP)</P>
</TD>
<TD VALIGN="TOP">
<P>1. Aspirin/</P>
<P>2. aspirin*.ti,ab.</P>
<P>3. cyclooxygenase 2 inhibitor*.ti,ab.</P>
<P>4. ("anti-inflammatory agent*" or "antiinflammatory agent" or "antinflammatory agent*").ti,ab.</P>
<P>5. aceclofenac.ti,ab.</P>
<P>6. acemetacin.ti,ab.</P>
<P>7. betamethasone.ti,ab.</P>
<P>8. dexibruprofen.ti,ab.</P>
<P>9. dexketoprofen.ti,ab.</P>
<P>10. "diclofenac sodium".ti,ab.</P>
<P>11. diflunisal.ti,ab.</P>
<P>12. diflusinal.ti,ab.</P>
<P>13. etodolac*.ti,ab.</P>
<P>14. etoricoxib*.ti,ab.</P>
<P>15. (fenbufen* or fenoprofen*).ti,ab.</P>
<P>16. flurbiprofen*.ti,ab.</P>
<P>17. (hydrocortison* or ibuprofen*).ti,ab.</P>
<P>18. (indometacin* or indomethacin*).ti,ab.</P>
<P>19. ketoprofen*.ti,ab.</P>
<P>20. lumiracoxib*.ti,ab.</P>
<P>21. "mefenamic acid".ti,ab.</P>
<P>22. meloxicam*.ti,ab.</P>
<P>23. methylprednisolone.ti,ab.</P>
<P>24. nabumeton*.ti,ab.</P>
<P>25. naproxen.ti,ab.</P>
<P>26. nimesulide.ti,ab.</P>
<P>27. "non-steroid* anti-inflammatory agent*".ti,ab.</P>
<P>28. prednisone.ti,ab.</P>
<P>29. piroxicam.ti,ab.</P>
<P>30. sulindac.ti,ab.</P>
<P>31. tenoxicam.ti,ab.</P>
<P>32. "tiaprofenic acid".ti,ab.</P>
<P>33. triamcinolone.ti,ab.</P>
<P>34. Anti-Inflammatory Agents, Non-Steroidal/</P>
<P>35. Anti-Inflammatory Agents/</P>
<P>36. NSAID*.ti,ab.</P>
<P>37. or/1-36</P>
<P>38. Alzheimer Disease/</P>
<P>39. (alzheimer* or AD or dement*).ti,ab.</P>
<P>40. alzheimer*.ti,ab.</P>
<P>41. (AD or dement*).ti,ab.</P>
<P>42. or/38-41</P>
<P>43. 37 and 42</P>
<P>44. randomized controlled trial.pt.</P>
<P>45. controlled clinical trial.pt.</P>
<P>46. randomized.ab.</P>
<P>47. placebo.ab.</P>
<P>48. drug therapy.fs.</P>
<P>49. randomly.ab.</P>
<P>50. trial.ab.</P>
<P>51. groups.ab.</P>
<P>52. or/44-51</P>
<P>53. (animals not (humans and animals)).sh.</P>
<P>54. 52 not 53</P>
<P>55. 43 and 54</P>
<P>56. (2008* or 2009* or 2010* or 2011*).ed.</P>
<P>57. 55 and 56</P>
</TD>
<TD VALIGN="TOP">
<P>193</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3. EMBASE</P>
<P>1980-2011 week 15 (Ovid SP)</P>
</TD>
<TD VALIGN="TOP">
<P>1. Aspirin/</P>
<P>2. aspirin*.ti,ab.</P>
<P>3. cyclooxygenase 2 inhibitor*.ti,ab.</P>
<P>4. ("anti-inflammatory agent*" or "antiinflammatory agent" or "antinflammatory agent*").ti,ab.</P>
<P>5. aceclofenac.ti,ab.</P>
<P>6. acemetacin.ti,ab.</P>
<P>7. betamethasone.ti,ab.</P>
<P>8. dexibruprofen.ti,ab.</P>
<P>9. dexketoprofen.ti,ab.</P>
<P>10. "diclofenac sodium".ti,ab.</P>
<P>11. diflunisal.ti,ab.</P>
<P>12. diflusinal.ti,ab.</P>
<P>13. etodolac*.ti,ab.</P>
<P>14. etoricoxib*.ti,ab.</P>
<P>15. (fenbufen* or fenoprofen*).ti,ab.</P>
<P>16. flurbiprofen*.ti,ab.</P>
<P>17. (hydrocortison* or ibuprofen*).ti,ab.</P>
<P>18. (indometacin* or indomethacin*).ti,ab.</P>
<P>19. ketoprofen*.ti,ab.</P>
<P>20. lumiracoxib*.ti,ab.</P>
<P>21. "mefenamic acid".ti,ab.</P>
<P>22. meloxicam*.ti,ab.</P>
<P>23. methylprednisolone.ti,ab.</P>
<P>24. nabumeton*.ti,ab.</P>
<P>25. naproxen.ti,ab.</P>
<P>26. nimesulide.ti,ab.</P>
<P>27. "non-steroid* anti-inflammatory agent*".ti,ab.</P>
<P>28. prednisone.ti,ab.</P>
<P>29. piroxicam.ti,ab.</P>
<P>30. sulindac.ti,ab.</P>
<P>31. tenoxicam.ti,ab.</P>
<P>32. "tiaprofenic acid".ti,ab.</P>
<P>33. triamcinolone.ti,ab.</P>
<P>34. NSAID*.ti,ab.</P>
<P>35. nonsteroid antiinflammatory agent/</P>
<P>36. antiinflammatory agent/</P>
<P>37. or/1-36</P>
<P>38. ALZHEIMER DISEASE/</P>
<P>39. (alzheimer* or AD or dement*).ti,ab.</P>
<P>40. or/38-39</P>
<P>41. 37 and 40</P>
<P>42. randomly.ti,ab.</P>
<P>43. trial.ti,ab.</P>
<P>44. placebo.ab.</P>
<P>45. clinical trial/</P>
<P>46. "double-blind*".ti,ab.</P>
<P>47. (2008* or 2009* or 2010* or 2011*).em.</P>
<P>48. or/42-46</P>
<P>49. 41 and 48</P>
<P>50. 47 and 49</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>460</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4. PSYCINFO</P>
<P>1806-April week 2 2011 (Ovid SP)</P>
</TD>
<TD VALIGN="TOP">
<P>1. Aspirin/</P>
<P>2. aspirin*.ti,ab.</P>
<P>3. cyclooxygenase 2 inhibitor*.ti,ab.</P>
<P>4. ("anti-inflammatory agent*" or "antiinflammatory agent" or "antinflammatory agent*").ti,ab.</P>
<P>5. aceclofenac.ti,ab.</P>
<P>6. acemetacin.ti,ab.</P>
<P>7. betamethasone.ti,ab.</P>
<P>8. dexibruprofen.ti,ab.</P>
<P>9. dexketoprofen.ti,ab.</P>
<P>10. "diclofenac sodium".ti,ab.</P>
<P>11. diflunisal.ti,ab.</P>
<P>12. diflusinal.ti,ab.</P>
<P>13. etodolac*.ti,ab.</P>
<P>14. etoricoxib*.ti,ab.</P>
<P>15. (fenbufen* or fenoprofen*).ti,ab.</P>
<P>16. flurbiprofen*.ti,ab.</P>
<P>17. (hydrocortison* or ibuprofen*).ti,ab.</P>
<P>18. (indometacin* or indomethacin*).ti,ab.</P>
<P>19. ketoprofen*.ti,ab.</P>
<P>20. lumiracoxib*.ti,ab.</P>
<P>21. "mefenamic acid".ti,ab.</P>
<P>22. meloxicam*.ti,ab.</P>
<P>23. methylprednisolone.ti,ab.</P>
<P>24. nabumeton*.ti,ab.</P>
<P>25. naproxen.ti,ab.</P>
<P>26. nimesulide.ti,ab.</P>
<P>27. "non-steroid* anti-inflammatory agent*".ti,ab.</P>
<P>28. prednisone.ti,ab.</P>
<P>29. piroxicam.ti,ab.</P>
<P>30. sulindac.ti,ab.</P>
<P>31. tenoxicam.ti,ab.</P>
<P>32. "tiaprofenic acid".ti,ab.</P>
<P>33. triamcinolone.ti,ab.</P>
<P>34. NSAID*.ti,ab.</P>
<P>35. Anti Inflammatory Drugs/</P>
<P>36. or/1-35</P>
<P>37. exp Alzheimer's Disease/</P>
<P>38. (AD or alzheimer* or dement*).ti,ab.</P>
<P>39. or/37-38</P>
<P>40. 36 and 39</P>
<P>41. (random* or trial or placebo or "double-blind*" or "single-blind*").ti,ab.</P>
<P>42. exp Clinical Trials/</P>
<P>43. 41 or 42</P>
<P>44. 40 and 43</P>
<P>45. (2008* or 2009* or 2010* or 2011*).up.</P>
<P>46. 44 and 45</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>26</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5. CINAHL (EBSCOhost)</P>
</TD>
<TD VALIGN="TOP">
<P>S1 (MH "Dementia+")  </P>
<P>S2 (MH "Delirium") or (MH "Delirium, Dementia, Amnestic, Cognitive Disorders")</P>
<P>S3 (MH "Wernicke's Encephalopathy")  </P>
<P>S4 TX dement*  </P>
<P>S5 TX alzheimer* </P>
<P>S6 TX lewy* N2 bod*  </P>
<P>S7 TX deliri* </P>
<P>S8 TX chronic N2 cerebrovascular  </P>
<P>S9 TX "organic brain disease" or "organic brain syndrome"  </P>
<P>S10 or/S1-S9</P>
<P>S11 MH non-steroidal anti-inflammatory agent</P>
<P>S12 MH Aspirin</P>
<P>S13 TX aspirin</P>
<P>S14TX "cyclooxygenase 2 inhibitor*" OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflunisal OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indometacin OR indomethacin OR ketoprofen OR lumiracoxib OR mefenamic OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR "anti-inflammatory" OR prednisone OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone</P>
<P>S15 or/S11-S14</P>
<P>S16 S10 AND S15</P>
<P>S17 TX random* OR placebo* OR trial OR group OR &#8220;double-blind*&#8221;</P>
<P>S18 MH Clinical Trial</P>
<P>S19 S17 AND S18</P>
<P>S20 S19 AND S16</P>
</TD>
<TD VALIGN="TOP">
<P>74</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6. ISI Web of Knowledge &#8211; all databases [includes: Web of Science (1945-present); BIOSIS Previews (1926-present); MEDLINE (1950-present); Journal Citation Reports]</P>
</TD>
<TD VALIGN="TOP">
<P>Topic=(aspirin OR "cyclooxygenase 2 inhibitor*" OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflunisal OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indometacin OR indomethacin OR ketoprofen OR lumiracoxib OR mefenamic OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR "anti-inflammatory" OR prednisone OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone) AND Topic=(Alzheimer* OR AD) AND Topic=(randomized OR randomised OR placebo OR "double-blind*" OR randomly OR RCT OR trial OR CCT) AND Year Published=(2008-2011)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>244</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7. LILACS (BIREME)</P>
</TD>
<TD VALIGN="TOP">
<P>aspirin OR anti-inflammatory [Words] and alzheimer OR AD [Words]</P>
</TD>
<TD VALIGN="TOP">
<P>18</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8. CENTRAL (<I>The Cochrane Library</I>) (Issue 1 of 4, Jan 2011)</P>
</TD>
<TD VALIGN="TOP">
<P>#1 aspirin OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR "cyclooxygenase 2 inhibitor*" OR deflazacort OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflunisal OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indometacin OR indomethacin OR ketoprofen OR lumiracoxib OR mefenamic OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR "anti-inflammatory" OR prednisone OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic OR triamcinolone</P>
<P>#2 alzheimer* OR AD</P>
<P>#3 (#1 AND #2), from 2008 to 2011</P>
</TD>
<TD VALIGN="TOP">
<P>88</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9. Clinicaltrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>)</P>
</TD>
<TD VALIGN="TOP">
<P>alzheimer OR alzheimers OR AD | aspirin OR anti-imflammatory OR celecoxib OR cortisone OR ibuprofen | received from 01/01/2008 to 04/20/2011</P>
</TD>
<TD VALIGN="TOP">
<P>6</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10. ICTRP Search Portal (<A HREF="http://apps.who.int/trialsearch">http://apps.who.int/trialsearch</A>) [includes: Australian New Zealand Clinical Trials Registry; ClinicalTrilas.gov; ISRCTN; Chinese Clinical Trial Registry; Clinical Trials Registry &#8211; India; Clinical Research Information Service &#8211; Republic of Korea; German Clinical Trials Register; Iranian Registry of Clinical Trials; Japan Primary Registries Network; Pan African Clinical Trial Registry; Sri Lanka Clinical Trials Registry; The Netherlands National Trial Register]</P>
</TD>
<TD VALIGN="TOP">
<P>(aspirin OR anti-inflammatory OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflunisal OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indometacin OR indomethacin OR ketoprofen OR lumiracoxib OR mefenamic OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR "anti-inflammatory" OR prednisone OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic OR triamcinolone OR NSAIDS) AND (rec from: 01/01/2008 to 20/04/2011)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>77</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>TOTAL before de-duplication</P>
</TD>
<TD VALIGN="TOP">
<P> 1223</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>TOTAL after de-dupe and first-assess</P>
</TD>
<TD VALIGN="TOP">
<P> 116</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-06-05 17:34:24 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-04-26 13:48:06 +0100" MODIFIED_BY="[Empty name]">Initial search: September 2008</TITLE>
<APPENDIX_BODY MODIFIED="2011-04-26 13:47:54 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="11">
<TR>
<TH>
<P>Source searched</P>
</TH>
<TH>
<P>Date of search</P>
</TH>
<TH>
<P>Search strategy used</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PubMed (MEDLINE)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>8 September 2008</P>
</TD>
<TD VALIGN="TOP">
<P>(aspirin OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR prednisone OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indomethacin OR indometacin OR ketoprofen OR lumiracoxib OR mefenamic acid OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR cyclooxygenase 2 inhibitor* OR anti-inflammatory agent*) AND (Alzheimer* OR dementia OR ((cognit* or memory* or mental*) and (declin* or impair* or los* or deteriorat*)) AND (randomized OR randomized OR double blind* OR single blind* OR placebo* OR controlled)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE (Ovid SP)</P>
</TD>
<TD VALIGN="TOP">
<P>9 September 2008</P>
</TD>
<TD VALIGN="TOP">
<P>as PubMed</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CINAHL (Ovid SP)</P>
</TD>
<TD VALIGN="TOP">
<P>9 September 2008</P>
</TD>
<TD VALIGN="TOP">
<P>as PubMed</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>PsycINFO (Ovid SP)</P>
</TD>
<TD VALIGN="TOP">
<P>9 September 2008</P>
</TD>
<TD VALIGN="TOP">
<P>as PubMed</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>LILACS (Bireme)</P>
</TD>
<TD VALIGN="TOP">
<P>9 September 2008</P>
</TD>
<TD VALIGN="TOP">
<P>(aspirin OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR prednisone OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indomethacin OR indometacin OR ketoprofen OR lumiracoxib OR mefenamic acid OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR cyclooxygenase 2 inhibitor* OR anti-inflammatory agent*) AND (Alzheimer* OR dementia)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CDCIG Specialized Register</P>
</TD>
<TD VALIGN="TOP">
<P>8 September 2008</P>
</TD>
<TD VALIGN="TOP">
<P>(aspirin OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR prednisone OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indomethacin OR indometacin OR ketoprofen OR lumiracoxib OR mefenamic acid OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR cyclooxygenase 2 inhibitor* OR anti-inflammatory agent*)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD VALIGN="TOP">
<P>Issue 3/2008</P>
</TD>
<TD>
<P>(aspirin OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR prednisone OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indomethacin OR indometacin OR ketoprofen OR lumiracoxib OR mefenamic acid OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR cyclooxygenase 2 inhibitor* OR anti-inflammatory agent*) AND (Alzheimer* OR dementia OR ((cognit* or memory* or mental*) and (declin* or impair* or los* or deteriorat*))</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ISI Conference Proceedings</P>
</TD>
<TD VALIGN="TOP">
<P>10 September 2008</P>
</TD>
<TD VALIGN="TOP">
<P>(aspirin OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR prednisone OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indomethacin OR indometacin OR ketoprofen OR lumiracoxib OR mefenamic acid OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR cyclooxygenase 2 inhibitor* OR anti-inflammatory agent*) AND (Alzheimer* OR dementia)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>mRCT including ISRCTN Register,</P>
<P>ClinicalTrials.gov</P>
</TD>
<TD VALIGN="TOP">
<P>10 September 2008</P>
</TD>
<TD>
<P> (aspirin OR aceclofenac OR acemetacin OR betamethasone OR celecoxib OR cortisone OR deflazacort OR prednisone OR dexamethasone OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen OR hydrocortisone OR ibuprofen OR indomethacin OR indometacin OR ketoprofen OR lumiracoxib OR mefenamic acid OR meloxicam OR methylprednisolone OR nabumetone OR naproxen OR nimesulide OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triamcinolone OR cyclooxygenase 2 inhibitor* OR anti-inflammatory agent*) AND (Alzheimer* OR dementia)</P>
</TD>
</TR>
<TR>
<TD>
<P>IFPMA, UMIN Japan trials register, Netherland trials register, Australasian Digital theses, Theses Canada, DATAD</P>
</TD>
<TD VALIGN="TOP">
<P>10 September 2008</P>
</TD>
<TD VALIGN="TOP">
<P>Alzheimer&#8217;s disease</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-06-05 17:34:31 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-02-15 18:14:13 +0000" MODIFIED_BY="Darin   Jaturapatporn">measurement agreement</TITLE>
<APPENDIX_BODY MODIFIED="2011-06-01 14:02:04 +0100" MODIFIED_BY="[Empty name]">
<P>Kappa statistic was used to measure agreement between 2 authors who make a decision for inclusion and exclusion.From calculation, kappa is 0.782. It should be noted that this calculation is based on the first decision making of both reviewers.</P>
<P>Meaning of kappa statistic</P>
<UL>
<LI>0.40-0.59: fair agreement</LI>
<LI>0.60-0.74: good agreement</LI>
<LI>0.75 or more: excellent agreement</LI>
</UL>
<P>From 488 studies, there were 19 studies that we did not agree and required more discussion. Although measuring agreement showed excellent agreement, it should be considered that the discussion is still the main part of the decision making. However, kappa helped us to revisit inclusion criteria again whether it is clear enough for both reviewers in case of poor agreement. Occasionally, we have to revisit and clarify the inclusion and exclusion criteria to assure that all reviewers are on the same page. For example, three reviewers at one point were not sure if we should include all studies of anti-inflammatory. After the discussion, we understood that we will only focus on aspirin, steroidal and non-steroidal anti-inflammatory. This leaded to the change of the review&#8217;s title.</P>
<TABLE COLS="9" ROWS="6">
<TR>
<TD>
<P/>
</TD>
<TD ROWSPAN="6" VALIGN="TOP">
<P/>
<P> </P>
<P/>
<P> </P>
<P/>
<P>
<B>Review</B>
</P>
<P/>
<P>
<B>Author 1 (DJ)</B>
</P>
<P/>
<P> </P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD COLSPAN="5" VALIGN="TOP">
<P/>
<P>
<B>Review author 2 (MI)</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P> </P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>
<B>Include</B>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>
<B>Exclude</B>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>
<B>Unsure</B>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>
<B>Total</B>
</P>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>
<B>Include</B>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>39 (a)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>1 (b)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>1 (c)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>41 (A1)</P>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>
<B>Exclude</B>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>11 (d)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>546 (e)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>2 (f)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P> 559(E1)</P>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>
<B>Unsure</B>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>0 (g)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>4 (h)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>0 (i)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>4 (U1)</P>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>
<B>Total</B>
</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>50 (A2)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>551 (E2)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>3 (U2)</P>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P/>
<P>488 (K)</P>
<P/>
</TD>
<TD>
<P/>
<P/>
</TD>
</TR>
</TABLE>
<P/>
<P>Po = a+e+i /  K                                                Po = 39+546+0 /604 = 0.969</P>
<P>PE = (A1xA2) + (E1+E2) + (U1+U2) / K<SUP>2</SUP>    PE = (41x50) + (559x551) + (4x3) /604<SUP>2 </SUP>= 0.850    </P>
<P>
<B>Kappa = Po PE/ 1-PE                                        Kappa =  0.969-0.850/ 1-0.850 =  0.793</B>
</P>
<P>
<B> </B>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2011-06-05 17:34:31 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-02-23 02:53:51 +0000" MODIFIED_BY="Darin   Jaturapatporn">Translation sheet</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-23 02:55:59 +0000" MODIFIED_BY="Darin   Jaturapatporn">
<P>
<B>
<U>Cochrane Dementia and Cognitive Improvement Group</U>
</B>
</P>
<P>
<U>Translation sheet.</U>
</P>
<P>To be completed by the translator.</P>
<P>Please note: full translations of papers are not necessary. The following questions are designed to assist in the extraction of necessary information for the inclusion of randomised controlled trials.</P>
<P>Date of translation:</P>
<P>Translator:</P>
<P>Language of the paper:</P>
<P>
<B>1. <U>Publication details</U>
</B>
</P>
<P>Authors:</P>
<P>Title (in English):</P>
<P>Original title:</P>
<P>Publication details:</P>
<P>(journal, volume, year, page nos)</P>
<P>If details are not reported, please indicate so.</P>
<P>
<B>2. <U>Materials and Methods</U>
</B>
</P>
<P>Is the trial described as RANDOMISED?</P>
<P>(NB - if the paper is not described as randomised, we do not require any further information, but please give a description of the study, ie, a review article, a case controlled trial, a letter to a journal, a double blind trial in which treatment was not randomised etc).</P>
<P>If YES, the following details are necessary:</P>
<P>Was it a parallel or cross-over study?</P>
<P>What were the patients described as suffering from? </P>
<P>Diagnostic criteria</P>
<P>Number of patients involved:</P>
<P>Gender ratio:</P>
<P>Age groups (please give Means and SDs) (+/- values if reported):</P>
<P>Where were the patients recruited from?</P>
<P>Was the treatment double blinded?</P>
<P>Are the allocation of treatment methods described, if so what were they?</P>
<P>What was the treatment compared with (placebo or standard therapies)?</P>
<P>Where did the study take place (city, multi-centre, hospital, community)?</P>
<P>How long did the trial last for?</P>
<P>Was there a follow-up period? If yes, over how long did it take place? </P>
<P>What were the inclusion/exclusion criteria?</P>
<P>What was the dosage involved (if the treatment was pharmacological)?</P>
<P>What were the dosages for the control/placebo group?</P>
<P>
<B>3. <U>Results</U>
</B>
</P>
<P>How were baseline measurements recorded?</P>
<P>What were the outcome measures?</P>
<P>Over what period were values recorded for the outcome measures?</P>
<P>Were there any drop outs reported? If so, how many?</P>
<P>
<B>
<U>Data:</U>
</B>
</P>
<P>Were the continuous data reported as Means and SDs/SEMs/Confidence Intervals? Please provide page numbers where results were presented to facilitate double-checking</P>
<P>What outcomes were presented as binary data?</P>
<P>Were the results reported in tables/graphs?</P>
<P>If, so please indicate on the axes of the copy sent to you, what the headings mean in English, and return with this sheet. </P>
<P>What is the value (e.g. % or otherwise) to describe the increase for each of the outcome measures that are reported? Please give +/- values if reported. Please indicate where these values can be found in the original article (this will help to facilitate validation).  </P>
<P>Is there any additional information which you consider significant?</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>